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Abstract 
 
Ageing is a major factor contributing to human morbidity and disease, including cancer. To 
study the possible involvement of epigenetic changes in ageing, murine haematopoiesis was 
used as a model system. The key cells determining ageing in this system are thought to be 
lower side population (LSP) cells of the bone marrow, which are enriched for long-term 
reconstituting haematopoietic stem cells (LT-HSCs). In this thesis, rare primary LT-HSCs 
from young, middle-aged and old mice were isolated and phenotyped. A protocol, termed 
Nano-MeDIP-seq was developed for methylome analyses on such rare cells. DNA and RNA 
from these cells were then subjected to comprehensive methylome (MeDIP-seq) and 
transcriptome (RNA-seq) analysis.   
Age-related changes in the LT-HSC methylome and transcriptome were observed in this 
study, many at genes associated with migration/adhesion and not previously implicated in 
ageing. These changes also include directional (young to old) global loss of DNA 
methylation of approximately 5%, 111 significantly (FDR < 0.2) age differentially methylated 
regions (aDMR) and more than one thousand significantly (FDR < 0.05) differentially 
expressed transcripts. Ingenuity pathway analysis (IPA) identified significant (p << 0.0001) 
age-related decline in B-Cell development and significant (p << 0.0001) alterations in 
pathways and functions associated with cell movement.  
A number of genes were identified to be significantly age differentially methylated and 
differentially expressed. One aDMR, associated with the Serum deprivation protein response 
(Sdpr) gene, was functionally validated to demonstrate a negative correlation between 
promoter methylation and differential expression. 
The findings in this thesis support a model involving an epigenetic dysregulation of the 
genes that control the interaction between LT-HSCs and their regulatory niche, during 
physiological ageing.  
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1  
1.1 Theories of Ageing 
There are many theories of ageing, most of which are modelled under the evolutionary 
theory of ageing. Common ageing theories include the disposable soma theory of ageing, 
mutation accumulation theory of ageing and the theory of antagonistic pleiotropy [1]. The 
disposable soma theory of ageing was formulated by Thomas Kirkwood [2]. It suggests that 
an organism has to balance the efforts put in maintaining somatic cells with that of 
reproduction. This theory is likely based on Weissman‘s germ-plasm theory [3]. This theory 
suggests that organisms which segregate germ-line and somatic cells, will dedicate 
resources to the maintenance of the germ-line to ensure reproduction, while the soma 
(somatic cells) will be left to accumulate mutations overtime, leading to organismal ageing 
[3]. Likewise, the mutation accumulation theory is based on Peter Medawar‘s observation 
that the forces of natural selection decline with age [4]. Natural selection is an active force 
early in an organism‘s life, acting to eradicate deleterious mutations and selecting for genes 
that are beneficial earlier in life [4]. The forces of natural selection in a young organism act to 
maximize the chances of reproducing and to ensure that favourable genes are passed on to 
the next generation. However, later acting gene mutations will escape selection and an 
accumulation of such mutations is thought to contribute to the ageing process [4]. The 
antagonistic pleiotropy theory of ageing as put forward by G. C Williams [5], proposes that 
some genes that are beneficial earlier in life are harmful later in life. Such genes are selected 
for earlier in life, and since the forces of natural selection are less powerful with age, these 
genes persist [5]. An example in humans is the p53 tumour suppressor gene, which prevents  
excessive cell proliferation that could lead to cancer [6]. However, constitutive p53 
expression in stem cells could result in disrupted cellular homeostasis and accelerated 
ageing [6].   
Several other theories have been put forward in an attempt to explain the ageing process; 
however, a consistent feature in multicellular organisms is the progressive decline in organ 
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function and reduction in their regenerative potential. Somatic stem cells (SSC) are 
multipotent cells that are present in most tissues and responsible for replacing lost and/or 
damaged cells, thus acting to maintain organ integrity throughout an organism‘s lifespan.   
1.2 Somatic Stem Cells 
Somatic stem cells (SSC) are long lived cells and they are likely to suffer damage at some 
point in the course of their existence. Damage to somatic stem cells may be especially 
catastrophic, due to their ability to self-renew as well as differentiate into more specialized 
cell types. For example, haematopoietic stem cells (HSCs) are SSCs that generate all blood 
cell types. Damage to such a cell will be propagated to all subsequent cells arising from this 
single stem cell, eventually leading to haematological malignancies. It is therefore essential 
that damage be avoided in such cells. To this end, SSCs have evolved sophisticated 
damage avoidance mechanisms. Such mechanisms include the expression of drug 
transporters on their cell surfaces, which help efflux toxins and prevent potential DNA 
damage [7] . Additionally, SSCs are more likely to undergo apoptosis than attempt a fault 
prone repair [7,8]. This ensures that DNA replication errors are not retained in this cell 
population. However, despite these mechanisms, there is evidence that stem cell activity 
declines with age. The damage-induced stem cell theory of ageing predicts a decline in HSC 
numbers with age [9]. This theory was thought to explain the observed decline in HSC 
activity with age; however, it is now known that the number of phenotypically defined HSCs 
increases with age [9]. 
1.3 Haematopoietic stem cells 
Haematopoietic stem cells (HSCs) are self-renewing, multipotent cells that reside in the 
bone marrow (BM) and are capable of differentiating into all specialized cells of the blood 
lineage (Fig. 1). The HSC population in the mouse bone marrow is a heterogeneous mix of 
long-term reconstituting HSCs (LT-HSCs) and short-term reconstituting HSCs (ST-HSCs). 
These cells, together with multipotent progenitors (MPP), are collectively referred to as KLS 
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cells or haematopoietic stem and progenitor cells (HSPCs) (Fig.1.1).  LT-HSCs are a rare 
subset of bone marrow cells and are estimated as less than 0.01% in young mice [9]. These 
cells are largely non-cycling (quiescent) and most remain in the G0 phase of the cell cycle 
during steady state haematopoiesis [10]. 
Figure 1-1: Hierarchy of cells in the mouse bone marrow.  
The most primitive cells in this hierarchy are the long-term reconstituting HSCs (LT-HSCs). ST-HSCs are short-term 
reconstituting HSCs. Curly arrow denotes self-renewal. KLS cells are c-Kit positive, Sca-1 positive and lineage negative cells. 
HSPC stands for haematopoietic stem and progenitor cells.  A cell above each arrow is capable of differentiating into the cells 
below it, forming a succession of increasingly committed downstream progenitors (not shown), through to mature short lived 
blood cells. 
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Canonical HSC properties include; expression of the c-kit receptor (K), the absence of 
lineage markers (Lin- or L) and the presence of the stem cell antigen-1 (Sca-1 or S) [11]. 
However, as mentioned earlier, KLS cells consist of both haematopoietic stem and 
progenitor cells. Additional markers of adult mouse HSCs, such as; the absence of CD34 
[12,13], high and negative expression of Slam markers, CD150 and CD48 respectively 
[14,15], and Hoechst dye exclusion [16], are therefore required to enrich for LT-HSCs. 
Antibody or Hoechst labelled HSCs are typically isolated by fluorescence activated cell 
sorting (FACS).  
Hoechst dye exclusion  is a cheap and easy method for isolating LT-HSCs [16]. This method 
involves the active efflux of the Hoechst 33342 DNA binding dye by the ABCG2 multidrug 
resistant (MDR) transmembrane transporter, which is expressed on cell surfaces [17]. 
ABCG2 is exclusively expressed by stem cells and is highly expressed on HSCs [17].  As a 
result, HSCs retain the least Hoechst staining compared to other haematopoietic cells and 
are distinctively separated from other cells when excited by ultraviolet (UV) lasers, during 
FACS analysis.  HSCs identified in this manner are referred to as side population (SP) cells 
(Fig. 1.7) and the SP, especially the lower SP, fraction of the mouse bone marrow has been 
shown to contain a cell population that is highly enriched for phenotypically and functionally 
determined LT-HSCs [7,16,18,19]. The availability of several well established markers, 
necessary for the identification and isolation of a homogeneous LT-HSC population, makes 
HSCs a convenient model for the study of SSC during mammalian ageing.  
1.4 Assays for studying HSCs 
Regardless of the availability of reliable markers to identify and isolate HSCs, functional 
assays are still required to identify bona fide HSCs. Such assays include in vitro and in vivo 
assays that examine the ability of putative HSCs to differentiate into mature progenitors, 
over a relatively long period of time. The latter property measures self-renewal, which is the 
key difference between true HSCs and MPPs (Fig. 1.1). Assays, such as the cobble-stone 
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area forming cell (CAFC) and the long-term culture initializing cell (LTC-IC) assays, can be 
used to confirm HSC activity in vitro.  
1.4.1 CAFC Assay 
CAFC involves the in vitro culture of putative HSCs on supportive stromal feeder cells, for a 
minimum of 28 days, followed by the visual confirmation (using a light microscope) of the 
presence of ‗cobble-stone areas‘ (phase dark cells) [20,21]. It is assumed that mature 
progenitor cells would have been exhausted by 28 days; therefore, the observation of 
colonies after this period is indicative of the primitiveness of the original test cells. A 
drawback of this assay is that it is a retrospective measure of primitiveness and validated 
test cells cannot be recovered. Additionally, self-renewal cannot be measured directly. The 
CAFC assay is therefore unable to differentiate between LT- and ST- HSCs or MPPs, and is 
thus, only useful for the detection of HSPC activity. 
1.4.2 LTC-IC 
LTC-IC [22] is similar to the CAFC assay in that they both involve the in vitro culture of test 
cells on stromal feeder cells; they however differ in their end-points. Following the initial 
culture of test cells for approximately 4 weeks, LTC-IC cells are harvested and seeded on 
semi-solid (methyl-cellulose) media, to determine the presence of colony forming cells 
(CFC). The rationale behind this is that only primitive cells will differentiate, over prolonged 
culture periods, into progenitor cells (CFCs), which are then able to form colonies of mature 
blood cells when transferred to a suitable secondary media. Similar to CAFC above, LTC-IC 
and CFCs do not provide a measure of LT-HSC activity [23]. 
Other in vitro assays include the short-term ex vivo (<12 days) maintenance of HSCs in 
serum-free liquid medium and growth factors. Ex vivo assays are typically used to expand 
HSCs numbers in vitro, while maintaining them in an undifferentiated state. This is achieved 
by the addition of several growth factors such as Angiopoietin-like proteins, Fibroblast 
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growth factor 1 (FGF-1), Insulin-like growth factor 2 (IGF-2), Thrombopoietin and Stem cell 
factor (SCF) [24,25]. The advantage as well as disadvantage of this assay is its ability to 
maintain HSCs in an undifferentiated state. This is useful for the expansion of HSC numbers 
for various therapeutic purposes, however, the fact that expanded HSCs cannot differentiate 
in this system could be a disadvantage. This is because although cell surface markers may 
remain unchanged, one cannot be sure of the functionality of ex vivo expanded HSCs, which 
can only be ascertained by their ability to differentiate into mature blood cells and 
permanently reconstitute haematopoiesis. 
1.4.3 Transplantation assays 
In vivo reconstitution assays are the gold standard for determining HSC activity. These 
assays involve the transplantation of test (donor) HSCs into host mice, followed by the 
assessment of its engraftment and long-term reconstituting abilities [26]. Many variations of 
this assay exist; these include the use of myelo-ablated or non-ablated hosts, as well as a 
variation in the requirements for serial transplantation. Transplantation of HSCs into 
genetically different hosts, such as; across mouse strains or xenografts of human donor 
HSCs into mice, can also be performed. This is typically achieved by transplantation into 
immunocompromised hosts e.g. SCID mice. Nevertheless, the end-point assessment for 
HSC functionality remains the same, and must provide clear evidence of its ability to self-
renew and reconstitute haematopoiesis. A typical HSC transplantation assay is the 
competitive repopulating unit (CRU). CRU assays (Fig. 1.2) [26] involve the transplantation 
of HSCs into myelo-ablated hosts, such that true HSCs will permanently reconstitute 
haematopoiesis in such hosts.  Serial transplantation of HSCs into secondary hosts is often 
used to further ascertain self-renewal in LT-HSCs. 
Introduction Chapter 1 
 
20 
 
Figure 1-2: Competitive repopulating unit (CRU) assay.  
 
 
 
 
 
 
 
 
Test (donor) and recipient cells are genetically identical, 
except for congenic differences at the CD45 locus. The 
different CD45 alleles (CD45.1 and CD45.2), aid the 
identification of donor HSC derived haematopoietic cells. 
Lightning bolt indicates myelo-ablation by irradiation, which 
occurs before transplantation. LTR stands for long term 
reconstitution by LT-HSCs. Secondary recipients are 
typically analysed for LT-HSC activity after 24 weeks.  
 
 
 
1.5 The Haematopoietic Stem Cell Niche 
The concept of a HSC niche was first proposed in 1978 by Schofield [27]. The niche as 
referred to here, is a regulatory micro-environment where HSCs reside, and are supported 
by specialised growth-factor secreting cells, and various other cytoskeletal and cell-adhesion 
molecules [28]. HSCs reside in various niches during development (Fig.1.3 [29-31]) before 
migrating to their final location, which is the bone marrow. This migration is thought to occur 
in embryos after approximately 18 days (E18) post conception (dpc) [29] and adult HSCs 
subsequently remain in the bone marrow throughout life. An exception to this is observed 
during pathological extramedullary haematopoiesis, where HSCs leave the bone marrow for 
other sites such as the spleen or liver, to proliferate and differentiate [32].  
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This thesis focuses on adult murine HSCs, which are resident in the bone marrow. The bone 
marrow is thought to consist of two anatomically distinct niches i.e. the endosteal and the 
vascular niche (Fig. 1.4 [33,34]). The endosteal region of the trabecular bone (endosteal 
niche) is thought to be involved in LT-HSC regulation and the maintenance of quiescence 
during steady state [34]. Osteoblasts are the main regulatory cells in this niche and they 
secrete key HSC factors such as osteopontin, angiopoietin, and stromal derived factor-1 
(SDF-1, also known as CXCL12) [35-37]. Proliferation and differentiation into more 
specialized blood cells are thought to occur in a second niche, the vascular niche of the 
perivascular area [38], and resident cells such as megakaryocytes, mesenchymal stem cells 
and CXCL12 abundant reticular (CAR) cells, also produce angiopoietin and SDF-1. This 
overlap in regulatory factors and the observation that HSCs are able to interact 
simultaneously with both niches, without a change in their functional and cycling properties 
[14], makes the concept of distinct HSC niches untenable, and is currently a subject of high 
debate in HSC biology [39]. Although the exact mechanism by which HSCs are regulated in 
their niche is currently unclear, the bone marrow has been proven to be important in HSC 
maintenance and regulation [33-35,40].  
Figure 1-3: HSPCs reside in, and migrates to, various niches during ontogeny.  
Primitive haematopoiesis begins in the yolk sac, while definitive haematopoiesis is first observed in the AGM of day 10.5 
embryos (E10.5). The bone marrow is the final niche in adult haematopoiesis. AGM, Aorta-gonad mesonephros. 
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1.6 HSC Regulation 
The two key defining properties of HSCs are the ability to differentiate into all mature cells of 
the blood lineage and to self-renew for a relatively long period of time. The latter property is 
typically indexed by persistent reconstituting ability, following two to three rounds of serial 
transplantation (Section 1.4.3). As detailed above, the niche plays an important role in 
regulating these properties, but many other factors have also been shown to be involved in 
HSC regulation. Majority of LT-HSCs are quiescent at steady state [41], however, it is 
frequently necessary for these cells to proliferate in response to systemic signals, for the 
replenishment of all blood cell types.  Therefore, a balance between HSC quiescence and 
proliferation is required to maintain homeostasis and prevent exhaustion. This is achieved by 
the action of transcription factors (TF) such as Hoxb4, Pbx1, JunB and Bmi-1. Hoxb4 
positively regulates HSC self-renewal and cells overexpressing this TF exhibited an 
enhanced expansion, during ex vivo culture [42]. Hoxb4 also appears to collaborate with p21 
Figure 1-4: The endosteal and vascular niche of the mouse bone marrow. 
Osteoblasts of the endosteal niche and sinusoid endothelium of the vascular niche both contribute in the maintenance of 
HSCs in the bone marrow. Other specialised cells such as CAR cells and MSCs are also present in both niches and 
these, as well as the main cells of each niche, secrete growth factors that regulate HSCs. It is currently unclear whether 
these niches are truly distinct or if they form parts of a single HSC niche. CAR- CXCL12 abundant reticular; MSC – 
Mesenchymal stem cell; HSC - Haematopoietic stem cell 
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in the regulation of HSC self-renewal [43].  p21 is a cyclin-dependent kinase inhibitor (CKI) 
that governs HSC quiescence, by regulating its entry into the cell cycle [44]. Overexpression 
of Hoxb4 in p21 mutant HSCs resulted in a significant increase in self-renewal, compared to 
wild-type (wt) HSCs or HSCs overexpressing Hoxb4 alone [43]. Conversely, Pbx1 regulates 
HSC quiescence and Pbx1 deficient LT-HSCs lost their self-renewal activity due to 
excessive proliferation, concomitant with exhaustion, and displayed ST-HSC functionality 
and a gene expression profile akin to that of MPPs [45]. Similarly, Bmi-1 mutants were 
unable to self-renew, suggesting a role for Bmi-1, in the control of HSC self-renewal [46]. 
Other factors such as cytokines and signalling pathways such as the Tgf-β, Wnt and Notch 
pathways have all been shown to be important regulators of HSC properties [19,47,48].   
1.7 Epigenetic regulation of HSCs 
Epigenetics, as defined by Adrian Bird, is ―the structural adaptation of chromosomal regions 
so as to register, signal or perpetuate altered activity states‖ [49]. HSCs are required to 
maintain a tight balance between self-renewal and differentiation into mature cells of vastly 
different gene expression profiles [50]. As a result, a degree of plasticity in gene expression 
is necessary to allow fluid changes from quiescence, to proliferation and to differentiation. 
Epigenetic mechanisms are important in phenotypic plasticity [51], and are thus likely to be 
involved in the regulation of HSCs. Indeed, intricate epigenetic modifications at the 
promoters of lineage restriction genes, show a distinct pattern between HSCs and mature 
blood cells [52]. Epigenetics encompass the modification of histone tails, DNA methylation 
and gene regulation by non-coding RNA (ncRNA).  
1.7.1 Histone Modification 
Histones are proteins that are involved in the high order packaging of DNA into chromatin, 
within cells. The main proteins involved in this process are the core histones; H2A, H2B, H3 
and H4, and the H1 linker histone. Key post translational histone modifications include 
acetylation by histone acetyltransferases (HATs) and methylation by histone 
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methyltransferases (HMTs). The recognition of these modifications by other (non-histone) 
proteins, results in dynamic changes in chromatin structure i.e. from transcriptionally inactive 
heterochromatin to active euchromatin and vice versa (Fig. 1.6) [53]. Gene expression is 
therefore regulated by histone modifications, which influence the accessibility of 
polymerases and TFs to DNA. Several studies have highlighted the importance of histone 
modifications in the determination of HSC fates [52,54,55]. HSCs exhibit a low level 
expression of lineage specific genes [56,57]. This is thought to be important in priming them 
towards lineage commitment, and the presence of bivalent (activating and repressive) 
histone marks on such genes [54], suggests that histone modifications are important in the 
regulation of lineage commitment in HSCs. 
1.7.2 DNA Methylation 
DNA methylation (DNAm) is an important epigenetic modification in the regulation of gene 
expression, and involves a stable but reversible addition of a methyl group to the carbon-5 
position of cytosines, without a change in the underlying DNA sequence [58]. This process 
occurs de novo, through the action of DNA methyltransferase 3 (Dnmt3a and b), or as a 
maintenance mechanism in hemi-methylated DNA by DNA methyltransferase 1 (Dnmt1). In 
mammalian genomes, DNAm exists as variations of 5-methyl cytosine (5mC). 5mC DNA 
modifications are found mostly at Cytosine-Guanine (CpG) dinucleotides (mCG) and are 
recognised by protein complexes with methyl-CpG binding domains (MBD), which often act 
with other chromatin remodelling proteins, to modify gene expression [58,59].  
 mCG is enriched in the mammalian genome and its role in the regulation of gene 
expression is well appreciated.  Genomic regions of high CpG density are known as CpG 
islands (CGI) and these are present in the promoter region of approximately 56% human 
genes [60]. Promoter CGIs are typically hypomethylated and DNAm of this region is 
associated with gene repression [60] (Fig. 1.5). In contrast, independent DNAm within gene 
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bodies maintain genome stability by preventing nonsense transcription from cryptic start 
sites and by suppressing intragenic repeat and mobile elements [60,61].  
 
Figure 1-5: Gene regulation by DNA methylation.  
Top; promoter (green bar) hypomethylation (open circle lollipops) allows gene expression i.e. transcription of DNA to protein 
coding mRNA (red squiggle), while gene body (blue bars) hypermethylation (closed circle lollipops) maintains genome stability, 
by repressing repeat elements (blue squiggle) and transcription from cryptic start site (green line). Bottom; transcription is 
repressed (red cross) in the case of promoter hypermethylation and gene body hypomethylation likely results in genome 
instability. Changes in promoter DNAm can modify gene expression, independently of those within the gene body. 
 
As mentioned previously, there are other variations of 5mC. These include non CpG (mC) 
and 5HmC methylation.  mC is structurally identical to mCG but occurs in the absence of a 
guanine nucleotide and is asymmetrical with regards to its presence on DNA strands [62]. In 
contrast to mCG which is equally represented in most mammalian cells, mC is only enriched 
in ESCs [63,64] and perhaps in SSCs. 5HmC, is another form of mammalian DNAm and 
involves the conversion of 5mC to 5HmC, in a 2-oxoglutarate (2OG) and Fe (II) dependent 
manner [65]. This conversion is catalysed by Tet proteins [66] and Tet1, Tet2 and Tet3 have 
all been shown to act as mCG dioxygenases [67]. Although the exact function of 5HmC is 
currently unknown, its presence on ES cells gene promoters coincides with increased gene 
expression [68]. Additionally, the downregulation of Tet1, as well as a decrease and increase 
in promoter 5HmC and 5mC respectively, is observed during ES cell differentiation [68]. 
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These findings are consistent with a dynamic relationship between 5HmC and 5mC, as well 
as a possible mechanism for active demethylation, through the action of Tet proteins.  
Although, DNAm and histone modifications may act in isolation to modulate gene 
expression, recent evidence indicates that these mechanisms may cooperate during gene 
regulation (Fig. 1.6) [59,69]. This is seen in the repression of p53BP2, as a result of the 
interaction between MBD1 and SETDB1, in the formation and maintenance of 
heterochromatin. MBD1 is a mCG binding protein (MBP) while SETDB1 is a histone 
methyltransferase (HMT) and MBD1 bound to mCG, recruits SETDB1 into a repressive 
complex that mediates the methylation of H3K9, resulting in gene repression [59]. 
As well as modulating gene expression by promoter methylation or through interactions with 
other epigenetic factors, DNAm has various functional consequences that indicate a possible 
role in the regulation of HSCs. The following sections detail the aspects of DNAm that 1) are 
relevant to this study, and 2) provide evidence for the possible involvement of DNAm in HSC 
ageing.   
1.7.2.1 DNAm During Development 
The first epigenetic regulation of the mammalian genome occurs very shortly after 
fertilization. Reprogramming of the zygote epigenome occurs before any DNA replication, 
and involves rapid demethylation of the paternal genome [70,71]. The maternal genome also 
undergoes passive demethylation following multiples rounds of DNA replication [70,71]. 
While demethylation of the paternal genome is clearly an active mechanism, the factors 
involved in this event are currently unknown. However, DNA replication-independent 
accumulation of 5HmC, and Tet3 knockdown experiments, in one-cell embryos suggest that 
this process involves the direct conversion of 5mC to 5HmC by Tet3 [72]. Remethylation of 
the zygote genome begins in E6.5 mouse epiblasts, during implantation, by Dnmt3b 
catalysed de novo methylation of gene promoters [73]. Genes involved in pluripotency are 
targeted for methylation in early embryos, possibly as a mechanism to limit the differentiation 
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capacity of epiblast cells [73]. Reprogramming of the epigenome during embryogenesis is 
important in the maintenance of imprinting and in preventing the transmission of deleterious 
DNAm and/or epimutations, which could lead to diseases or shortened lifespan [74,75].  
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Figure 1-6: Simplified model of gene regulation.  
Top; Hypomethylation of promoter CGIs and histone modifications, such as acetylation and H3K4 methylation, inhibit DNMT 
binding and result in an open chromatin (euchromatin). This allows the binding of transcription factors (TF) to DNA, thus 
allowing gene expression. Middle; putative intermediate step between gene expression and repression by Tet mediated DNA 
demethylation. HMT - histone methyltransferases, HAT – Histone acetyltransferase. Bottom; heterochromatin formation and 
gene repression, following histone deacetylation by histone deacetylases (HDAC) and promoter hypermethylation by DNMTs. 
mCG binding protein (MBP) binds to methylated DNA and recruits co-repressors (rTF) and repressive HMTs, e.g. SETDB1. 
This results in a stabilisation of heterochromatin and gene silencing [59,67,69,74]. 
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1.7.2.2 DNAm and Lineage Specification 
The link between cell-type specific gene expression and DNA methylation was first 
demonstrated for the MASPIN gene, where its promoter was found to be unmethylated only 
in the cells that expressed the gene [76]. The advent of next generation methylome analysis 
techniques (Section. 1.11.2) has aided further elucidation of this mechanism, and it is now 
widely accepted that this phenomenon extends beyond single gene promoters. For example, 
analysis of several CGIs in human blood, brain, muscle and spleen, revealed multiple inter- 
and intragenic CGIs that were differentially methylated between these tissues [77]. These 
tissue-differentially methylated regions (tDMRs) were found to be enriched for 
developmentally relevant genes such as Pax and Hox genes [77]. Similarly, a study by the 
same group identified several cell-type specific DMRs (ctDMR), between human CD4+ blood 
and brain cells [78]. ctDMRs were enriched at intragenic CGIs and although, many of these 
were not associated with promoters (orphan CGIs), DNAm at gene-associated intragenic 
CGIs was negatively correlated with gene expression. This indicates a functional role for 
intragenic CGIs in the regulation of cell specific gene expression. These findings are in slight 
contrast to related studies, which found tDMRs to be enriched at CGI shores [79-81], which 
are regions of relatively low CG density that are found approximately 2 Kb upstream of CGIs. 
CGI shore-tDMRs overlapped with cancer differentially methylated regions (cDMRs) and are 
evolutionary conserved between mice and humans [80]. Likewise, induced pluripotent stem 
cells (IPSCs) and the mature fibroblasts from which they were derived, were differentially 
methylated at CGI shores. These DMRs, termed rDMRs, showed considerable overlap with 
CGI shores-tDMRs [81]. These suggest that CGI shores are important regulatory regions in 
the maintenance of cell identity. Conversely, IPSCs generated from distinct cells retain 
certain DNAm marks that are reminiscent of the cells from which they originated [79]. 
Irrespective of the precise location of the DMRs highlighted above, these studies 
demonstrate that DNAm is important in high level cell lineage and tissue specification, as 
these marks define cellular identity and persist even after genome-wide reprogramming. 
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They also suggest that DNAm is involved in the choice between lineage specification and 
pluripotency and a disruption of this mechanism is likely involved in carcinogenesis. 
1.7.2.3 DNAm in Cancer 
The link between global DNA hypomethylation and cancer was made several years ago [82] 
and there has since been a remarkable improvement in our understanding of the dynamic  
involvement of DNAm in oncogenic transformation. Indeed, several instances of global and 
gene specific changes in DNAm have been observed in almost all cancer types [83,84]. 
Global loss of DNAm results in chromosome instability (Section 1.7.2), and increased tumour 
incidence, as demonstrated in mice carrying hypomorphic alleles of Dnmt1 [85,86]. Likewise, 
hypermethylation at the promoters of several tumour suppressor genes, and their 
subsequent downregulation, is known be involved in carcinogenesis [83]. Additionally, 
overexpression and silencing of specific genes in stem cells, through aberrant DNAm, has 
been proposed as an initial step in neoplastic transformation [84]. 
1.7.2.4 DNAm in Stem cells 
The involvement of DNAm in embryonic stem cell (ESC) maintenance and differentiation is 
well appreciated [58,67,87]; but, until recently, its relevance in SSCs has been relatively 
understudied. Since the commencement of this study, several studies have highlighted the 
role of DNAm in HSPCs regulation. Such studies have demonstrated the importance of 
DNAm in maintaining HSC homeostasis and Dnmt mutant mice show defects in HSC self-
renewal and differentiation [88-90].  Similarly, global hypomethylation in mice with reduced 
Dnmt1 activity resulted in phenotypically defined LT-HSC expansion, but markedly impaired 
self-renewal in vivo, as well as a skewed lineage potential towards myeloerythropoiesis, at 
the expense of lymphopoiesis [88]. Lineage skewing here was as a result of markedly 
altered gene expression in HSCs, to one more similar to that of myeloerythroid progenitors.  
These changes in gene expression include the downregulation of several genes that are 
involved in self-renewal, and an upregulation of myeloid specification genes. Conversely, 
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Dnmt3a mutant HSCs upregulate multipotency genes and showed enhanced in vivo self-
renewal at the expense of differentiation into mature blood cells [90].  
The studies highlighted above (Section. 1.7.2), provide evidence for the role of DNA 
methylation in mammalian gene regulation and in the maintenance of cellular identity and 
integrity. Several of these studies also suggest an involvement of DNAm in HSC 
maintenance and differentiation, and in support for the latter, significant changes in DNAm 
were identified during haematopoietic lineage specification [91]. In the next sections, I 
discuss the ageing of HSCs and the possible mechanisms that are involved in this process. 
1.8 Haematopoietic Stem Cell Ageing 
HSCs from old mice show a reduction in the ability to efficiently reconstitute haematopoiesis 
in lethally irradiated hosts [7,9,92-94]. This functional defect is accompanied by an age-
dependent increase in the number of phenotypically defined HSCs (Fig. 1.7) and a skewed 
differentiation potential towards myelopoiesis, at the expense of lymphopoiesis [93,95]. 
Additionally, aged HSCs show reduced ability to home to the bone marrow [7,96,97], which 
would affect their regulatory interaction with the niche. These reports are consistent with a 
decline in immune functions and an increase in the incidence of myelo-proliferative cancers 
with age [98].  
Functional changes in HSCs during ageing have been well characterised, but the exact 
mechanism directing this change remains elusive. Nevertheless, various mechanisms have 
been postulated and these are summarised in the next section. 
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Figure 1-7: FACS plot of mouse side population (SP) cells. 
These cells (arrowed) increase with age  [7]. Figure was provided by Dr Daniel Pearce. 
 
 
 
 
1.9 Theories of Haematopoietic Stem Cell Ageing 
1.9.1 Intrinsic Ageing of HSCs 
Gene expression analyses have provided evidence for an intrinsic change in HSCs during 
ageing [7,94,99]. A study by Rossi et.al [94] suggested that lineage skewing in aged HSCs is 
a result of upregulated myeloid specification transcripts and a corresponding downregulation 
of lymphoid transcripts during ageing [94]. The cell intrinsic nature of this change was further 
demonstrated by transplantation assays, which showed that exposure of HSCs from young 
mice to an aged niche, was not sufficient to recapitulate the defects observed in HSCs 
during ageing [94].  The cell intrinsic theory of HSC ageing was confirmed by another study, 
which observed an NF-kB mediated dysregulation of HSC gene expression during ageing 
[99].  Likewise, HSC activity in chimeric mice provided in vivo evidence for the intrinsic 
nature of HSC ageing [92]. Briefly, cellular chimeras were generated from two different 
mouse strains, C57BL/6 and DBA/2. The former is a long lived strain, living up to three 
years, while the latter is shorter lived and survives for up to two years. Haematopoiesis in 
young chimeras was evenly supported by both C57BL/6 and DBA/2 derived HSCs, however 
this was not the case in aged chimeras.  Coinciding with the end of their natural lifespan, 
DBA/2 derived HSCs (D2-HSCs) appeared to have senesced in two year old chimeras, 
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leaving haematopoiesis to be sustained by C57BL/6 derived HSCs (B6-HSCs). Serial 
transplantation of ‗senescent‘ D2-HSCs, into young chimeras, enforced their continued 
contribution to haematopoiesis, albeit for a few months [100].  Findings from this study 
support an intrinsic model of HSC ageing, as D2-HSCs appeared to age earlier than B6-
HSCs, despite being exposed to identical niches. This study also hints at a role for the niche 
in HSC ageing, as ‗senesced‘ D2-HSCs were temporarily reactivated upon exposure to a 
younger, and unoccupied, niche.  As senescence involves the irreversible cessation of all 
replicative activity, it is unlikely that D2-HSCs in two year old chimeras were senescent, as 
they maintained the ability to proliferate in certain conditions. It is also possible that 
transplanted D2-HSCs were in fact ST-HSCs, which would explain their ability to proliferate 
only for a short period of time after transplantation. This is however unlikely, as these cells 
continued to be reactivated, after at least two rounds of serial transplantation [100]. Taken 
together, these findings suggest that intrinsic programmes cause HSCs to become deeply 
quiescent during ageing and certain niche conditions or indeed the process of 
transplantation and homing to a new unoccupied niche could restore or alter the functionality 
of aged HSCs.    
1.9.2 Clonal Compositional change of HSCs during ageing 
It has recently been shown that the mouse LT-HSC compartment consists of lineage biased 
subpopulations, which show a difference in their ability to differentiate into either the myeloid 
or the lymphoid lineage [101]. These subpopulations, termed myeloid biased (My-bi), 
balanced (Bala) and lymphoid biased (Ly-bi) HSCs, can be isolated based on their 
expression of the CD150 antigen [19,102]  and their differential ability to efflux the Hoechst 
dye during SP analysis [19]. Lower SP and CD150hi LT-HSCs are thought to be enriched for 
My-bi clones while the upper SP and CD150low clones are enriched for lymphoid biased LT-
HSCs [19,102].  The lineage bias shown by these cells is stable with age, such that specific 
subpopulations isolated from mice at any age point, consistently displays the same 
propensity towards a particular cell lineage [19]. This is particularly important during HSC 
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ageing, as it is the My-bi enriched lower SP fraction of LT-HSCs that increase with age 
[7,19]. This suggests that HSCs change in composition with age and the increase in 
myelopoiesis observed during ageing, is a consequence of this. My-bi clones have been 
shown to be more quiescent and longer lived that Ly-bi clones [19]. Additionally, My-bi 
clones show a greater ability to self-renew and generate Ly-bi clones, than the converse 
[102], suggesting that My-bi cells may be the most primitive HSC subsets. This ability to self-
renew and persist for longer periods of time, than their Ly-bi counterpart, probably accounts 
for their accumulation with age and subsequent enrichment in old mice. 
1.10 Molecular Mechanisms of Haematopoietic Stem Cell Ageing 
Functional and expression studies of HSCs during ageing have identified a catalogue of 
genes, as well as HSC properties, that are altered with age [7,9,94,103]. Differentially 
expressed genes range from those that are involved in cell signalling pathways [94] and 
polarity [104], to those implicated in DNA damage, cell cycle and cancer [105-107]. Although 
these findings represent a significant improvement in our understanding of HSC ageing, the 
exact mechanism driving these age-related changes remains unknown. Stem cells are long 
lived and are therefore likely to accumulate DNA damage in the course of their lifespan 
[108]. The self-renewing properties of somatic stem cells also make them ideal targets for 
oncogenic transformation [84] and it is possible that age related alterations in HSCs are the 
initial steps to neoplasia (Fig. 1.8). Indeed, Chronic myeloid leukaemia (CML) is a cancer 
that becomes prevalent with age and has been shown to arise from oncogenic 
transformation of HSCs in mice [109]. Likewise, age-dependent promoter hypermethylation 
of genes that promote stem cell differentiation, suggest that aberrant DNAm may alter stem 
cell potentials during ageing [110]. Although the preferential production of myeloid cells in 
old age is now thought to be a result of clonal compositional changes in HSCs during ageing 
[19,102], it remains unclear why these clones increase in quantity or why there is a loss in 
their functionality with age. As discussed above, DNAm is important in HSCs regulation and 
its aberration is implicated in carcinogenesis [82,110]. Age is one of the greatest risk factors 
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in carcinogenesis, and cancers such as CML and other myelodysplastic syndromes (MDS), 
which have a high incidence in the older population, are currently being treated with DNA 
methylation altering agents such as 5-Aza‘deoxyCytidine (5-Aza‘dC) [111].  
 
 
Figure 1-8: Ageing is a major risk factor in carcinogenesis.  
a) Inevitable age related HSC changes could leave these cells vulnerable to neoplastic transformation; b) an additional hit 
(lightning bolt) on ageing HSCs could trigger malignant transformations, leading to age associated leukaemias.  
           
1.10.1 DNA Methylation and Cellular Ageing 
The otherwise identical genomes of monozygotic twins are differentially methylated with age 
[112], and similar to changes in DNAm during carcinogenesis, human CD4+ blood cells gain 
DNAm at CGI promoters and become globally hypomethylated during ageing [113]. 
Likewise, multiple mouse tissues become differentially methylated with age [114]. An 
underlying problem of old age is a decline in the body‘s ability to respond adequately to 
damage; a problem that is attributable to the loss of phenotypic plasticity in SSCs. In the 
event of damage, normal SSCs respond to signals, which instruct them to differentiate and 
replace lost cells [115]. HSCs are quiescent at steady state [41], but proliferate rapidly to 
reconstitute haematopoiesis in myeloablated hosts. The transcriptome of quiescent cells has 
been shown to be distinct from that of proliferating cells [116]. Such changes in gene 
expression, and thus the switch from quiescence to proliferation (or vice versa), are likely 
underlined by epigenetic modifications. Indeed, recent studies of HSPC differentiation have 
identified several changes in DNAm, during lineage commitment [91,117].  
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Additionally, various studies have shown a dysregulation of DNAm in SSCs during ageing 
[110,117]. Teschendorff et.al found that human polycomb-group-proteins target genes 
(PcGTs), which are stably repressed in stem cells, also become hypermethylated with age in 
mature blood cells [110]. Similarly, analysis of human HSPCs identified several PcGTs to be 
de novo methylated at gene promoters, during HSPC ageing [117]. Additionally, several 
myeloid specification genes become hypomethylated in aged HSPCs [117]. These findings 
indicate an involvement of DNAm in the ageing of HSCs, and suggest that myeloid bias in 
aged HSCs is a result of DNAm-dependent upregulation of myeloid specification genes. It is 
also likely that promoter hypermethylation of PcGTs leads to enhanced self-renewal, at the 
expense of differentiation, culminating in the HSC expansion that is observed in aged mice.  
In order to further elucidate the mechanisms of HSC ageing, I investigated the dynamics of 
DNAm, during mouse LT-HSCs ageing. In the next sections, I describe the techniques used 
to study DNAm in this thesis and conclude this Chapter with an overview of my 
investigations and findings. 
1.11 DNA Methylation Profiling 
Common techniques for DNAm analysis are bisulfite conversion based or enrichment based 
[118]. Each of these methods have multiple strengths and drawbacks, however, the most 
appropriate technique for any study is ultimately dependent on the type of information 
required, and the feasibility of applying the selected method to the samples being 
investigated.  Nevertheless, the initial consideration, when deciding on a suitable method for 
DNAm analysis, is the scale at which the investigation is required. This can be separated 
into two categories; locus-specific and global DNAm (methylome) analysis. 
1.11.1 Locus-Specific Analysis of DNAm 
This approach requires a priori knowledge of the regions that will be analysed, and is 
commonly used to determine the DNAm status of candidate regions.  Most locus-specific 
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(LS) DNAm techniques are bisulfite conversion and PCR based. Bisulfite conversion 
involves the chemical treatment of DNA with sodium bisulfite, which results in the 
deamination of unmethylated cytosine bases to uracil (converted to thymidine, following PCR 
amplification) [119]. This modification is methylation sensitive and is such that methylated 
cytosines remain unconverted and distinguishable from unmethylated cytosines, which will 
be converted to thymidine [119]. Depending on the information required, multiple end-point 
assays can be used to determine LS methylation (Fig.1.9).  
1.11.1.1 Methylation specific PCR (MSP)  
MSP [120] is a sensitive method that can be used to determine the presence of DNAm at a 
particular locus when the amplified sequence data is not required. In MSP, PCR primers that 
are specific to either the methylated (MSP_m) or unmethylated sequence (MSP_u) are used 
in separate PCR reactions. Methylation is quantified by gel electrophoresis (or quantitative 
PCR, in the case of MethylLight [121]) and is based on the ability of MSP primers to 
generate products (Fig. 1.9). This method allows the sensitive detection of fully methylated 
and unmethylated regions, but does not take partial methylation into consideration. Another 
drawback is the labour intensive process of optimal primer design.  
1.11.1.2 Combined Bisulfite Restriction Analysis (COBRA) 
This method is similar to MSP; in that it is only suitable for when the underling sequence 
data is not required. However, in contrast to MSP, PCR primers are not methylation specific 
but are designed to promote equal amplification of both methylated and unmethylated DNA. 
COBRA [122] involves the sequence-specific restriction enzyme (RE) digestion of PCR-
amplified BS-treated DNA. BS conversion will result in a change in DNA sequence, and RE 
DNA digestion will be prevented. Therefore, only sequences that are resistant to BS 
conversion, i.e. methylated DNA, will remain unconverted, and thus cleaved. Digestion 
products are subsequently investigated by gel electrophoresis, and DNAm status is 
determined by the presence and intensity of digested and/or undigested fragments (Fig. 1.9). 
Introduction Chapter 1 
 
38 
 
A key limitation of this method is its dependence on restriction enzyme recognition sites, 
which may not be present in all regions of interest. 
1.11.1.3 Locus Specific Bisulfite Sequencing (LS-BS-seq) 
Bisulfite sequencing [119] is considered the gold standard for DNAm detection. It involves 
the sequencing of PCR amplified BS-converted DNA, which provides a single nucleotide 
resolution of DNAm. There are two main variations of LS-BS-seq, allele-specific BS-seq 
[119] and BS- Pyrosequencing (BS-Pyroseq) [123]. Both of these methods provide a 
quantitative measure of DNAm levels at single cytosines nucleotides. A key advantage of 
BS-Pyroseq, over allele-specific BS-seq, is that cloning of PCR products is not required to 
determine absolute methylation.  However, a major disadvantage is that a maximum of only 
50 bp can be sequenced in a single reaction. Both methods require the design of efficient 
primers that, specifically amplify the desired region, and does this at equal efficiency in both 
methylated and unmethylated sequences. Due to the redundant nature of converted DNA, 
primer design is probably the most challenging step in bisulfite conversion based methods. 
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Figure 1-9: Bisulfite conversion (BS) of DNA and various quantification methods.  
DNA on the left contains methylated cytosines (C with black stalks), which are resistant to BS conversion, while those on the 
right are unmethylated and thus BS converted. MSP; Methylated DNA will be amplified using MSP_m PCR primers, while 
unmethylated DNA will not. The reverse is the case, if MSP_u PCR primers are used. (MSP_m, methylation specific PCR for 
methylated DNA, MSP_u, methylation specific PCR for unmethylated DNA). COBRA; involves restriction enzyme (RE) 
digestion of DNA, following BS conversion and PCR amplification. Here, restriction enzyme cleavage will only occur in 
methylated and thus, unconverted sequences (lanes 1 and 2), while unmethylated sequences will remain uncut (lane 3). Row 
‗3‘ depicts undigested products, while ‗1‘ and ‗2‘ depict digested fragments. Varying concentration of DNA will appear in either 
lane 3 (unmethylated) or lane 1 and 2 (methylated), depending on DNAm level. Allele Specific BS-seq; PCR amplified BS 
converted DNA is cloned and sequenced (Sanger sequencing). Absolute methylation level is then quantified by appropriate 
software, which assesses the resulting electropherogram for C/T mismatches. BS-Pyroseq; Absolute DNAm is determined 
directly, by pyrosequencing, following BS conversion and PCR, without the need for prior cloning. 
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1.11.2 Global DNA Methylation Analysis 
DNAm analysis at this scale is commonly referred to as methylome analysis and will be 
described as such throughout this thesis. As mentioned earlier, common DNAm analyses 
are either bisulfite conversion based or enrichment based [118]. Commonly used global 
bisulfite conversion based methods are either quantified by next generation sequencing 
(NGS) as with whole-genome bisulfite sequencing (MethylC-seq or BS-seq) [62] and 
reduced representation bisulfite sequencing (RRBS) [124], or by hybridization to 
microarrays, the most frequently used being the Illumina Infinium Beadchip arrays (Currently 
450K). Sequencing based methods are generally preferred to microarrays, as they do not 
require prior selection of regions of interest and are more informative with regards to repeat 
regions [118,125]. Additionally, MethylC-seq is more informative than RRBS, as the latter is 
biased for CpG rich regions [118] and is therefore not a true global analysis technique. 
Indeed, MethylC-seq is the gold standard method for methylome analysis as it provides a 
single-nucleotide resolution of the methylome; however, its application on large genomes 
remains prohibitively expensive. Other methods involve the enrichment of methylated 
portions of the genome, by antibody precipitation e.g. Methylated DNA immunoprecipitation 
(MeDIP) [126,127] or by precipitation with MBPs, as in the case of methyl-binding domain 
(MBD) assays [128,129]. These enrichment based methods are similar in terms of cost, 
technique, and principles [125], however, MBD assays are unable to detect non-CG 
methylation i.e. mC, as MBPs are only known to bind methylated DNA in the context of CG 
dinucleotides (mCG).  
To carry out the necessary investigations for this thesis, an economic and sensitive method 
for mouse methylome analysis was required. Methylome analysis was favoured because 
several genes are thought to be involved in HSC ageing, and due to limited time and 
resources (HSCs are rare bone marrow cells), it was not feasible to investigate each of 
these individually. Likewise, due to limited funds, whole genome BS-seq was beyond the 
scope of this study. RRBS and MBD assays are biased towards CGIs and mCGs 
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respectively [118] and there were no suitable hybridization arrays for mouse methylation 
studies. In aggregate, MeDIP-sequencing (MeDIP-seq) [127] was the most cost effective 
method for an unbiased analysis of the mouse methylome. I therefore used this method for 
methylome analysis of HSC ageing. 
1.12 MeDIP-Seq 
MeDIP-seq [126,127] involves the use of antibodies, directed against 5mC, to enrich for 
methylated regions of the genome, followed by next generation sequencing of enriched DNA 
(Fig. 1.10). 5mC antibodies recognize DNAm in CpG and non-CpG contexts, thus offering an 
unbiased analysis of the methylome. MeDIP-Seq provides a 100–250 bp resolution of the 
methylome and although this is low compared to BS-seq (1 bp), this resolution is sufficient 
for most applications, as DNAm of neighbouring CpGs show a high correlation for up to 1000 
bp [130]. Therefore, MeDIP-Seq strikes a good balance between resolution, coverage and 
cost. Indeed, MeDIP-Seq was used to generate the first unbiased methylome of any 
mammalian genome [127] and has been shown to yield accurate and comparable results to 
the gold standard method (MethylC-seq) [118]. 
The original MeDIP-Seq protocol requires a starting genomic DNA concentration of ≥ 5 µg. 
However, HSCs are a rare cell population in mouse bone marrow (0.01–0.2%) and the 
maximum amount of DNA available for my investigation was ≤ 300 ng per sample. It was 
therefore necessary to improve the sensitivity of the MeDIP-seq assay. Additionally, a 
recently developed automated version of MeDIP-Seq, termed AutoMeDIP-Seq, was used in 
this thesis [131]. AutoMeDIP allows high throughput methylome analysis and is able to 
generate precise and accurate results [131], by minimizing human error during reactions.  
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Figure 1-10: Overview of the MeDIP-seq reaction.   
DNA is fragmented (1) and incubated with monoclonal antibody that is specific to 5mC (2 and 4). Antibody-bound 
immunoprecipitated, methylated DNA (mDNA) is then incubated with magnetic beads (3 and 4), which bind to the 5mC 
antibodies and is used to purify mDNA by magnetic capture (5). mDNA is further purified, whole genome amplified (not shown) 
and subjected to next generation sequencing on Illumina sequencing platforms (6). 
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1.13 Aims and Hypothesis 
This thesis aims to investigate the dynamics of DNA methylation during haematopoietic stem 
cell ageing. Mouse HSCs were used as a model to study mammalian HSC ageing because, 
they are easily isolated and obtainable and are the most characterised of all mammalian 
HSCs. 
I hypothesise that changes in DNA methylation occur during HSC ageing and may underlie 
the functional changes that are observed during this process. 
1.13.1 Overview of Thesis 
 Hoechst exclusion and side population analysis of the mouse bone marrow is currently the 
most cost effective method for the isolation of rare LT-HSCs [132]. I selected and used this 
method to obtain LT-HSCs and demonstrated the validity of its use in Chapter 3 of this 
thesis. As LT-HSCs are a rare cell population, it was necessary to improve the sensitivity of 
the MeDIP-seq method for use with limited starting material. I successfully optimized the 
MeDIP-seq method for a little as 50ng starting DNA concentration (Chapter 3). The 
optimized method is known as Nano-MeDIP-seq and this part of my thesis was published in 
a peer reviewed journal (Appendix) [133].  
I used Nano-MeDIP-seq to generate and compare the methylome of mouse HSCs across 
three age time points; Young (8–12 weeks), Middle aged (~12 month), Old (22-24 months). 
Based on current evidence of the mechanisms by which DNAm alters cell and tissue 
dynamics during lineage specification, ageing and carcinogenesis (Section. 1.7 and 1.10); I 
hypothesised that a global loss of DNAm will accompany HSC ageing, and several genes 
that are involved in HSC regulation will be silenced by promoter hypermethylation.  This 
hypothesis was partially supported, and I show in Chapter 4 that HSC ageing is indeed 
accompanied by global hypomethylation.  
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Previous studies have either investigated the ageing of heterogeneous HSPCs, or 
inadvertently introduced a sampling bias into their studies, by not selectively isolating the 
main population that change with age (My-bi HSCs). It is therefore likely that currently 
available gene expression data are not truly reflective of the changes that occur during HSC 
ageing.   To address this, I purified a homogenous population of lower side population cells, 
which are the cells that specifically increase with age, and performed gene expression 
(transcriptome) analysis on these (Chapter 5). Analysis of my transcriptome data identified 
novel and key biological processes that elucidate the mechanism of HSC ageing. 
I investigated the functional significance of aDMRs in HSC ageing, by integrated analysis of 
my methylome data and transcriptome data and functional validation of a candidate aDMR 
(Chapter 6). This analysis confirmed the role of DNAm in gene regulation and provided new 
insights into the dynamics of DNAm and gene expression during HSC ageing. 
Finally, I discussed my main findings and their potential implications (Chapter 7) and 
concluded by identifying areas of my thesis that could be expanded upon, to further 
elucidate the mechanisms of HSC ageing. 
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2  
2.1 Samples 
Wild type young (8-12 weeks), middle aged (~12 month) and old (22-24 months) C57BL/6 
mice were sacrificed using an approved (‗Schedule 1‘) method. A 5 month old C57BL/6 
Mouse was used for the trial sequencing run. Mice were originally from the Jackson 
immunoresearch laboratories (Bar Harbour, ME) and some of the old and middle-aged mice 
were sourced from Harlan Laboratories (Holland). All the animals used in this thesis were 
bred as well as maintained in a specific pathogen-free animal facility. 
2.2 Nucleated Bone Marrow Cells Isolation  
Whole bone marrow cells were isolated from mouse femur, tibia and in some cases, hip 
bones, as follows; 
1. Bone marrow was isolated from bones by flushing with RT 1x HBSS (Invitrogen) and 
10mM Hepes solution (Sigma Aldrich) using a 27G syringe 
2. Isolated bone marrow was chilled on ice for 5 min 
3. Erythrocytes were lysed by adding 3 volumes of cold ammonium chloride (Stem Cell 
Technologies, Vancouver, Canada) to bone marrow suspension, and incubating on 
ice for 30 sec. 1 ml FCS was then added to marrow suspension to stop the lysis 
reaction 
4. Cells were pelleted by centrifugation at 300g for 5–7 min at 40C  
5. Cell supernatant was removed by aspiration and resuspended in cold 1 ml DMEM 
(Invitrogen) with 2% FCS (Invitrogen) and 10 mM Hepes solution; henceforth referred 
to as DMEM+ 
6. Debris were removed by filtering suspension through a 40 µM nylon cell strainer 
7. 1–10 µl of isolated nucleated bone marrow cells (NBMCs) was stained with Trypan 
Blue solution and counted with a haemocytometer, under 10x magnification, using an 
inverted microscope (Leica). 
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2.3 Fluorescent Assisted Cell Sorting (FACS) 
2.3.1 Side Population Cells Phenotyping and Isolation 
1. Filtered NBMCs were pre-warmed to 370C in a closed, circulating water bath; 
henceforth referred to as water bath 
2. Pre-warmed NBMCs were transferred to tissue culture flasks (vented cap, Corning) 
and resuspended at 1x106 cells per ml of 370C DMEM+ 
3. Cell suspension was briefly incubated in a 370C water bath for 5 min 
4. Hoechst 33342 (Sigma Aldrich) DNA binding dye; henceforth referred to as Hoechst, 
was added to cell suspension at 5 µg per ml and incubated for 90 min at 370C, with 
constant mixing at 30 min intervals 
5. After 90 min, cells were transferred to 50 ml falcon tubes (BD Falcon) and pelleted by 
centrifugation, at 300g for 5–7 min at 40C 
6. Supernatant was removed by aspiration and cell preparation varied depending on 
experimental end points, as described below. 
2.3.1.1 SP Sort 
1. Cell pellets were resuspended in 1 ml cold DMEM+ and filtered using a 40 µM nylon 
cell strainer (BD plastics) 
2. Filtered cells were resuspended in DMEM+ and 2 µg per ml Propidium iodide (PI, 
Sigma Aldrich) at approximately 1x107 cells/ml 
3. Cells were sorted on the Moflo cell sorter (Beckman Coulter)  
4. Dead cells were excluded based on positive PI staining and cells with the least 
amount of Hoechst staining and an appropriate scatter profile, were isolated as lower 
SP (LSP) cells 
5. LSP cells were sorted directly into 1.5 ml Eppendorfs containing either 1x PBS 
(Invitrogen) for pooled sorts, RLT cell lysis buffer (Qiagen) for single RNA extraction 
or Stemspan Serum-Free Expansion Media  (SFEM, Stem Cell Technologies)  for ex-
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vivo culture. Cells sorted into PBS were pelleted and resuspended in up to 350 µl 
RLT cell lysis buffer (Qiagen). 
2.3.1.2 SP Phenotyping 
Here, Hoechst stained NBMCs were analysed for LT-HSC phenotype by SP; KLS; CD150 
staining. Antibody labelling was performed in a dark room, using the antibodies listed in 
Table 2.1 as follows;  
1. Approximately 1x107 cells were washed with cold 1x PBS, 2% FCS (Invitrogen) and 
10mM Hepes solution, henceforth referred to as PBS+ 
2. Cells were pelleted by centrifugation, at 300g and at 40C for 5–7 min. Supernatant 
was removed by aspiration 
3.  Cell pellets were cooled on ice for 2 min and resuspended in up to 3x106 cells/ 50 µl 
human gamma globulins (HgG) 
4. A master mix of appropriate antibodies was prepared in the case of multiple samples, 
and transferred into the bottom of a 5 ml polypropylene snap top tubes (FACS tube) 
by pipetting 
5.  1–5x106 cells-HgG suspension per sample was added to antibodies, and incubated 
in the dark at 40C for 30 min 
6. Approximately 1x106 cells-HgG suspension was incubated separately with individual 
antibodies as single staining (compensation) controls.  
7. After 30 min, cells were washed with 20 volumes of 1x PBS+ and pelleted at 40C by 
centrifugation at 300g 
(For biotinylated antibodies; after 30 min of primary antibodies incubation, cells were 
washed and pelleted as described above and resuspended in streptavidin conjugated 
fluorochromes and PBS+. Cells were then incubated at 40C for 30 min, after which 
they were washed according to step 7). 
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8. Cell supernatant was removed by aspiration and cells were resuspended in 1 ml 
PBS+ and 2 µg per ml PI 
9. Hoechst and antibodies stained cells were analysed on the LSRII (BD Biosciences). 
 
Table 2-1: Phenotyping antibodies 
Antibody (antimouse) Fluorochrome Source 
CD150 Phycoerythrin (PE) Biolegend 
Sca-1 PE - Cyanine 7 (PE/Cy7) Biolegend 
CD 117 (c-Kit) Allophycocyanine - Cy7 (APC/Cy7) eBioscience 
Lineage antibody cocktail Biotin BD Bioscience 
Streptavidin Percp BD Bioscience 
CD45.2 Fitc Biolegend 
CD 48 PE – Cy5 Biolegend 
 
2.3.1.3 Post Sort SP Phenotying  
Approximately 1000–10000 freshly isolated or ex vivo cultured LSPs in a background of 
1x105 human KG1a cells, were analysed for LT-HSC enrichment by KS; CD150; CD48 
antibody staining (Table. 2.1) staining, as described in Section 2.3.1.2. However, here cells 
were resuspended in 500 µl PBS+ and 1:1000 Dapi (Sigma Aldrich) and analysed on the 
Cyan ADP (Beckman Coulter). Mouse cells were differentiated from background human cells 
by positive staining for the anti-mouse CD45.2 antibody.  
2.4 Cell Culture 
2.4.1 KG-1a Cell lines 
KG-1a, human acute myeloid leukaemia cell line, was cultured in 10% FCS RPMI cell culture 
medium and maintained at approximately 8x105 cells/ml under 5% CO2 in a 37
0C incubator; 
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2.4.2 Ex vivo Culture of Primary HSCs  
1. SP cells were sorted into 1.5 ml falcon tubes containing 300 µl serum free 
enrichment media (SFEM)  
2. Sorted cells were resuspended at 1000–2000 cells per 200 µl SFEM  
3. 200 µl cell suspensions were transferred to a well in a round bottom 96 well plate 
(Corning) and cultured at 370C under 5% CO2 
4. Cells were cultured ex vivo for 4–5 days in the presence of 2 µg Heparin and STIFA 
cytokine cocktail (Table. 2.2). 
      Table 2-2 : Ex vivo cytokines (STIFA) 
Cytokines (STIFA) Concentration/200 µl Source 
recombinant mouse SCF 3 ng Peprotech 
recombinant mouse TPO 6 ng Peprotech 
recombinant mouse IGF-II 6 ng R&D 
recombinant human FGF-I 3 ng R&D 
recombinant mouse ANGPTL3 30 ng R&D 
 
2.4.2.1 Azacytidine Treatment of HSCs 
SP cells were cultured ex vivo as described above (Section 2.4.2). Cells were treated with 
two doses of 0–2 µM 5-Aza‘deoxyCytidine (5-Aza‘dC). The first dose was applied 
approximately 18 h after culture was initiated. Cells were maintained for a further 30 h after 
which 50% of media was replaced with fresh 100 µl SFEM, 1 µg Heparin and 33.3% STIFA 
cytokine cocktail.  50% of the initial 5-Aza‘dC dose was added to cells 18 h after media 
replacement and cells were maintained in culture for a further 30 h. Treated SP cells were 
cultured ex vivo for a total of 4 days.   
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2.5 Dual DNA/RNA Extraction 
For pooled sorts, DNA and RNA were simultaneously isolated from up to 8x104 LSP cells.  
1. Cells were pelleted by centrifugation at 300g for 5–7 min at 40C, and the supernatant 
was removed by gentle pipette aspiration 
2. Cells were resuspended and lysed in 75 µl RLT plus lysis buffer (Qiagen) and 1% β-
Me (Sigma Aldrich) 
3. Up to four sets of 75 µl cell lysates were pooled for a total of 8x104 cells 
4. Cell lysate volume was adjusted to 350 µl with RLT plus lysis buffer and 1% β-Me 
5. For single sorts, up to 1.5x104 LSP cells were sorted directly into 350 µl RLT plus 
lysis buffer with 1% β-Me 
6. DNA and RNA were extracted using the AllPrep DNA/RNA Micro Kit (Qiagen), 
according to manufacturer‘s instruction 
7. Extracted DNA was eluted in approximately 85 µl or 35 µl EB buffer for pooled sorts 
and single sorts respectively, while RNA was eluted in 15 µl RNAse free water.  
Cells in lysis buffer and extracted RNA were maintained at -800C until used. Extracted DNA 
was maintained at -200C for long term storage. 
2.6 Post Reaction DNA Purification 
DNA was purified from reactions using Agencourt Ampure XP (Beckman Coulter). Ampure 
XP is a Solid Phase Reversible Immobilisation (SPRI), paramagnetic-bead-based 
technology, which allows the highly efficient purification and recovery of DNA fragments from 
reactions. Ampure XP was used to purify DNA and cDNA from reactions according to 
manufacturer‘s instruction. 
1. DNA or cDNA was mixed with 1.8x RT beads and incubated at RT for 5–15 min to 
allow beads to bind to DNA  
2. Beads were separated from supernatant by magnetic capture 
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3.  Immobilised beads were washed twice with 70% ethanol 
4. Beads were left to air dry at room temperature for at least 5 min 
5. Beads were resuspended with EB buffer (Qiagen) and left for 1 min at room 
temperature 
6. Beads were separated from supernatant by magnetic capture 
7. The supernatant, which contains purified DNA was collected and stored at -200C or 
used in downstream applications as appropriate. 
 In addition to using Ampure for reaction purification, I also adapted this protocol for the 
retention or exclusion of specific DNA fragment sizes, by varying the ratio of beads to DNA 
between 1.8x and 0.8x during purification (Section 3.4.2). 
2.7 Nucleic Acid Quantification  
2.7.1 NanoDrop Spectrometer 
Purified high concentration (≥10 ng/ul) DNA and RNA samples were quantified by 
spectrometry, using the NanoDrop spectrometer (Thermo SCIENTIFIC). 1 µl of samples was 
typically loaded on the NanoDrop for quantification. The ratio of absorbance at 260nm and 
280nm was used to asses sample quality. DNA samples with a ratio of 1.8 were generally 
accepted as good quality, while a ratio of 2.0 was accepted for RNA samples. 
2.7.2 Bioanalyzer Microfludics Platform 
The Bioanalyzer (Agilent) is a microfluidics based quantification assay. This was used to size 
and quantify samples of low concentrations and/or for which highly accurate size 
determination was required. The Bioanalyzer was also used to determine RNA Integrity 
Numbers (RIN) of RNA samples. 1 µl of samples were typically quantified using Bioanalyzer 
DNA High Sensitivity assay and chips or the Bioanalyzer RNA Pico assay and chips, all by 
Agilent and used according to manufacturer‘s instructions. 
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2.7.3 Qubit Fluorometer 
Qubit (Life technologies) was used to quantify low concentration single and double stranded 
DNA and RNA samples, for which highly accurate and precise quantification was essential. 1 
µl of samples were typically quantified using the Qubit DsDNA High Sensitivity assay, Qubit 
SsDNA assay or Qubit RNA assay, according to manufacturer‘s instructions. 
2.8 MeDIP-seq 
160–300 ng mouse genomic DNA was analysed for genome wide methylation, using an 
optimised version of the original MeDIP-seq protocol, termed Nano-MeDIP-seq (Section 
3.4). The MeDIP-seq method included multiple steps, which are outlined below. 
2.8.1 DNA Fragmentation 
 Genomic DNA was fragmented by sonication on the Bioruptor (Diagenode).  
1. Sonicator was pre-chilled by filling water bath with crushed ice and leaving for 15 min 
2. DNA was placed in a 1.5 ml tube and sonicated on ‗high‘ for six, 15 min, cycles, each 
consisting of 30 sec on/off periods, to generate a fragment size range of 100–400 bp 
and fragment peak size of approximately 200 bp 
3. DNA fragment size was validated on the Agilent Bioanalyzer 2100, using DNA high 
sensitivity chips and reagents, according to manufacturer‘s instructions. 
2.8.2 Library Preparation (Part 1) 
Library preparation was carried out using the NEBNextTM DNA Sample Prep Master Mix Set 
1 Kit (New England BioLabs - NEB), according to manufacturer‘s instruction.  
2.8.2.1 End Repair 
1. End Repair reaction was prepared on ice as follows: 
Table 2-3: End repair mix 
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Component Volume 
NEBNext End Repair Enzyme mix 5 µl 
NEBNext End Repair Reaction Buffer (10X) 10 µl 
Fragmented DNA 85 µl 
Total Volume 100 µl 
 
2. The reaction mix was incubated at 200C for 30 min 
3.  End repaired DNA was purified using Ampure beads and eluted in 37 µl EB buffer 
(Qiagen). 
2.8.2.2 dA- Tailing 
1. dA-Tailing reaction was prepared on ice as follows: 
Table 2-4: dA-Tailing mix 
Component Volume 
Klenow Fragment (3‘        5‘ exo) 3 µl 
NEBNext dA-tailing Reaction Buffer (10X) 5 µl 
Sterile H2O 5ul 
Purified End-Repaired, blunt-ended DNA  37 µl 
Total Volume 50 µl 
 
2. The reaction was incubated in a thermocycler at 370C for 1 h  
3. dA tailed DNA was purified using Ampure beads and eluted in 25 µl EB buffer 
(Qiagen). 
2.8.2.3 Adapter Ligation  
1. Adaptor ligation reaction was prepared on ice as follows: 
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Table 2-5: Adapter ligation mix 
Component Volume 
Quick T4 DNA Ligase 5 µl 
Quick Ligation Reaction Buffer (5x) 10 µl 
DNA Adaptors (up to 5 µM) 10 µl 
End Repaired, Blunt, dA- Tailed DNA  25 µl 
Total Volume 50 µl 
 
2. The reaction was incubated in a thermocycler at 180C for 2 h 
3. Adaptor ligated DNA was purified using Ampure beads and eluted in 57 µl EB buffer. 
2.8.3  Methylated DNA Immunoprecipitation 
MeDIP was automated using the SX-8G IP-Star (Diagenode), according to manufacturer‘s 
instruction. Reagents (Diagenode) were prepared and dispensed in the appropriate wells of 
0.2 ml 12-well strip tubes and loaded on the IP-Star as described below. 
1. 150 µl 1x MagBuffer was prepared per sample by adding 120 µl of sterile H2O to 30 
µl 5x MagBuffer  
2. A minimum of 16 µl of diluted antibody was prepared for up to six IP reactions, by 
adding 15 µl of sterile H2O to 1 µl (2 µg) of 5-mC monoclonal mouse IgG1 antibody 
(Clone. b MeDIP-grade, Diagenode) 
3. Antibody mix was prepared on ice as follows:  
Table 2-6: Antibody mix 
Antibody Mix Volume/IP 
Diluted antibody 2.40µl 
MagBuffer A (5X) 0.60 µl 
MagBuffer C 2.00 µl 
Total Volume 5.00 µl 
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4. Incubation (IC) mix was prepared on ice as follows:  
Table 2-7: Incubation mix 
IC Mix Volume/IP 
MagBuffer A (5X) 24 µl 
MagBuffer B 6 µl 
Methylation control DNA  3 µl 
Purified Adapter Ligated DNA 57 µl 
Total Volume 90 µl 
 
a. IC mix was incubated at 1000C for 10 min  
b. Samples were immediately placed on ice and incubated for 10 min.  
c. 75 µl of incubation mix was used in the immunoprecipitation (IP) reaction, 
while the remaining 15 µl was stored at -200C for later use as the negative IP 
control, henceforth referred to as Input DNA 
5. IP mix was prepared on ice as follows: 
Table 2-8: Immunoprecipitation mix 
IP Mix Volume/IP 
Antibody Mix (step 3) 5 µl 
1x MagBuffer A (step 1) 20 µl 
IC Mix (step 4) 75 µl 
Total Volume 100 µl 
 
6. Reagents were dispensed in appropriate wells of a 12-well strip 0.2 ml tube, as listed 
in Table 2.9, and loaded onto the IP-Star 
Table 2-9: Auto-MeDIP reagents 
Well 
number Reagent Volume  
1 DNA isolation Buffer (DIB) 92.5 µl 
2 N/A N/A 
Materials and Methods Chapter 2 
 
57 
 
    
 
7. IP was performed for 15 h and MeDIP DNA was eluted into DIB in well 12 of the 12-
well strip tube 
8. 7.5 µl of Input DNA was manually dispensed into DIB in well 1 of the 12-well strip 
tube 
9. 1 µl of 20 mg/ml PCR grade proteinase K (Roche) was manually added to MeDIP 
and Input reactions, to digest antibody and release antibody-bound methylated DNA  
10. The proteinase K reaction was incubated at 550C for 15 min, then to 1000C for 15 
min to stop the reaction 
11. MeDIP DNA was separated from Dynabeads by magnetic capture 
12. 9 µl of MeDIP and Input DNA was analysed by quantitative polymerase chain 
reaction (qPCR) to assess the recovery of spiked-in methylation control DNA and 
specificity of the MeDIP reaction (QC1; Section 2.8.3.1) 
13. The remaining Input and MeDIP DNA were purified using Ampure beads and eluted 
in 15–30 µl EB buffer. Purified DNA was stored at -200C until used. 
2.8.3.1 Quality Control (1) – QC1 
Here, the methylation control DNA that was included in the IC mix; a combination of 
methylated and unmethylated lambda fragments and henceforth referred to as Lambda 
spike, was analysed. Efficiency of the MeDIP reaction was measured by qPCR, using nested 
primers directed against either the methylated or the unmethylated lambda fragment. 
3 Magnetic (Dyna)beads ( Dynabeads M-280 Sheep anti-mouse IgG) 10 µl 
4 1x Magbuffer A  50 µl 
5 1x Magbuffer A  50 µl 
6 N/A N/A 
7 IP mix (See step 5 above) 100 µl 
8 MagWash Buffer - 1 100 µl 
9 MagWash Buffer - 1 100 µl 
10 MagWash Buffer - 1 100 µl 
11 MagWash Buffer - 2 100 µl 
12 DNA isolation Buffer (DIB) 100 µl 
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Lambda spike and primers (Table. A-1) were obtained from Dr L.M Butcher and were 
constructed as previously described [131].  
1. The qPCR assay was performed in triplicates for both MeDIP and Input DNA and 
prepared on ice as follows: 
Table 2-10: qPCR reaction mix 
Component *Volume/Reaction   
10 µM Primer Pair  0.625 µl 
Sterile H2O 4.375 µl 
2x SYBR qPCR master mix (Eurogentec)  6.25 µl 
MeDIP or Input DNA 1.25 µl 
Total Volume 12.5 µl 
 
*A reaction master mix was prepared for a minimum of three reactions, as stated 
amounts, such as 0.625 µl, are difficult to pipette accurately.  
2. qPCR was carried out on a real time PCR machine (Applied Biosystems) using the 
following program:  
Table 2-11: qPCR program 
STEP TEMP TIME CYCLES 
Activation 950C  5 min 1 
Denature 950C 
600C 
15 s 
1 min 
40 cycles 
Anneal/Extend 
Dissociation (melting curve) 
 
3. Recovery and specificity was calculated as follows: 
a. Recovery -  As the quantity of Input DNA is only 10% of that of MeDIP, the Ct 
value obtained for Input was adjusted prior to calculating Recovery, using the 
formula;  
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Adjusted Input Ct = Input Ct – log [2AE(10)] 
Where AE is the amplification efficiency expressed as a number, e.g. 100% AE = 1 and 10 
represents the dilution factor of Input to MeDIP (i.e. x10) 
Recovery was then calculated as;   
Recovery (%) = 2AE (Adjusted Input Ct - MeDIP Ct) x 100 
 
b. Specificity was calculated as; 
 
 
 
A MeDIP experiment was considered to be successful if specificity was ≥ 90% and recovery 
of unmethylated DNA was ≤ 1%. 
2.8.4 Library Preparation (Part 2) 
MeDIP reactions, which had passed QC1, were used in the second part of library 
preparation. This involves adapter-mediated PCR amplification of MeDIP and Input DNA. As 
the lambda DNA spike was not adapter ligated, only the sample DNA was amplified and 
sequenced here.  
1. The PCR reaction was set up on ice as follows: 
Table 2-12: Adapter-mediated PCR reaction mix 
Component Volume/reaction   
PCR. PE. 1.0 (10 µM stock) 5 µl 
PCR.PE.2.0 (10 µM stock) 5 µl 
MeDIP or Input DNA 15 µl 
 Specificity = 1 –     
                                 
 
Methylated DNA recovery    
Unmethylated DNA recovery    
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2. PCR reaction was incubated on a thermocycler, under the following conditions:    
Table 2-13: Adapter-mediated PCR program 
STEP TEMP TIME CYCLES 
Initial Denaturation 980C 30 sec 1 
Denaturation 
Annealing 
Extension 
980C 
650C 
720C 
10 sec 
30 sec 
30 sec 
12-15 
Final Extension 720C 5 min 1 
           40C                              Hold 
 
3. PCR products were purified with Ampure beads and eluted in 18 µl EB buffer. 
Purified DNA was stored at -200C until used 
4. 1.5 µl of purified DNA was quantified on the Nanodrop spectrophotometer 
5. 0.5 µl of purified DNA was diluted up to 1 µl with sterile water and analysed on the 
bioanalyzer. 
2.8.5 Library Size Selection 
PCR amplified DNA was size selected to obtain uniform DNA sequencing libraries, with the 
required insert size. An insert size of 180–230bp was created for all MeDIP samples in this 
project.  
1. 2% Tris Acetate EDTA (TAE, Thistle Scientific), Low melting point (LMP) agarose 
(VWR) gels were prepared as described below: 
i. 2 g of LMP agarose gel was dissolved in 100 ml 1xTAE (for small 
gels) 
PhusionTM or KapaTM High-Fidelity PCR Master Mix, 2x 25 µl 
Total Volume 50  µl   
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ii. Agarose mix was heated in a microwave oven at 800watts for 2 min 
iii. Gel was cooled to ~300C 
iv. Ethiduim bromide (EtBr) was added to agarose to obtain a final 
concentration of 0.5 µl/ml  
v. Gel was transferred to a casting tray with 3 mm-wide gel combs and 
left to set on an even surface, at room temperature. 
2. Sample DNA was mixed with 6x loading dye (Fermentas) and loaded onto wells 
within the agarose gel 
3. Sample DNA was flanked by two wells containing 1 µg of 50bp DNA ladder (NEB). A 
gap of at least 2cm was retained between sample DNA and DNA ladder wells, or 
between multiple DNA samples 
4. Gel electrophoresis was performed for 100 min at 100 volts, in TAE buffer containing 
EtBr (0.5µg/ml)  
5. After electrophoresis, gel was visualised on a UV transilluminator 
6. A strip of aluminium foil was placed underneath the gel to prevent cross linking of 
DNA  
7. A library size of 300–350bp was excised with a clean scalpel. This provided an insert 
size of 180–230bp, which is the library size without the 120bp adapter/primer 
sequences 
8. For contingency purposes, two 50bp size-range gel bands above and below the 300–
350bp library were also excised 
9. Samples were purified from agarose with the Minelute Gel DNA extraction kit 
(Qiagen), according to a modified version of manufacturer‘s instructions (Section 
3.4.6)  
10. Library DNA was eluted in 12 µl Elution buffer (Qiagen).  
11. 1 µl of library DNA was quantified and size verified on the Bioanalyzer and DNA high 
sensitivity kit (Agilent).  
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12. 1 µl of library DNA was quantified with the Qubit fluorometer and Qubit high 
sensitivity dsDNA quantification kit (Invitrogen) 
13. 2 ng of library DNA was diluted up to 9 µl with sterile H2O and analysed by qPCR to 
validate the enrichment of known methylated genomic regions as detailed in Section 
2.8.5.1 
2.8.5.1 Quality Control (2) – QC2 
The aim of QC2 was to verify that the gel extracted library remained enriched for methylated 
DNA, and depleted for unmethylated fragments, following PCR. In contrast to QC1, QC2 
involves the qPCR of endogenous DNA fragments, as the lambda DNA spike used in QC1 
was not PCR amplified and therefore exists as negligible amounts in the library. Two mouse 
regions (Table. A-1) of known methylation status and of the similar CpG density (8%) were 
used as methylated and unmethylated controls. The methylation status of these regions was 
previously ascertained within the ‗Medical Genomics‘ group.  qPCR assays were performed 
in triplicates as described in Section 2.8.3.1. The comparative Ct method was used to 
calculate fold enrichment (FE) as follows: 
)Ct(Ct
)Ct(Ct
thMeDIP_unmethinput_unme
MeDIP_methinput_meth
2AE
2AE
 ratio enrichment Fold


 
                                
Fold enrichment was occasionally calculated without the use of Input DNA. This is because 
the primers used for QC2 in this study were verified to have similar amplification efficiency 
(Appendix-Figure 1). Fold enrichment without Input DNA was calculated as shown above.  
2.8.6 MeDIP - Sequencing 
MeDIP libraries with a minimum fold enrichment of 100 for endogenous methylated regions 
were subjected to next generation sequencing. 
Sequencing was carried out at a core facilities centre on the Genome Analyzer IIx or the Hi-
SEQ platform (Illumina), by a specialist technician, according to manufacturer‘s instructions.  
Or if no Input DNA = 2AE (CtMeDIP_unmeth
  _  Ct
MeDIP_meth
) 
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2.9 Bisulfite Pyro-sequencing 
2.9.1 Assay Design 
Forward, reverse and sequencing primers were designed for each pyro-sequencing assay, 
using the PyroMark assay design software v2.0 (Qiagen) as follows; 
1. DNA sequence of target region was obtained from the UCSC genome browser (July 
2007, NCBI Build 37), using the ‗get DNA‘ function. Target DNA was flanked at either 
side with at least 50 bp extra, to allow flexibility during assay design 
2. UCSC sequence was in silico bisulfite converted by the assay design software. 
3. Multiple primer sets were designed for each assay 
4. Top scoring primer sets were manually inspected and selection parameters were 
adjusted as required 
5. PCR Primers were selected for further analysis, based on the following criteria: 
 Primer length of 20–32 nucleotides 
 High test CpG coverage 
 Amplicon length of less than 200 nucleotides 
 Melting temperature (Tm) of between 500C and 600C 
 Maximum Tm difference of 30C 
 No self-complementarity or secondary structures  
 %GC of 25–50 
 No alternate annealing sites on DNA template. When this was unavoidable, a 
maximum of two sites were permitted, provided annealing was very weak and 
outside of target DNA region. 
6. Sequencing Primers were selected for further analysis, based on the following criteria 
 Primer length of 15–25  
 No alternate annealing sites on PCR amplicon 
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 No self-complementarity or secondary structures 
2.9.2 Assay Validation 
Test PCR reactions were performed for each PCR primer to confirm that the primer 
specifically amplified target DNA, and no primer dimers were generated during the PCR 
reaction. Primers not meeting these criteria were discarded or redesigned where possible. 
HPLC purified assay primers were obtained from Sigma Aldrich and one PCR primer, 
usually the reverse, was 5‘ biotinylated. 
Bisulfite converted in vitro methylated, and whole genome amplified (WGA) DNA, were pyro-
sequenced to validate the sensitivity of selected assays. 
2.9.2.1 In vitro Methylation 
1. In vitro methylation reactions were set up on ice as follows 
Table 2-14: In vitro methylation reaction mix 
Component Volume/reaction 
10× NEBuffer 2 2 µl 
S-adenosylmethionine (1.6 mM) 2 µl 
SssI methyltranseferase (4 U/µl) 1 µl 
Sterile H2O 10 µl 
DNA (3 µg) 5 µl 
Total Volume/Reaction 20 µl 
 
2. Reaction was incubated in a thermocycler and incubated for 2 h at 370C, followed by 
20 min at 65°C   
3. Reaction was purified using Ampure beads, and eluted in 60 µl EB buffer 
4. In vitro methylation of DNA was verified by digestion with methylation sensitive 
restriction (HPAII, HpyCH4IV and BSTVI) enzymes. Whole genome amplified (WGA) 
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DNA was also digested in parallel, and used as the unmethylated control. Digestion 
reaction was prepared on ice as follows:  
Table 2-15: Methylation-sensitive restriction enzyme digestion mix 
Component Volume/reaction 
10× NEBuffer 1 4 µl 
HPAII (10 U/µl) 1 µl 
HpyCH4IV (10 U/µl) 1 µl 
DNA (200 ng) 
Up to 34 µl 
Sterile H2O 
Total Volume 40 µl 
 
5. Digestion reaction was incubated in a thermocycler for 1 h at 370C 
6. 1 µl BSTVI (10 U/µl) restriction enzyme was added to the digestion incubation, at the 
end of step 5. (A separate reaction was required for this digestion as BSTVI is active 
at 600C, while HPAII and HpyCH4IV at 370C) 
7. Reaction was incubated for 1 h at 600C 
8. DNA fragment size was verified on 2% agarose gel (prepared as described in 
Section 2.8.5, but using standard agarose) 
9. Gel electrophoresis was performed for 1 h at 120 volts 
2.9.2.2 Whole genome Amplification 
1. 10 ng of DNA was fragmented and whole genome amplified, using the GenomePlex 
WGA 2 kit (Sigma Aldrich), according to manufacturer‘s instructions 
2. WGA DNA was purified using Ampure beads, and eluted in 60 µl EB buffer 
3. WGA reaction was validated by quantifying DNA, and by restriction enzyme digestion 
as described above (Section 2.9.2.1) 
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2.9.3 Bisulfite Conversion 
1. 50 ng DNA or 1x104 cells per sample were bisulfite converted, and purified using the 
EpiTect Plus (LyseAll) Bisulfite Kit (Qiagen), according to manufacturer‘s instructions 
2. Conversion efficiency was determined by qPCR (Section 2.8.3.1) 
3. Bisulfite converted DNA was maintained at -200C until used. 
2.9.4 PCR Amplification of Bisulfite Converted DNA 
Target regions were PCR amplified from bisulfite converted DNA, using the primers 
described in Section 2.9.1 and the PyroMark PCR kit, according to manufacturer‘s 
instructions, using the following cycling conditions: 
Table 2-16: Bisulfite conversation PCR reaction 
        STEP TEMP TIME CYCLES 
Initial Denaturation 950C 15 sec 1 
Denaturation 
Annealing 
Extension 
940C 
560C 
720C 
30 sec 
30 sec 
30 sec 
45 
Final Extension 720C 10 min 1 
         40C                                  Hold 
 
PCR products were verified by gel electrophoresis on standard agarose gels, as previously 
described (Section 2.9.2.1) 
2.9.5 Pyro-sequencing 
Pyro-sequencing of bisulfite converted PCR amplified DNA was performed on the PyroMark 
Q96 MD Pyro-sequencer, using PyroMark Gold Q96 reagents, according to manufacturer‘s 
instructions. Briefly; 
1. Biotinylated PCR products were bound to Streptavidin beads 
Materials and Methods Chapter 2 
 
67 
 
2. Bead-bound PCR products were washed with freshly prepared 70% ethanol  
3. Bead-bound PCR products were denatured with 0.2 M NaOH 
4. Bead-bound PCR products were washed with 1x Wash buffer (Qiagen) 
5. PCR products were released into 96 well PSQ plates (Qiagen), containing the 
appropriate sequencing primer (0.3 µM) (Section. 2.9.1) 
6. Sequencing primer was annealed to PCR products by heating the PSQ plate to 800C 
for 2 min 
7. PCR products were cooled to room temperature and pyro-sequenced. 
2.10 RNA-seq 
RNA-sequencing libraries were prepared with the Tru-seq RNA sample preparation kit 
(Illumina), according to manufacturer‘s instructions. Enzymatic reactions were purified using 
1.8–0.8x Ampure beads as previously described. 
 Briefly; 
1. mRNA was isolated from 50–100 ng total RNA by oligo(dT) magnetic-bead 
enrichment 
2. Purified mRNA was fragmented and converted to double stranded cDNA 
3. cDNA was end repaired, A-tailed and adapter ligated 
4. Adapter-ligated cDNA was whole genome amplified in a thermocycler, under the 
following cycling conditions: 
Table 2-17: RNA-seq PCR reaction 
STEP TEMP TIME CYCLES 
Initial Denaturation 980C 30 sec 1 
Denaturation 
Annealing 
Extension 
980C 
650C 
720C 
10 sec 
30 sec 
30 sec 
12 
Materials and Methods Chapter 2 
 
68 
 
Final Extension 720C 5 min 1 
          40C                               Hold 
 
5. 1 µl  PCR amplified sequencing library was assessed on the Bioanalyzer, to verify 
fragment size 
6. Sequencing libraries were quantified, using the Qubit fluorometer and dsDNA assays 
7. cDNA libraries were subjected to next generation sequencing, at a core facilities 
centre, on the Genome Analyzer IIx or a Hi-SEQ platform (Illumina), by a specialist 
technician, according to manufacturer‘s instructions.  
2.11 Candidate Gene Expression Analysis 
The expression of single genes were analysed for quantitative reverse transcription-PCR 
(qRT-PCR), on a real time PCR machine (Applied Biosystems) 
2.11.1 cDNA Synthesis 
0.5–1x104 cells per sample were converted into single stranded cDNA, using the SuperScript 
III CellsDirect cDNA Synthesis kit (Invitrogen), according to manufacturer‘s instructions. 
Briefly; 
1. Cells were resuspended in lysis buffer to lyse cells.  1 µl RNaseOUT (40 U/µl, 
Invitrogen) and 0.5 µl SUPERase.In (20 U/µl, Ambion) RNase inhibitors were 
included, per 10 µl, to prevent RNA degradation by RNases during cell lysis. (The 
addition of SUPERase.In is a deviation from the original protocol) 
2. Cell lysate was treated with DNase I to digest any contaminating DNA 
3. cDNA was synthesised from mRNA using oligo(dT) primers and SuperScript III 
reverse transcriptase 
4. 2 units of RNase H were added per 30 µl reactions, to degrade any remaining 
template RNA. 
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2.11.2 RT-qPCR 
The equivalent of 250–500 cells was used for each RT-qPCR reaction. TaqMan gene 
expression assays, which span exon boundaries, were used in this study. A stably 
expressed housekeeping gene, β-Actin, was used as reference control for all gene 
expression assays. Each reaction was performed in two to three technical replicates.  
1. RT-qPCR reactions were prepared on ice as follows: 
Table 2-18: RT-qPCR reaction 
Component Volume/reaction 
20x TaqMan Assay 1 µl 
2x TaqMan Universal Master Mix II 10 µl 
cDNA 
Up to 9 µl Sterile H2O 
Total Volume 20 µl 
 
2. RT-qPCR reaction was performed on a real time PCR machine (Applied Biosystems) 
as follows: 
Table 2-19: RT-qPCR program 
 
2.11.3 RT-qPCR Data Analysis 
The comparative CT (ΔΔCT) method was used to calculate relative gene expression in this 
study as follows; 
STEP TEMP TIME CYCLES 
Activation 950C 10 min 1 
Denature 950C 
600C 
15 s 
1 min 50 cycles Anneal/Extend 
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ΔCT (test) = CT(test_target) - CT(test_ref) 
ΔCT (control) = CT(control_target) - CT(control_ref) 
ΔΔCT = ΔCT (test) - ΔCT (control) 
FC = 2-ΔΔCT  
1. The Ct value for target gene was normalised to that of β-Actin (reference). This was 
calculated individually for both test and control samples as follows: 
 
 
 
2. Normalised CT values (ΔCT) were compared to determine differences in gene 
expression as follows: 
 
 
3. Fold change (FC) was calculated from ΔΔCT as follows: 
 
2.12 Data Analysis 
2.12.1 MeDIP-seq Data Analysis 
MeDIP-seq data was analysed by Dr Gareth A. Wilson of UCL Cancer Institute, Medical 
Genomics group, using the MeDUSA [134] and MEDIPS [135] computational tools as 
follows: 
1. Two separate FASTQ files, each corresponding to either the forward or the reverse 
DNA sequence reads were generated from raw MeDIP-seq data 
2. FastQC v0.9.4 (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) was used to 
perform quality control of the reads   
3. BWA [136] v0.5.8 was used to align MeDIP-seq reads to the mouse reference 
genome (mouse genome build 37) using default settings 
4. Aligned reads were filtered to retain only the reads that mapped as a true pair 
5.  MeDUSA v1.0.0 was used to discard read pairs in which neither read scored a BWA 
alignment score ≥ 10,  and to discard all but one read from groups of non-unique 
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reads (i.e. reads that aligned to the exact same start and stop position on the same 
chromosome)  
6. The MEDIPS package was used to perform MeDIP-seq specific quality control and to 
generate genome-wide methylation scores  
7. Genome-wide correlation between and within sample sets were calculated using 
QCSeqs from the Useq package [137]. A 500 bp sliding (250 bp increments) window, 
consisting of at least 5 reads, was used to calculate sample correlations. 
8. Regions containing a minimum of 10 reads (summed from a comparison set) were 
assessed for  differentially methylated regions (DMRs), using the Bioconductor 
package DESeq v2.10 [138] 
9. DMRs were placed in their relevant Ensembl (Build 62) annotated features, using 
custom perl scripts and bedtools [139] v2.10.2 
2.12.2 RNA-seq Data Analysis 
RNA-seq data was analysed by Dr Warren Emmett of UCL Genomics, using the RSEM [140] 
and DESeq [138] computational tools as described below: 
1. BOWTIE [141] was used to align cDNA sequence reads to the mouse reference 
transcriptome library (mm9 genome build) 
2. Aligned files were used to estimate transcript counts and transcript abundance 
3. DESeq v2.10 was used to normalise count data according to library size, and to 
estimate the variance between observed data and the calculated mean 
4. Differential expression of transcripts between samples was assessed by DESeq 
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2.12.3 Gene Enrichment Analysis 
2.12.3.1 DMR Enrichment Analysis 
GREAT; Genomic Regions Enrichment of Annotations Tool, was used to predict the 
biological functions of DMRs, by looking for enriched annotations that were associated with 
the genomic regions. 
1. The genomic coordinates of DMRs were used as input for GREAT v2.0.2 
(http://great.stanford.edu/public/html/index.php) 
2. The GREAT association rule was adjusted such that, each gene in the genome was 
assigned a proximal regulatory domain of at least 5 kb upstream, and 1 kb 
downstream of the TSS, and a distal regulatory domain of up to 100 kb in both 
directions  
3. Each DMR was associated with all the regulatory domains (described in Step 2) it 
overlapped, as well as with their putative target genes. GREAT then performed 
enrichment analysis of functional annotations that were associated with DMRs. 
2.12.3.2 Differentially Expressed Gene (DEG) Enrichment Analysis 
Ingenuity pathway analysis (IPA, https://analysis.ingenuity.com/pa/) was used to determine 
functional enrichment of differentially expressed genes; 
1. Ensembl transcript ID of differentially expressed genes were input onto IPA 
2. Annotated experimental and prediction based evidence from mammalian species, 
within the Ingenuity knowledge base, was used to determine functional associations 
within data sets. 
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3  
3.1 Introduction 
One aim of this thesis was to analyse the methylome of phenotypically defined long-term 
haematopoietic stem cells (LT-HSCs) with age. To do this, I isolated LT-HSCs using the side 
population (SP) method [16]. The SP compartment contains all the primitive cells of the 
mouse bone marrow (BM) [16] and these cells can be isolated based on their unique ability 
to effectively efflux the Hoechst DNA binding dye. SP is a cost effective method for isolating 
LT-HSCs as this method does not require the use of additional markers [13]. Commonly 
used markers for defining HSCs are summarised in Table 3.1 
 Table 3-1: Common HSC phenotyping markers. 
 
LT-HSCs are a rare population of cells, accounting for 0.01–0.2% of the mouse bone 
marrow [7]; as a result, a methylome analysis method with low DNA input requirements was 
needed to complete this study. As discussed in Chapter one, MeDIP-seq was the most 
Phenotype HSC Property Pros Cons 
c-Kit
+
,
 
Sca-1
+
, Lin
 -/low 
(KLS) 
LT-HSCs; Short-Term 
HSCs (ST-HSCs) and 
Multi-potent progenitors 
(MPPs) [142] 
Well established and 
requires the use of fewer 
markers. Contains a 
higher frequency of 
primitive cells 
Heterogeneous mix of 
cells 
Lower Side Population 
(LSP) LT-HSCs [13] 
Cheap and identifies 
HSCs based on functional 
(ABC/G2) activity 
Requires careful expertise 
as under-stained non 
HSCs will also appear as 
SP cells (False positives). 
 
KLS; CD48
-
; CD150
+ 
LT-HSC [14] 
Identifies a homogeneous 
population of LT-HSCs. 
LT-HSCs can be sub 
fractionated based on 
CD150 expression 
Costly, requires many 
markers and extensive 
set-up. Prone to false 
negatives (e.g. under-
stained cells). LT-HSCs 
are heterogeneous for 
CD150
 
expression [15] 
KLS; CD34
-
; Flk2
- 
LT-HSC [12,143] 
Identifies a homogeneous 
population of LT-HSCs 
Costly, requires many 
markers and extensive 
set-up. Prone to false 
negatives (e.g. under-
stained cells). 
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suitable method for methylome analysis, as it offers a relatively unbiased view of the 
methylome. However, at the time of this study, MeDIP-seq required at least 5 µg starting 
DNA concentrations. It was therefore necessary to optimise the sensitivity of this method for 
the analysis of rare samples such as LT-HSCs.   
In this Chapter, I first describe the successful isolation of C57BL/6 (b6) mouse LT-HSCs at 
three age time points; Young, 8–12 weeks; Middle-aged (Mid), ~12 Months; Old, 22–24 
Months. I then outline the development of a more sensitive version of the MeDIP-seq 
method, termed Nano-MeDIP-seq, and demonstrate its application for the methylome 
analysis of rare LT-HSCs, using 160–300 ng starting DNA. 
3.2 Study Design 
Prior to starting the full-scale ageing project, I performed experiments to estimate the 
number of animals that would be required to complete this study, as well as the overall 
feasibility. To this end, I sorted and isolated DNA from bone marrow (BM) lymphocytes 
(BML) that were obtained from one adult C57BL/6 mouse. BMLs were sorted based on their 
cell profile (Fig. 3.1), which is similar to that of LT-HSCs, as determined by their forward 
scatter (FSC, correlates with cell volume/size) and side scatter (SSC, correlates with cell 
complexity e.g. granularity).  
Figure 3-1: Diagrammatic representation of the scatter profile of nucleated bone marrow cells. 
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I extracted approximately 400 ng of DNA from 1x105  FACS purified BMLs. Based on this, I 
estimated that ~7.5x104 FACS purified (B6 mouse) LT-HSCs would yield ~300 ng of DNA. 
Considering the frequency of LT-HSCs in the B6 mouse bone marrow (0.01–0.2% of 3–
5x107), 15–30 young B6 mice were estimated to provide 300 ng of LT-HSC DNA.  This was 
expected to be approximately 5–10 times lower for middle-aged and old B6 mice, based on 
the known accumulation of HSCs with age [95,144].  
3.3 Isolation and Validation of Ageing LT-HSCs 
The SP method used to isolate LT-HSCs in this study was first described by Margaret 
Goodell, in 1996 [16], for the isolation of HSC from mouse bone marrow.  This method has 
since been widely used to purify stem cells from various other tissues as well as from other 
organisms [145,146]. I isolated the fraction of SP cells with the least amount of Hoechst 
staining (lower SP cells (LSPs)), as these cells have previously been shown to sustain long 
term haematopoiesis [13] and can therefore be referred to as LT-HSCs. Additionally, the 
LSP fraction of SP cells is the primary HSC population that undergoes age-related changes 
[7,19]. It was therefore appropriate that this population was selectively studied for DNA 
methylation and gene expression changes during ageing. 
Before deciding to sort the LT-HSCs solely on their SP phenotype, I carried out a number of 
experiments to validate my staining and sorting techniques. Firstly, I investigated the SP 
phenotype of KLS; CD150+; CD34- defined LT-HSCs (Table. 3.1) and found these cells to be 
enriched (80.2%) within the LSP region (Fig. 3.2a). I also confirmed the LT-HSC phenotype 
of LSPs (Fig. 3.2b) and found LSPs to be enriched for phenotypically defined LT-HSCs. This 
validated the use of the Hoechst exclusion (without the use of additional markers) for the 
identification and isolation of LT-HSCs in this thesis. 
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Figure 3-2: Side population phenotype of KLS, CD34
+
 and CD150
+ 
defined HSCs. 
A) FACS dot plot of total BM cells, which were stained with fluorescent antibodies to LT-HSC antigens as 
indicated on the x and y axis. Antibody stained cells were analysed on the LSRII flow cytometer. Each plot 
shows the phenotype of cells gated on the previous (left) plot, as indicated by the curly arrow.  The final plot 
shows the Hoechst profile of antibody defined LT-HSCs. Data shown is from 24 months old mice. B) The lower 
SP (LSP) fraction of Hoechst stained bone marrow cells were analysed for LT-HSC cell surface markers. KLS 
antibodies are as previously described (measures HSPCs), KLS_Slam shows the frequency of KLS cells that are 
CD150+, while KLS_Slam shows the overall frequency of cells that are KLS and CD150+. Plot shows that LSP is 
enriched for phenotypically defined LT-HSCs (KLSSLAM). Data shown is from 24 months old mice. Two 
biological replicates are shown. Error bar is Standard Deviation. 
 
As a result of this observation, I isolated phenotypically defined LT-HSCs by Hoechst 
staining alone throughout this thesis. However, to maintain stringency during the cell sorting, 
I also gated LSP cells on their FCS – SSC profile. Figure 3.3 shows a typical LSP cells/LT-
HSC sort schematic. The phenotype shown in this figure is representative of the LSP cells 
used in this study, and demonstrates that these cells were a homogeneous population and 
not a mix of under-stained bone marrow cells. 
A 
B 
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Figure 3-3: LSP sort.  
FACS dot plot of a typical LSP sort, Hoechst stained whole bone marrow cells are shown on the left. Only the LSP cells that fall 
within the oval gate shown above (far right) were collected in this study                      
 
As a final validation of the sorting techniques in this study, I analysed the purity of sorted 
LSP cells, by investigating the expression of LT-HSC markers on these cells (Fig. 3.4). I 
confirmed that the LSP cells isolated in this study were Sca-1+ and c-Kit+.  I also confirmed 
that the sorted LSP cells were enriched for CD150 positive cells and negative for the 
expression of CD48 as previously described [14].  
 
Figure 3-4: Antibody phenotyping of sorted lower side population cells. 
FACS plot of sorted LSP cells, ~ 1x10
5
 human KG-1a cells were used as carrier for 1–2x10
3
 LSP cells, which were stained with 
fluorescent antibodies as indicated on the x axis. Mouse CD45.2 antibodies were used to distinguish mouse cells from human 
carrier cells (top plot) 
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Having validated the techniques used to identify LT-HSCs; I isolated phenotypically defined 
LT-HSCs from young, middle-age and old C57BL/6 mice and confirmed previous findings 
that these cells increase with age (Fig. 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5:  Age-related increase in side population cells. 
Figure shows (A) a representative FACS dot profile of Hoechst stained bone marrow cells of young and old B6 mice as 
indicated. Lower SP cells are depicted as blue dots, and show an increase from young to old mice. Hoechst fluorescence, Red 
and Blue are shown the x and y axis respectively (B) The frequency of FACS sorted LSP cells from female b6 mice, at three 
independent time points. Error bar denotes standard error of the mean. 17, 11 and 10 biological replicates were used for 
Young, Mid and Old points respectively. Each biological replicate consists of 5 – 1 pools of mice. A pool of 5 mice was typically 
sorted for Young, while 3 – 1 were sorted for Mid and Old. 
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Figure 3-6: Electropherograph of sonicated DNA.  
A) A standard sonication time of 30 min generates fragments that are mostly over the required 200bp mark (green arrow). A 
huge proportion of the DNA is therefore lost following library size selection. b) Optimised sonication, with a fragment peak size 
of 200bp. 35bp and 10380bp peaks represent the lower and upper DNA ladder peaks respectively. Electropherograms were 
generated as part of DNA analysis on the Bioanalyzer Microfluidics Platform. The graph is a plot of the DNA fragment size (bp) 
against fluorescence units (FU). DNA concentration is proportional to FU.    
3.4 Development of Nano-MeDIP-seq  
I optimised MeDIP-seq for low DNA concentrations to allow the analysis of LT-HSC 
methylomes. As the availability of LT-HSCs was limited in this study, I used DNA from FACS 
purified BML for the development of the Nano-MeDIP-seq protocol described below. 
3.4.1 DNA Fragmentation  
The methylation status of individual CpG sites is highly correlated over distances up to 1 kb 
across the genome [11]. Therefore, MeDIP libraries with an average sequence insert size of 
200 bp were prepared (which represents a good balance between costs and resolution) and 
used throughout this study to analyse LT-HSC methylomes at 200 bp resolution. Randomly 
and evenly fragmented DNA is required as input into the MeDIP-seq reaction and DNA was 
fragmented by sonication in this study. I identified this step as a source of significant DNA 
loss, which was due to suboptimal sonication and fragmentation (Fig. 3.6a).  I optimised the 
DNA sonication protocol such that majority of the fragmented DNA fell within the 200 bp 
library size range (Fig. 3.6b). The key optimisations were: 1) Longer sonication time of 90 
min; 2) temperature was maintained below 100C throughout sonication. Additionally, I 
sonicated DNA in LoBind 1.5 ml tubes (Eppendorf), to minimize DNA loss due to non-
specific DNA adhesion to tube walls during sonication.  
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3.4.2 Reaction Purification 
There are at least five purification steps in the MeDIP-seq protocol. I estimated a minimum of 
30% loss of DNA, following each standard (affinity column based) purification step, making 
reaction purifications a main source of DNA loss. This estimate was derived from pre and 
post- affinity column –purification, quantification of (previously) purified genomic DNA, 
performed during the course of my project. As a result, I replaced all affinity column based 
purification steps with Solid Phase Reversible Immobilisation (SPRI) bead purification [147] 
and observed a marked improvement in DNA recovery. These paramagnetic beads (Trade 
name: Ampure) are able to bind reversibly to DNA in the presence of polyethylene glycol 
(PEG) [147]. I recovered at least 80% of high quality DNA following standard Ampure clean–
up steps. Additionally, Ampure was able to exclude contaminating oligonucleotides such as 
excess primer and adapter dimers, from clean–up reactions. The DNA fragment size range 
recovered after Ampure purification is dependent on the PEG concentration in the Ampure 
beads buffer [148]. I adjusted PEG concentrations during DNA purification, by varying the 
ratio of Ampure mix to reaction volume i.e. between the standard 1.8x to 0.8x (Fig. 3.7). I 
used lower PEG concentrations (< 1x Ampure/reaction ratio) for the purification of DNA from 
PCR and adapter ligation reactions. This selectively excluded interfering excess and 
dimerised oligonucleotides (oligos), which are typically less than 150 bp, from downstream 
reactions.  
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Figure 3-7: Ampure purification. 
 
   
DNA Electropherogram shows the results of Ampure purification of 200 ng DNA, at the indicated ratios (legend; top right). 
Fragment sizes of 100bp and 200bp are marked by black arrow. DNA was purified in two replicates at each test ratio and these 
were compared to unpurified control (0x). The 35bp and 10380bp lower and upper DNA ladder peaks are shown on the far left 
and far right (tallest peak) respectively. Electropherograms were generated as part of DNA analysis on the Bioanalyzer 
Microfluidics Platform. The graph is a plot of the migration time (s) against fluorescence units (FU), which is a measure of size 
and concentration respectively.  
 
3.4.3 Library Preparation (Part 1) 
This part of the MeDIP-seq protocol involves DNA end repair, 3‘-dA tailing and adapter 
ligation.  DNA end repair is necessary to repair the sheared ends of sonicated DNA, while A-
tailing provides the 3‘dA overhang that is required for adapter ligation by complementary 
base pairing to adapter 5‘ thymidine. DNA-Adapter ligation provides a universal sequence 
that allows whole genome amplification from a single primer pair.  
 A key limitation in this part of the protocol was the inability to accurately determine the 
optimal adapter concentration that was required to ligate adapters to all DNA fragments in 
the reaction. This resulted in either unsuccessful ligation or a build-up of excess adapter 
dimers which inhibit subsequent PCR amplification and sequencing reactions. Generic 
library preparation protocols recommend a 10-fold molar excess of adapter sequences to 
DNA fragments ends. However, this recommendation is based on the starting DNA 
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concentration and does not take into account the DNA loss in steps prior to adapter ligation, 
or the size into which the genomic DNA was fragmented, resulting in different molarities of 
ends. To circumvent this problem, I determined DNA molarity, using Bioanalyzer DNA high 
sensitivity reagents, following dA-tailing and prior to adapter ligation. This was used to 
calculate the optimal concentration of adapters that was required for the ligation reaction. 
Additionally, I purified adapter ligated DNA using low PEG concentration-Ampure clean-up. 
This helped to minimize the presence of adapter dimers in purified DNA (Fig. 3.8).  
3.4.4 MeDIP 
I performed MeDIP reactions as described in Section 2 but with minor modifications. For 
example, I adjusted reagent set-up to avoid the use of small volumes where possible. The 
Ab mix detailed in Step 3 of Section 2.8.3 originally required the addition of 0.30 µl diluted 
antibodies to the mix. 0.30 µl is an incredibly small volume and is in fact near invisible to the 
naked eye. As this could easily result in failure to add (sufficient) antibodies to the MeDIP 
reaction, I adjusted the concentration of stock antibodies, such that a more manageable 
volume was used, whilst maintaining the same reaction concentration. 
 
Figure 3-8: Ampure purification efficiently removes unwanted oligos from sample DNA. 
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3.4.5 Library Preparation (Part 2) 
I typically obtained 2–10 ng purified immunoprecipitated (IP) DNA from MeDIP reactions, 
with ~7.5x104 cells. IP DNA is amplified in this part of the MeDIP-seq protocol, to increase 
DNA concentration for use in subsequent step. There is a caveat to PCR amplification; too 
few PCR cycles results in insufficient DNA for downstream use, while too many cycles lead 
to clonal amplification of small fragments present in the reaction. In order to determine the 
optimal conditions for amplifying MeDIP DNA (mDNA), I investigated the use of alternative, 
next generation DNA polymerases, and performed MeDIP PCR (mPCR) reactions under 
various conditions (Table. 3.2). 15 cycles of mPCR, using KAPA polymerase (Kapa 
Bioscience) resulted in the highest DNA yield and all subsequent mPCR reactions were 
performed under these conditions. 
A) PCR Amplified MeDIP DNA was purified using affinity columns (Qiagen). The purified sample remained heavily 
contaminated with dimerised oligos (arrowed).  B) Purification with Ampure beads consistently reduced the presence of 
contaminating oligos (arrowed). 35bp and 10380bp peaks represent the lower and upper DNA ladder peaks respectively. 
Electropherograms were generated as part of DNA analysis on the Bioanalyzer Microfluidics Platform. The graphs are plots of 
DNA fragment size (bp) against fluorescence units (FU). 
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Table 3-2: Optimization of adapter-mediated PCR. 
Condition Pros Cons 
Standard 15 cycle PCR 
amplification of mDNA using 
the standard library prep 
polymerase (Phusion) 
Optimal number of cycles for 
amplifying 10–20 ng mDNA 
Insufficient yield from low 
concentration (< 20 ng) 
mDNA 
Standard 15 cycle PCR 
amplification of mDNA using 
an alternative polymerase 
(Kapa) 
Up to three times higher 
DNA yield than when using 
Phusion polymerase. 
Starting concentrations of as 
low as 3 ng mDNA was 
successfully amplified. 
None observed. 
‗Dual mPCR‘ – mDNA is split 
into 2 equal parts and each 
part is amplified separately in 
a 12 cycle reaction, using 
Phusion polymerase 
A higher DNA yield is 
obtained in most cases and it 
involves the use of lower 
PCR cycles which reduces 
the generation of clonal DNA 
fragments 
mDNA is single stranded and 
thus difficult to quantify, so 
one cannot be sure of the 
exact concentration of 
mDNA used in PCR 
reactions. Using too little 
DNA can lead to complete 
failure of the PCR reaction.  
Dual mMeDIP PCR is not 
recommended where a low 
mDNA yield is expected, 
without prior extensive DNA 
quantification. 
‗Dual mPCR‘ – mDNA is split 
into 2 equal parts and each 
part is amplified separately in 
a 12 cycle reaction, using 
Kapa polymerase 
A higher DNA yield than 
when using Phusion 
polymerase under the same 
condition. 
Same as with Phusion 
polymerase under the same 
condition 
 
3.4.6 Library Size Selection 
PCR amplified mDNA (amDNA) is size selected to generate a uniform sequence library 
insert size of approximately 200bp. This is done by running the entire amDNA on agarose 
gels (Section 2.8.5) and excising a gel slice within the appropriate size range. DNA is then 
extracted from the gel slice with an affinity column based gel extraction kit (Qiagen). A 
significant amount (> 90%) of DNA was typically lost at this stage. As a result, I developed 
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an optimised gel extraction protocol. The key changes to the standard protocol are 
summarised in Table 3.3 below. 
Table 3-3: Optimization of the Gel extraction protocol. 
Optimisation Benefits 
Extracted  DNA from  ≤ 
300 mg gel per column 
Small gel slices dissolve more easily. It is important that gel is 
completely dissolved to fully release DNA from agarose and to 
prevent the clogging up of column membrane with undissolved 
gel fragments. 
Dissolved gel slices in 
LoBind tubes 
Prevents DNA loss by adhesion to reaction tubes 
Added 3 M sodium 
acetate (pH 5.0) to buffer 
QG gel dissolution buffer 
(Qiagen) 
Adsorption of DNA to column membrane is severely reduced at 
pH of > 7.0 and can result in total loss of DNA. Sodium Acetate 
lowers pH to facilitate DNA adsorption. 
Eluted DNA in small 
volumes with 500C EB 
elution buffer (Qiagen) 
Eluting in small volumes help concentrate the purified DNA. This 
can later be diluted if necessary. EB buffer has the optimal pH of 
7.5–8, which is required to release DNA bound to column 
membrane. Distilled or purified H2O typically used in 
laboratories have a much lower pH and is therefore unsuitable. 
Eluted in DNA with 500C 
EB elution buffer 
(Qiagen) 
Elution with warm  EB buffer increases permeability of column 
membranes which allows DNA to be released more efficiently 
 
3.4.7 Nano-MeDIP-seq 
I successfully prepared Nano-MeDIP-seq libraries from 50–300 ng starting DNA 
concentrations and sequenced one library generated from 300 ng starting DNA. The 
resulting sequence data was enriched for CpGs and covered the methylome at a sufficient 
depth for methylome analysis [133].  These results showed that Nano-MeDIP-seq can be 
used for methylome analysis from small amounts of DNA. I therefore used Nano-MeDIP-seq 
to analyse the methylome of LT-HSCs as detailed below. 
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3.5 Nano-MeDIP-seq of LT-HSCs  
I extracted 160–300 ng of DNA from three biological replicates of young, middle-aged and 
old C57BL/6 mice, and carried out methylome analysis using Nano-MeDIP-seq. Each 
replicate included 3-30 pooled isogenic mice. 
3.5.1 Quality Control of LT-HSC Nano-MeDIP Libraries 
I confirmed the enrichment of Nano-MeDIP-seq libraries for methylated fragments by 
performing qPCR on all LT-HSC samples following MeDIP (QC1, Fig 3.9) and PCR 
amplification of MeDIP DNA (QC2). These were indexed by ‗Recovery‘ (and ‗Specificity‘) and 
‗Enrichment‘ respectively (Fig. 3.9). The spiked-in Lambda control fragments were assessed 
in QC1, while mouse DNA regions, of predetermined methylation status, were assessed in 
QC2. The full QC method is detailed in Section 2.8.3.1 and Section 2.8.5.1. 
3.5.2 LT-HSC Nano-MeDIP Sequence Data 
Nano-MeDIP libraries were subjected to next generation sequencing. One Young (Young 1) 
and two Old samples (Old 1 and Old 2) were sequenced on an Illumina Genome Analyzer 
(GAIIx). All other samples were processed on an Illumina Hi-seq sequencer, which is a 
newer and improved version of the GAIIx. This resulted in an average of 5.25 Gb raw paired-
end reads per sample (S.D ±1.15 Gb) of which approximately 90% were successfully paired 
and aligned to the mouse genome (mm9 Genome Build 37). An average of 1.92 Gb (S.D ± 
0.3 Gb) high quality (q ≥ 10) uniquely mapping paired-end reads were obtained after filtering 
out clonal and low quality reads. Approximately 60% of all CpGs in the mouse genome were 
covered at least one fold (Fig. 3.10), and all MeDIP samples showed a clear CpG 
enrichment (Table. 3.4) when compared with Input control samples (Average MeDIP 
enrichment score = 2.73; S.D ± 0.12; n = 9, Average Input enrichment score of 1.11; S.D ± 
0.03; n = 2). Additionally, there was a good correlation for all LT-HSC MeDIP samples 
(Table. A-6; average Pearson‘s correlation of 0.84, S.D ± 0.09). One replicate for the ‗Old‘ 
Results Chapter 3 
 
88 
 
* * 
* 
A 
B 
time point had a lower correlation of approximately 0.7 and was excluded from global 
analyses to maintain stringency. 
 
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9: MeDIP QC.  
A) Quality control after MeDIP.  All samples show a highly specific recovery of methylated DNA. Recovery was assayed on 
spiked-in lambda DNA for all samples except those marked with *. A) All samples show a clear enrichment for methylated DNA 
following PCR amplification. Broken black line marks the minimum enrichment value (100) required for a successful 
experiment. This threshold was set based on previous observations within the Medical Genomic group. *a different lambda 
spike combination was included and assayed for this sample, *mouse genomic region were assayed for these samples and a 
low level recovery is typical for such regions. qPCR regions are detailed in Table. A-1. Recovery and Specificity were 
calculated as detailed in section 2.8.3.1 (QC1), while Enrichment was calculated as detailed in section 2.8.5.1 (QC2). 
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Sample 
CpG Enrichment 
 Score 
IP_Young_1 2.82 
IP_Young_2 2.77 
IP_Young_3 2.71 
IP_Mid_1 2.65 
IP_Mid_2 2.75 
IP_Mid_3 2.7 
IP_Old_1 2.98 
IP_Old_2 2.57 
IP_Old_3 2.65 
Input_Young  1.13 
Input_Old  1.09 
 
 
 
Figure 3-10: CpG coverage of ageing LT-HSC MeDIP-seq libraries.  
 
 
 
 
 
 
 
 
 
 
 
 
Average coverage at read depth (X) of 1, 5 and 10 was 60.5%, 30% and 17% respectively. (Standard deviation = 3.3%, 6% and 
3% respectively). Coverage is consistent with other (high DNA concentration) MeDIP-seq studies [118,127,133,134]. 
 
Table 3-4: CpG enchment of MeDIP and Input samples. 
 Enrichment scores were determined by the MEDIPS 
program. A score of >2.5 shows that MeDIP samples are 
enriched for CpGs, relative to input (Enrichment score of ~1).  
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3.6 Conclusion 
I successfully isolated mouse phenotypically defined LT-HSCs across developmentally 
relevant time points and developed the Nano-MeDIP-seq method for DNAm analysis of rare 
samples. I applied Nano-MeDIP-seq for the generation of LT-HSC (ageing) methylomes and 
demonstrated the high quality of the data that was generated (Section 3.5.2; [133]). 
3.7 Discussion 
Until now, methylome analysis of LT-HSCs has been unattainable because of their rarity and 
the cost of isolating them. I overcame the latter by isolating LT-HSCs using the SP method. 
Hoechst exclusion is a bona-fide method for isolating LT-HSCs; however, its efficacy is 
easily affected by slight variations in technique. As a result, this method is often used in 
conjunction with multiple antibodies to augment purity [149] . I validated the SP method and 
confirmed that my staining techniques efficiently and consistently identified a pure population 
of LT-HSCs. This demonstrated that additional antibodies were not required and allowed me 
to isolate LT-HSCs from a large sample size at a reasonable cost.  
Irrespective of the cost of isolating them, LT-HSCs remain a rare cell population in the bone 
marrow. This meant that an excessive number of animals would have been required to 
obtain sufficient cells for methylome analysis, using the methods that were available at the 
time of this study. I therefore developed the Nano-MeDIP-seq method for interrogating the 
methylomes from low numbers of cells and demonstrated its utility for the generation of 
ageing LT-HSC methylomes. The protocol developed here represents a higher than 10 fold 
improvement in sensitivity to the original MeDIP protocol and makes this method available to 
a wider range of studies. The full Nano-MeDIP-seq protocol and its development was 
published in the April 2012 issue of Nature Protocols [133] and can be found in the appendix 
of this thesis. 
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Chapter 4 
DNA Methylation Analysis of Ageing 
LT-HSCs 
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4  
4.1 Introduction 
Altered DNA methylation (DNAm) is linked to profound functional changes, and has been 
implicated in normal development as well as in various diseases [51,80,150]. Mice deficient 
in enzymes that catalyse DNAm at CpG dinucleotides, DNA methyltransferases Dnmt1 and 
Dnmt3a, have abnormal HSC self-renewal and differentiation [88,90,151]. Dnmt1 mutant 
mice were unable to support lymphopoiesis and showed a quantitative increase in LT-HSCs, 
which rapidly became exhausted after multiple rounds of transplantation [88,151]. Similarly, 
Dnmt3a-null mice showed enhanced self-renewal at the expense of differentiation [90]. 
These findings suggest that DNAm is important for HSC regulation and in maintaining the 
balance between self-renewal and differentiation. 
Aged mice show similar phenotypes to that of Dnmt mutants i.e. an increase in the number 
of phenotypically defined LT-HSCs and skewed differentiation towards myelopoiesis.  It is 
therefore possible that alterations in DNAm contribute to age-related decline in LT-HSC 
functionality.   
DNAm is a highly dynamic epigenetic mark which can fluctuate between cells of the same 
population [60]. This dynamism is a necessary feature of DNAm and is required for 
phenotypic plasticity [51]. In order to distinguish relevant age specific changes in DNAm from 
epigenetic noise, I generated methylomes for three biological replicates of Young, Mid and 
Old time points. Additionally, LT-HSCs were pooled from isogenic mice, further diluting out 
any random epigenetic signal that may exist within a particular sample. 
In this Chapter, I investigated the role of differential DNAm in ageing LT-HSCs as follows; 
1. I compared methylomes for three biological replicates of young, middle-aged and old 
C57BL/6 (b6) mice. From this, I identified age related changes in DNAm both on a 
global scale and at specific genomic regions. 
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2. I investigated the potential functional relevance of differentially methylated regions 
(DMRs) by assessing the regulatory features of the underlying loci. 
3. I reconciled relevant age related changes in DNAm, with the ageing LT-HSC 
phenotype.  
4.2 Methylome Analysis of Ageing LT-HSCs 
I investigated the role of DNAm in LT-HSC ageing, by studying their methylomes at three 
progressive age time points. The methylome of Young LT-HSCs was set as the baseline and 
used as a reference for Mid and Old samples, such that any significant deviation from Young 
was assumed to be biologically relevant.  Whilst I was primarily interested in absolute 
changes in DNAm with age, i.e. a change from Young to Old; Mid provided a progressive 
view of the methylome with age and was used to identify putative developmentally 
programed changes in DNAm. 
Normalised sequence data for each sample was converted into wiggle format which I 
uploaded and viewed on the UCSC genome browser (mm9, NCBI Build 37). This provided a 
web interface where the mouse LT-HSC ageing methylome could be easily interrogated. I 
visualised the methylomes of LT-HSC from Young, Mid and Old samples (collectively 
referred to as ageing samples) and confirmed a good correlation between biological 
replicates (Fig. 4.1, Table. A-6). DMRs were also queried using this interface; this permitted 
the visual confirmation of all aDMRs, in biological replicates of each age time point. 
Average methylation scores from all covered CpG sites in ageing samples were determined 
using MEDIPS, which converts enrichment into absolute DNAm values [135]. MEDIPS 
scores were then aggregated over all CpG sites for the three biological replicates, to 
generate a representative methylome for each sample. As mentioned in Chapter 3, one of 
the ‗Old‘ samples (‗Old 2‘) was excluded from global methylome analysis because of low (< 
0.9) correlation compared to the other biological replicates. 
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Methylomes were depicted on a Circos plot (Fig. 4.2) and I visually assessed the intensity of 
the blue colour, which indicates global methylation levels (dark blue - high to pale blue/green 
- low) for each sample. I observed a reduction in the colour intensity of ‗Old‘ methylomes 
compared to ‗Young‘ methylomes, suggesting a global reduction in DNAm with age (Fig. 
4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4-1: Screen shot of UCSC genome browser.  
Each track shows the LT-HSC methylomes for ageing samples as indicated. A good correlation between sample replicates 
can be observed. Peak height represents DNAm levels; scale is from 0 to 1, with 0 being the lowest. Browser scale is 
200kb 
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The observed differences in DNAm between the ageing methylomes were quantified using 
MEDIPS and a 5% (p < 0.001, Kolmogorov-Smirnov test) decrease in global DNAm was 
found in Old HSCs (Fig. 4.3a). This is in contrast to CpG islands (CGIs), which were globally 
hypermethylated in Old HSCs (Fig 4.3b). The gradual reduction in global DNAm described 
here is similar to that of a recent study, which found a progressive decrease in methylation 
levels in human CD4+ T cells with age [152]. This suggests that global decline in DNAm 
levels may be a common feature of mammalian ageing. 
  
Figure 4-2: Circos plot of LT-HSC methylomes. 
Outermost circle shows an ideogram of the mouse genome, dark bands are typically AT rich, heterochromatic regions, while 
light bands are typically GC rich euchromatic regions. The three blue circles show (from outer circle) Old, Mid and Young LT-
HSC methylomes respectively (2 -3 biological replicates). Global methylation level is proportional to colour intensity i.e. dark blue 
for high methylated and light blue for low. The innermost circle depicts CpG density (dark orange, high and light orange low). 
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Figure 4-3: Global DNAm levels. 
Box plots of A) global B) CGI DNA methylation levels for Young, Mid and Old LT-HSCs and. Global DNA methylation levels are 
expressed as MEDIPS scores.  
 
4.3 Age-specific Differentially Methylated Regions (aDMRs) in LT-HSCs 
aDMRs were determined using the MeDUSA pipeline [134] (v1.0.0), which compared 
normalised read counts for discreet regions between ageing samples as described in 
Chapter 2. The available tools for determining DMRs in this study were designed for 
samples where marked alterations in DNAm were expected (e.g. cancer studies). I reasoned 
that extreme changes in the DNAm of LT-HSCs will probably result in neoplastic 
transformation or cell death, none of which was observed in ageing LT-HSC samples. 
Moreover, I observed a high correlation between all LT-HSC methylomes, irrespective of age 
groups (Section 3.5.2, Section 4.2). It was therefore likely that subtle but significant changes 
in DNAm drive the ageing phenotype. In order to avoid excluding potential candidates, I 
selected a moderate FDR threshold of 0.2 for DMR calling in this study. This generated a list 
of 111 aDMRs, which were significantly differentially methylated between Young and Old 
samples. Of these aDMRs, 71 were hypermethylated (hyper-aDMRs) (Table. A-2) and 40 
were hypomethylated (hypo-aDMR) (Table. A-3) in Old samples compared to Young. These 
aDMRs appeared to be randomly distributed across all mouse chromosomes (Fig. 4.4), with 
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the exception of chromosome 14 and 16 (where no DMRs were detected) and chromosome 
5, where I found a hotspot that was significantly (p-value < 0.001) enriched for 
hypermethylated aDMRs. This hotspot corresponds to the location of at least 4 known 
members of the Speer gene family which includes 14 genes that encode putative glutamate-
rich proteins of unknown function (Fig. 4.5). Speer genes are thought to arise from partial 
duplications of the Dlg5 gene [153]. Dlg5 is a member of the MAGUK super-family, which 
are scaffolding proteins that are important in cell adhesion and cell polarity [154]. 
 
 
Figure 4-4: Mouse ideograph showing the location of aDMRs.  
Hypo-aDMRs are depicted as red peaks while hyper-aDMRs are in blue and are enriched on a region in chromosome 5 
(arrowed). Dark bands on mouse ideogram are AT rich, heterochromatic regions, while light bands are GC rich euchromatic 
regions.
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6 
Figure 4-5: UCSC genome browser methylation tracks of ageing samples.  
The screen shot shows aDMRs (red boxed) overlapping a group of Speer genes on mouse chromosome 5. Peak height represents DNAm levels; scale is from 0 to 6, with 0 being the 
lowest. Browser scale is 100kb 
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Using a previously determined cut-off of 100 Kb [155], 96% (107/111) of the identified 
aDMRs were associated with known genes; henceforth referred to as age-specific 
differentially methylated genes (aDMGs). I observed a progressive change in methylation 
with age for many aDMRs. Figure 4.6 shows a DNAm heatmap for 24 randomly selected 
aDMRs (from a total of 111 aDMRs), displaying progressive and directional DNAm change 
at during ageing.  A heatmap of all 111 aDMRs is shown in Appendix-Figure 7. 
 
 
Figure 4-6: Methylation heatmap of selected DMRs in during ageing.  
Blue represents hyper and yellow hypomethylation. Corresponding aDMGs are shown on the left. 
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I used GREAT v2.0.2 [156], a function and pathway enrichment analysis tool,  to investigate 
the biological significance and association of aDMRs but found no significant  enrichments. 
However GREAT, as most gene enrichment analysis tools, requires a large number of test 
data and the lack of significant enrichment in aDMRs could be as a result of low input data. 
Subsequently, aDMRs were categorised according to their annotated (Ensembl mm9, 
NCBIM37 genome build) genomic features.  Hypermethylated aDMRs (in Old versus Young) 
were found to be significantly enriched in CGIs (Fishers Exact p-value = 2.33e-09), CGI 
shores (p-value = 4.30e-09) and exons (p-value = 6.18e-11), while hypo aDMRs were 
significantly enriched in exons (p-value = 2.14e-06), CGI shores (p-value = 8.39e-05), 
introns (p-value = 3.6e-03) and intergenic regions (p-value = 0.028). Further analysis using 
the Ensembl regulatory build (mm9, NCBIM37 genome build) revealed that CTCF binding 
sites were most enriched in the hyper aDMRs and c-MYB sites were most enriched in hypo 
aDMRs. 
Many of the identified aDMRs were progressively differentially methylated with age (Fig. 
4.6), and therefore potentially associated with ageing. To further elucidate the functional 
relevance of aDMRs, I investigated the functions of aDMGs and evaluated the regulatory 
functions of the aDMRs within these genes; this analysis was performed as follows: 
1. I determined the biological functions of selected genes using annotations from 
scientific journals (PubMed: http://www.ncbi.nlm.nih.gov/pubmed) and from NCBI 
gene summaries (NCBI: http://www.ncbi.nlm.nih.gov/gene)  
2. I queried the corresponding aDMRs on the UCSC genome browser as described for 
Figure 4.1, however here, the UCSC ‗regulation‘ track was activated to show binding 
sites for  UCSC default transcription factors (TFs) such as, CTCF, GATA1 and that of 
the TF co-activator, p300. I also utilised UCSC TF binding site (TFBS) tracks from a 
recently published article, which detailed TFBS in haematopoietic stem and 
progenitor cells [157]. 
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3. From this analysis, I selected candidate genes (from a total of 107 aDMGs) that 
could be involved in the ageing of LT-HSCs and/or contained an aDMR that was 
enriched for TFBSs 
The selected candidate genes, with relevant biological functions, are summarised in Table 
4.1. Some of these DMGs were also shown on UCSC genome browser tracks in Figure 4.7. 
Table 4-1: Summary of candidate aDMGs 
aDMG Relevant Function Source DMR feature 
Cftr 
Similar function as ABC/G2 on LSP cells. Cftr, 
which is also known as ABC/C7, is a member of the 
ABC transporter super family which are involved in 
cell detoxification and multi-drug resistance (MDR) 
NCBI 
Genes 
Pronounced hypo-
aDMR within 2kb of 
TSS 
Cpne2 
A calcium-dependent membrane-binding protein. 
Involved in various signalling pathways and 
membrane trafficking 
PubMeD 
[158,159] 
intronic hypo-aDMR 
at CTCF, p300 and 
Pol2 binding site (fig. 
4.7G) 
Cyfip2 
Facilitates T-Cell adhesion. Overexpression 
increases fibronectin-mediated adhesion 
[160] 
3‘ hypo-aDMR at 
CTCF,p300 and Pol2 
binding site 
Dcps 
scavenger decapping enzyme, role in mRNA decay 
and nuclear pre-mRNA splicing 
[161]  
Age progressive 
hypo-aDMR in gene 
intron 
Hsf4 
Activates heat shock response proteins under 
stress conditions. Involved in the negative 
regulation of DNA binding activity 
NCBI 
Genes 
Exon boundary hyper-
aDMR 
Itgb3 
A cell surface protein which is important in cell 
signalling and cell adhesion 
NCBI 
Genes 
Binding site for 
several TFs within 
300bp of intronic 
hypo-aDMR  Fig 
4.7D) 
Kissr1 
G-protein coupled receptor with a role in cancer cell 
growth and metastasis 
PubMeD 
[162]  
3‘ CGI hyper-aDMR 
(fig 4.7E) 
Ltbp3 
Mediates the targeting of latent TGF-beta into 
extracellular cell matrix 
[163] 
Exon boundary CGI 
hyper-aDMR 
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Mrc1 
Mannose receptor with a role in immunity and 
inflammation  
NCBI 
Genes 
Pronounced hypo-
aDMR at 3‘UTR 
Nav2 Involved in cellular growth and migration 
NCBI 
Genes 
Intronic hyper-aDMR 
as well as hypo-
aDMR over  UCSC 
annotated region (Fig 
4.7C) 
Nr4a2 
Increases cell migration in response to stromal-
derived factor-1a (SDF-1a) 
PubMeD 
[164] 
Hyper-aDMR over 
CGI and AUG codon 
rich exon (Fig 4.7F) 
Obscn 
Role in cellular assembly and loss of function 
mutations in this gene results in apoptotic 
resistance. 
[165] 
3‘ Hyper-aDMR 
overlapping CTCF 
binding site and 
flanked by several 
TFBS (Fig 4.7A) 
Pde8 Regulates chemotaxis of activated lymphocytes [166] 
Hypo-aDMR in 8a and 
8b 
Ptger 
G-protein coupled receptor for prostaglandin E2 
that can activate T-cell signalling and enhance 
immature B-cell apoptosis 
NCBI 
Genes 
Marked intronic hypo-
aDMR which overlaps 
c-MYB, Pol2 and 
GATA-1 binding sites 
and is within 1 kb of 
several other TFBS 
(Fig 4.7B) 
Sdpr 
Involved in caveolae formation and signalling. The 
expression of this phospholipid-binding protein 
increases in serum starved cells and during HSC 
ageing   
[94,99,16
7,168]  
Two hypo-aDMR 
around TSS and 
within 500bp of CTCF 
binding site (Fig 4.7H) 
Trim30
a 
Negative regulator of NF-kappa B. Role in immunity 
and inflammation 
[169] 
Marked  hypo-aDMR 
within intron which 
completely overlaps a 
snRNA 
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Figure 4.7: UCSC genome browser tracks of DMRs (red boxed) in selected genes as indicated.  
Blue, orange and green peaks shown for all genes represent methylation in Young, Mid and Old samples respectively and peak height is proportional to methylation level. Solid black/grey bars in A, 
B, D, G and H represent TFBSs, green bars in B, E and F represent CGIs, and blue bars represent exons (solid) and introns (broken). Olive green bars shown for Nav 2 (C) represent UCSC 
annotated regulatory elements while the broken green lines shown for Nr4a2 (F) represent methionine start codons. 
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4.4 Conclusions 
I established that the ageing LT-HSC methylome becomes globally hypomethylated, and 
hypermethylated at some CGIs. I identified several aDMRs and their corresponding genes 
and highlighted many candidate genes that could account for age-dependent changes in LT-
HSCs. These genes were selected as potential candidates for LT-HSC ageing based on 
their known or predicted functions and many of these appear to have a role in cell signalling 
and adhesion, which is important in haematopoiesis and HSC regulation. The availability of a 
focused list of relevant candidate genes represents a significant improvement in the 
understanding of HSC ageing. 
 
4.5 Discussion 
A key step in carcinogenesis is global hypomethylation and local hypermethylation at some 
CGIs [82,84,155]; it is therefore interesting that the same changes were observed during LT-
HSC ageing. As age is a major risk factor for cancer, it is possible that these age-related 
changes in DNA methylation are a prerequisite for an oncogenic transformation in aged 
organisms. I identified several regions that were differentially methylated with age and found 
an enrichment of CTCF binding sites in regions that were hypermethylated in Old samples. 
CTCF is a methylation sensitive DNA binding transcription factor and boundary (insulator) 
element [170,171]. This TF binds DNA to insulate neighbouring genes from inappropriate 
(cross) regulation by cis-acting elements e.g. enhancers. CTCF has also been implicated in 
alternative splicing [172]. In this context, DNAm at CTCF binding sites promoted exon 
exclusion [172]. Hypermethylation of CTCF binding sites interferes with its binding to DNA 
resulting in aberrant gene expression, as observed in various diseases including imprinted 
diseases and cancer [170,173]. Similarly, hypermethylation of these sites during LT-HSC 
ageing could result in dysregulated gene expression, through the expression of normally 
silent genes or/and inappropriate activation of splice variants. Conversely, age-related 
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hypomethylated DMRs were enriched in binding sites for c-MYB, which is a key TF in 
haematopoiesis and HSC self-renewal [174,175]. Loss of methylation at these sites 
potentially enhances binding of c-MYB to DNA and perhaps has a wide-spread effect on the 
expression of several downstream targets. Age-related disruption of TF interaction with 
DNA, will most likely result in significant alterations in gene expression and may somewhat 
account for the loss of functionality that is observed in LT-HSCs, during ageing.   
As well as global changes in the LT-HSC methylome, several genes were also found to be 
differentially methylated (Table 4.1; Table. A-2 and A-3). These include several genes with 
functions in cell signalling and adhesion, inflammation and immunity, cellular assembly, cell 
growth and metastasis. HSCs reside in the bone marrow where cell-cell interactions with 
specialized niche cells regulate their fate. These interactions take place through factors such 
as calcium ions, adhesion molecules and various soluble factors, and act to provide 
instructive signals to HSCs [176]. Itgb3 is highly expressed on SP LT-HSCs [177] and was 
found to be hypomethylated in this study. This gene is a member of the Integrin family of 
adhesion molecules, which are involved in cell-cell/extracellular matrix (ECM) adhesion and 
HSC-niche interactions. These processes are crucial for HSC regulation [178]. Integrins 
mediate the adhesion process by binding to other ECM and cell surface molecules such as 
fibronectin [179].  Additionally, Itgb3  interacts with several proteins, such as matrix 
metalloproteinases (MMPs) and G proteins, within lipid rafts, to form so-called 
supramolecular complexes, which are potent signal transducers [180]. Other aDMGs that 
appear to be involved in the adhesion and cell signalling process include Cyfip 2, which is 
involved in fibronectin mediated cell-cell adhesion [160], Sdpr; a component of flask shaped 
lipid rafts (caveolae) [168], and Ptger and Kiss1r, which are both G-protein coupled 
receptors [162,181]. Additionally, genes involved in cell detoxification, inflammation and 
lymphocyte regulation were differentially methylated with age (Table. 4.1). DNAm associated 
dysregulation of genes that are involved in lymphopoiesis could account for the altered 
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differentiation capacity of aged HSCs, while alterations in inflammation genes could explain 
the proinflammatory environment and functional decline of the immune system with age.   
Age-related changes in the DNAm of primitive haematopoietic cells have previously been 
described [117]. This study identified an age-dependent hypomethylation of differentiation-
associated genes and reported several instances of de novo DNAm with age [117].   
However, a heterogeneous haematopoietic progenitor cell (HPC) population was studied. 
Additionally, these HPCs were obtained from different anatomical locations i.e. umbilical 
cord blood for Young HPCs and mobilized peripheral blood HPCs for Old samples. The 
findings in this study were therefore likely affected by the different environment and that of 
mobilization. Such confounders were avoided in this thesis, as a more homogenous 
population of phenotypically defined LT-HSCs was studied for age-specific differential 
DNAm. Furthermore, the relevance of LSP cells in the study of HSC ageing was 
demonstrated in Chapter 3, i.e. this specific cell population is one that changes during 
ageing. The findings presented here are therefore likely to reflect a more accurate picture of 
HSC ageing and represent the first comprehensive account of differential DNAm in these 
cells during physiological ageing. 
110 
 
Chapter 5 
Gene Expression Analysis of Ageing 
LT-HSCs
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5  
5.1 Introduction 
The ability of HSCs to self-renew and differentiate into other blood cell types is tightly 
regulated by both intrinsic mechanisms and the micro-environment or niche in which they 
reside [33,35,40,46,182]. Several studies have reported a decline in HSC functionality and a 
differentiation bias towards myelopoiesis with age [7,9,93-95,99]. Such studies carried out 
gene expression profiling of purified HSCs and provided evidence for an intrinsic change in 
HSCs with age [7,94,99], which involved an up-regulation of myeloid specific transcripts [94]. 
It has since been shown that myeloid skewing with age is due to a compositional change in 
the ageing HSC pool [19,102]. As previous studies of HSC ageing performed gene 
expression profiling on the entire HSC pool, it is likely that the observed myeloid signature is 
a result of the overrepresentation of myeloid biased (My-bi) HSC clones in aged samples, 
rather than an intrinsic up-regulation of myeloid transcripts in balanced HSCs. Recent 
findings indicate that My-bi HSC clones are the most primitive subset of HSCs. They 
possess long-term reconstituting potential and show a high ABC/G2 pump activity that can 
be identified via Hoechst dye exclusion assays [16,19]. Indeed, cells with the least Hoechst 
dye retention, i.e. lower side population (LSP) cells, are enriched for My-bi clones as well as 
for LT-HSCs (Fig. 3.2, [19]). The LSP phenotype and differentiation potential is thought to be 
stable with age [19], however, I and others have found that it is the LSP fraction of HSCs in 
particular that accumulates with age  (Fig. 3.5 [7,19]). Based on these notions, I concluded 
that the currently available data on HSC gene expression during ageing, most likely mirrors 
the change in composition of the HSC pool with age and is not a true reflection of the 
intrinsic changes that occur during LT-HSC ageing. In order to elucidate the mechanisms 
governing HSC ageing, I performed global gene expression analysis of LSP cells at the 
previously described ageing time points (Chapter 3) and investigated the changes that occur 
in gene expression during age. I analysed the transcriptomes of ageing HSCs by RNA-
sequencing (RNA-seq), which in this case involves the sequencing of expressed (mRNA) 
transcripts on next-generation sequencing platforms. RNA-seq offers several advantages 
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over microarray hybridisation, which is another major gene expression analysis method 
[183]. These include 1) a high sensitivity for detecting very low expressed and rare 
transcripts, 2) a negligible background noise compared to the high background noise in 
microarray data and 3) the ability to detect novel transcripts and splice variants/isoforms. 
The latter advantage is due to the fact that RNA-seq involves the generation of cDNA 
sequences within a given sample which is then mapped back to the relevant genome, while 
hybridization techniques rely on a prior knowledge of existing transcripts, in order for these 
to be tilled on arrays, and subsequently detected in gene expression studies. In aggregate, 
RNA-seq is a sensitive method, which allows the accurate detection of changes in gene 
expression without a priori assumptions.  
As this study concerns the ageing of an otherwise wild-type and homogeneous cell 
population, I hypothesised that HSC ageing will be accompanied by subtle but significant 
changes in gene expression, such as, the inappropriate activation of silent transcripts, splice 
variants and the generation of novel isoforms, all of which are only detectable by RNA-seq. 
As gene expression can vary within (allelic variation) and between (stochastic and 
population-specific variation) cells, I analysed the expression of three biological replicates for 
each time point, each consisting of HSCs pooled from several animals of a similar age. This 
ensured that biological noise was tapered and only significant and biologically relevant 
changes in gene expression were identified. 
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5.2  RNA-sequencing of the Ageing LT-HSC Transcriptome 
I performed RNA-sequencing of mRNA from three biological replicates of HSCs from young 
(Young), middle-aged (Mid) and old (Old) animals using Illumina next-generation sequencing 
technology. One replicate each of Young and Old samples were sequenced on the Illumina 
GAIIx sequencing platform, while all other samples were sequenced on the Illumina Hi-seq 
platform, an improved model of the Illumina sequencers. Although there was a slight 
decrease in the correlation between samples sequenced on different platforms, compared to 
those on the same platforms, the correlation scores in either scenario was remarkably high 
(average Pearson‘s correlation score 0.94 versus 0.98 respectively). Based on this, I 
concluded that the use of data from the two different sequencing platforms was unlikely to 
influence the findings in this study. Moreover, I performed two technical replicates (one 36 
bp and one 50 bp sequence read length) for all samples sequenced on the Hi-seq, and 
observed a perfect Pearson‘s correlation score of 1 for all samples (Table. 5.1), thus 
validating the reproducibility of the Hi-seq technology. 
Finally, I observed a high correlation between all replicates and age time points (Table. 5.1), 
which suggests that gene expression of HSCs is relatively stable during ageing. This finding 
supports my hypothesis that gross alterations in gene expression are unlikely to govern HSC 
ageing (Section 5.1).  
 
Results Chapter 5 
 
114 
 
 
Table 5-1: Table of Pearson’s correlation for RNA-seq libraries.  
Correlation values highlighted in grey represent a sample‘s correlation to itself while those in red text represent correlation between technical replicates. ‗YoungB6‘ and ‗OldB6‘ were sequenced on 
the Illumina GAIIx while all others were sequenced on the Hi-seq platform. Correlation values range from 0–1 with 1 being the highest score. 
Samples YoungB6 YoungB6_
2 
YoungB6_2_
50bp 
YoungB6_
3 
YoungB6_3_
50bp 
MidB6_
1 
MidB6_1_ 
50bp 
MidB6_
2 
MidB6_2_
50bp 
MidB6_
3 
MidB6_3_ 
50bp 
OldB6 OldB6_
2 
OldB6_2_
50bp 
OldB6_
3 
OldB6_3_
50bp 
YoungB6 1.00 0.85 0.89 0.89 0.91 0.90 0.92 0.93 0.95 0.97 0.97 0.96 0.86 0.89 0.88 0.88 
YoungB6_2 0.85 1.00 1.00 0.99 0.99 0.99 0.98 0.97 0.96 0.94 0.94 0.96 0.99 0.99 0.99 0.99 
YoungB6_2_50bp 0.89 1.00 1.00 1.00 1.00 0.99 0.99 0.97 0.97 0.96 0.96 0.97 0.99 0.99 0.99 0.99 
YoungB6_3 0.89 0.99 1.00 1.00 1.00 1.00 0.99 0.98 0.98 0.97 0.97 0.98 0.99 0.99 1.00 1.00 
YoungB6_3_50bp 0.91 0.99 1.00 1.00 1.00 0.99 1.00 0.99 0.98 0.97 0.98 0.98 0.99 0.99 0.99 0.99 
MidB6_1 0.90 0.99 0.99 1.00 0.99 1.00 1.00 0.99 0.98 0.98 0.98 0.98 0.99 0.99 0.99 0.99 
MidB6_1_50bp 0.92 0.98 0.99 0.99 1.00 1.00 1.00 0.99 0.99 0.98 0.98 0.99 0.99 0.99 0.99 0.99 
MidB6_2 0.93 0.97 0.97 0.98 0.99 0.99 0.99 1.00 1.00 0.99 0.99 0.98 0.97 0.98 0.98 0.98 
MidB6_2_50bp 0.95 0.96 0.97 0.98 0.98 0.98 0.99 1.00 1.00 1.00 1.00 0.99 0.96 0.97 0.97 0.97 
MidB6_3 0.97 0.94 0.96 0.97 0.97 0.98 0.98 0.99 1.00 1.00 1.00 0.98 0.95 0.96 0.96 0.96 
MidB6_3_50bp 0.97 0.94 0.96 0.97 0.98 0.98 0.98 0.99 1.00 1.00 1.00 0.98 0.95 0.96 0.96 0.96 
OldB6 0.96 0.96 0.97 0.98 0.98 0.98 0.99 0.98 0.99 0.98 0.98 1.00 0.96 0.98 0.98 0.97 
OldB6_2 0.86 0.99 0.99 0.99 0.99 0.99 0.99 0.97 0.96 0.95 0.95 0.96 1.00 1.00 1.00 1.00 
OldB6_2_50bp 0.89 0.99 0.99 0.99 0.99 0.99 0.99 0.98 0.97 0.96 0.96 0.98 1.00 1.00 1.00 1.00 
OldB6_3 0.88 0.99 0.99 1.00 0.99 0.99 0.99 0.98 0.97 0.96 0.96 0.98 1.00 1.00 1.00 1.00 
OldB6_3_50bp 0.88 0.99 0.99 1.00 0.99 0.99 0.99 0.98 0.97 0.96 0.96 0.97 1.00 1.00 1.00 1.00 
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5.3 Transcriptome Analysis of LT-HSC Ageing 
50,601 annotated ensembl transcripts were covered by the RNA-seq of ageing samples and 
these were analysed for gene expression and differential expression as described in 
materials and methods. Briefly, sequenced cDNA transcripts were mapped back to the 
mouse genome and each aligned transcript was used to determine relative transcript 
abundance, which was then compared across different age groups, to determine age-
differential expression. Of these 50,601 transcripts, a total of 1290 were found to be 
significantly (FDR < 0.05) differentially expressed between Young and Old samples, with 
430 genes downregulated and 860 genes upregulated in Old samples relative to Young 
samples (Y-O comparison). Additionally, 2074 transcripts were found to be differentially 
expressed between Young and Mid samples (Y-M comparison), while 1187 were 
differentially expressed between Mid and Old (M-O comparison).  A count of differentially 
expressed genes for all comparison sets, in this study, is shown in Table 5.2.  
67%, 59%, and 51% of differentially expressed transcripts were upregulated, in older 
animals of the aforementioned comparison sets, respectively. The observation that the 
majority of differentially expressed transcripts in HSCs were upregulated with age is 
consistent with an age-dependent global hypomethylation in HSCs (Chapter 4).  
 
Table 5-2: Counts of differentially expressed genes  
 
 
Comparison Set Upregulated 
with age 
Downregulated with 
age 
Total changed with 
age 
Young to Mid (Y-M) 1215 859 2074 
Mid to Old (M-O) 608 579 1187 
Young to Old (Y-O) 860 430 1290 
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I investigated the biological relevance of differentially expressed transcripts using the web 
based Ingenuity pathway analysis gene ontology tool (IPA).  From this, I determined 
predicted biological functions that were altered during HSC ageing. Figure 5.1 provides a 
summary of the top ten biological functions that were up- and down regulated in HSCs at the 
three age points studied. This was further summarised in Figure 5.2, where it can be seen 
that the most functionally significant (p-value = 3.13E-14) age-dependent downregulation of 
transcripts occurred between young and middle-age, and involves genes that regulate 
proliferation of cells (arrowed), while the most functionally significant (p-value = 1.16E-14) 
transcript upregulation occurred between middle- and old age, affecting genes involved in 
cell movement (arrowed).  
An important feature of foetal liver (FL) murine haematopoiesis is the presence of highly 
proliferative HSCs, which are necessary to rapidly establish haematopoiesis during ontology 
[41]. This highly proliferative state is observed in foetal and neonatal mice, where over 90% 
of all HSCs are actively cycling [184]. This is in contrast to haematopoiesis in adult mice (> 8 
weeks) where over 90% of all HSCs are quiescent [41,184]. I determined that genes 
involved in the regulation of cell proliferation were the most significantly downregulated 
genes from Young (8–12 weeks) to Mid (~12 months) mice. This includes Ikaros, an 
important gene in the development of FL HSCs, whose overexpression in adult HSCs leads 
to diminished quiescence [25]. These observations are consistent with a switch from 
proliferative to quiescent HSCs during adult mouse haematopoiesis. Although this switch is 
thought to occur at approximately 4 weeks after birth [184], it is possible that the expression 
of genes involved in foetal HSC proliferation, persists beyond this period, and is only fully 
downregulated after puberty (> 12 weeks). I performed phenotyping experiments involving 
6–7 week old adolescent mice and consistent with published observations [12,18], found that 
the majority of KLS defined HSCs from mice of this age did not possess the SP phenotype 
and were CD34+ (Fig. 5.3), both of which are properties associated with foetal and actively 
cycling HSCs [12,34].  The SP phenotype, which is a marker of HSC quiescence [185], and 
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is thus highly enriched in adult LT-HSCs, appears to emerge in 8 week old mice (selected as 
Young in this thesis), but remains extremely rare compared to older mice (Fig. 3.5). Although 
only SP and thus bona fide adult LT-HSCs were isolated and compared in this thesis 
(Chapter 3), it may be that adult LT-HSCs from young mice retain the expression of several 
genes that were required for the highly proliferative states of FL HSCs, and these genes are 
only fully downregulated after puberty and by middle-age. The identification of such genes is 
important in our understanding of how HSC quiescence is achieved and maintained. 
Following the downregulation of proliferation genes between Young and Mid, another highly 
significant change in gene expression appears to occur between Mid and Old. This involves 
the upregulation of genes involved in cell movement (Fig. 5.2). Cell movement is an 
important process in haematopoiesis and in the interaction of HSCs within specialised 
niches.  I found that several genes involved in HSC-niche interactions, such as Selectins, 
Integrins, Metalloproteinases and Cell adhesion molecules (CAMs), were upregulated 
between Mid and Old samples. It is possible that by the upregulation of cell movement 
genes, HSCs from old mice alter their affinity for a certain niche, which causes them to 
migrate to an alternative niche, which subsequently results in a change in their development 
potential(s). 
The Young - Old comparison dataset represents the ultimate change in gene expression 
during HSC ageing. I determined the overall age-dependent change in gene expression, by 
comparing HSCs from young- to that of old mice. I found that genes involved in the 
differentiation of blood cells (p-value = 3.42E-18) and cellular migration (p-value = 5.3E-12) 
were most significantly down- and upregulated respectively, during HSC ageing (Fig. 5.2). 
Additionally, IPA analysis of biological pathways that were differentially regulated in Old 
relative to Young samples revealed that the B-cell development (p-Value = 1.38E-07) and 
the glutamate degradation III (p-Value < 5E-03) pathways were most significantly down- and 
upregulated respectively, with age. While the relevance of the latter pathway in HSC ageing 
is currently unclear, age-dependent downregulation of the B-cell development pathway is 
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consistent with a reduction in the ability of aged HSCs to produce B-lymphocytes [94].  
Furthermore, I found that the T-helper cell differentiation pathway was the second most 
significantly (p-Value = 5E-03) upregulated pathway during HSC ageing. Interestingly, the 
previously described reduction in B-lymphopoiesis in aged HSCs was reported to be 
accompanied by an increase in the production of T-cells (and myeloid cells) [94]. Taken 
together, these results suggest that age-related alterations in the differentiation potential of 
HSCs are a result of cell intrinsic changes in gene expression. This is consistent with the 
findings of several other studies of HSC ageing [7,94,99].  
Finally, I performed IPA gene ontology analysis of all significantly age-dependent 
differentially expressed genes (Y-O). I detected a strong enrichment of genes involved in cell 
movement (p-value < 1E-10), 134 of which were upregulated and 85 downregulated (Table. 
A-4). These genes could be further subdivided into functional categories such as homing, 
migration, chemotaxis, and infiltration; both up- and downregulated, while other sub-
categories like transmigration and extravasation were exclusively downregulated in HSCs 
from older animals. Additionally, Aryl hydrocarbon receptor (AHR), which regulates HSC 
migration through binding of its agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
[186,187], was identified as one of the most significantly (p < 1E-08) overrepresented 
upstream regulators of age-dependant differentially expressed genes. These findings 
implicate cell movement in HSC ageing. 
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DOWNREGULATED FUNCTIONS 
UPREGULATED FUNCTIONS 
Figure 5-1: Top ten biological functions of  age up- and down regulated genes at various time points. 
 Y, M and O are young, middle-aged and old respectively. Change shown is from the youngest to the oldest time point in each comparison set.  
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Figure 5-2: The dynamics of gene expression during HSC ageing.  
Values shown on y axis is –Log(p-value). Cell Movement was the most significantly upregulated process during ageing, and 
this occurs between Mid and Old time points. Migration of cells appeared to be the overall most significantly upregulated 
process, from Young through Mid to Old. Proliferation of cells was the most significantly downregulated process during ageing, 
this occurs between Young and Mid time points. Differentiation of blood cells appeared to be the overall most significantly 
downregulated process from Young through Mid to Old. 
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Figure 5-3: Antibody and SP phenotype of HSCs from 6-7 week old mice. 
HSCs at this stage are reminiscent of foetal liver HSCs and are CD34+ and non-SP. Each plot shows the phenotype of 
cells gated on the previous plot as indicated by the curly arrow.  The final plot shows the Hoechst profile of 
CD34+CD150- KLS (Q1) cells. 
Age 
Up in Old from Mid 
Up in Old from Young 
Down in Old from Mid 
Down in Old from Young 
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5.4 Validation of RNA-seq by qRT-PCR  
To validate the RNA-seq data, I performed qRT-PCR on selected genes that were 
determined to be age-differentially expressed by RNA-seq. These candidates were selected 
based on their relevance to the aims of this thesis, as summarised below (Table. 5.3). The 
validation process also served as an independent confirmation of age differential expression, 
using independent biological replicates. 
Table 5-3: Selected genes for RNA-seq validation by qRT-PCR. 
Gene Change with age Summary 
Dnmt1 Downregulated 
Encodes the DNA methyltransferase enzyme which is responsible 
for the maintenance of DNA methylation marks in the genome. 
DNMT1 has been shown to be important in HSC regulation [151] 
Itgb3 Upregulated 
ITGB3 is a cell surface protein with a key role in cell signalling and 
cell adhesion (NCBI genes). This gene is hypomethylated in 
HSCs with age (Chapter 4) 
Mrc1 Downregulated 
Mannose receptor with a role in immunity and inflammation (NCBI 
genes). Hypomethylated in HSCs with age (Chapter 4) 
Nav2 Upregulated 
Involved in cellular growth and migration (NCBI genes) and both 
of these processes are differentially regulated in HSCs with age 
(Section 5.3). This gene is hyper- and hypomethylated in HSCs 
with age (Chapter 4) 
Sdpr Upregulated 
Involved in caveolae formation and signalling. The expression of 
this phospholipid-binding protein increases in serum starved cells 
and during HSC ageing [94,99,167,168]. hypomethylated in HSCs 
with age (Chapter 4) 
Selp Upregulated 
Has a key role in inflammation [188] and haematopoietic cell 
movement [189]. Previously identified as upregulated and 
important in HSC ageing [99] 
Sox4 Downregulated 
Encodes a transcription factor that is crucial for B lymphopoiesis 
[190] 
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I performed ‗two-step‘ qRT-PCR on LT-HSCs that were obtained from three independent 
biological replicates as detailed in materials and method (Chapter 2). Briefly, FACS sorted 
LSP cells were lysed and converted directly into cDNA, which was analysed for gene 
expression on a qPCR machine using TaqMan assays for selected genes. qRT-PCR 
expression data was then compared to normalised expression values from RNA-seq. Figure 
5.4 shows the expression of the genes detailed above as determined by RNA-seq (left) and 
by qRT-PCR (right).  Overall, I observed a good agreement in the trend of gene expression 
between; 
1. Genes - of the seven genes listed in Table 5.3, Selp and Itgb3 were found by RNA-
seq to show the highest expression in HSCs while Nav2 and Mrc1 had the lowest 
expression. This was confirmed by qRT-PCR.                        
2. Age groups for each gene – All seven genes were found to be differentially 
expressed with age by qRT-PCR and in the same direction as in RNA-seq. 
Additionally, Mid samples showed intermediate expression values for five out of the 
seven genes in both techniques. 
    
 
Plot show the gene expression of seven candidate genes in HSCs, from Young, Mid and Old mice. Gene expression was 
determined by RNA-seq and qRT-PCR. Data from the two technologies appear comparable. At least 3 biological replicates are 
shown for all samples. Error bar represents standard error of the mean. 
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Figure 5-4: Validation of RNA-seq by qRT-PCR 
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5.5 Comparison to Previous Studies of HSC Ageing  
As detailed in Section 5.1, there were two other similar data sets on adult HSC gene 
expression during ageing. These data sets were generated independently (Rossi et al and 
Chambers et al), and involved the expression profiling of HSCs from young and old C57BL/6 
mice, as done in this study [94,99]. However, in contrast to the current study, a 
heterogeneous mix of HSCs was profiled and gene expression was analysed using 
microarray technology. Nevertheless, I was interested in comparing these data sets with my 
data, in order to; 
1. Determine the degree of similarity between the gene expression of HSCs profiled by 
me and others. 
2. Identify genes and biological processes that are commonly age-differentially 
regulated in all three data sets. 
To perform this analysis, I obtained a list of genes that were differentially expressed between 
young and old mice in each of the three studies. These lists consisted of several genes, 
where more than one transcript was differentially expressed. I edited the lists such that each 
gene was represented only once (regardless of the number of differentially expressed 
transcripts. As a result, several ‗duplicate‘ genes were removed and this prevented an 
artificial inflation of the degree of overlap between these studies. Subsequently, I compared 
the edited gene lists between studies and identified genes that were common to the three 
data sets. This comparison was performed separately for specified up- and downregulated 
genes, and is represented as a Venn diagram in Figure 5.5. All three studies including the 
current had more genes that were up- than downregulated, reiterating the significance of 
gene upregulation in HSC ageing. Given that the Rossi et al. [94] and Chambers et al. [99] 
data sets were generated using  similar technology (microarray), and by purification 
strategies that supposedly yield very similar HSC populations (KLS;CD34-;Flk2- and SP; KLS 
respectively), it was surprising to find a low overlap of differentially expressed genes 
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between these studies. In fact, the identified overlap is only a little higher than between the 
current study and the Chambers study (Fig. 5.5).  
 
Figure 5-5: Comparative Analysis of the ageing HSC transcriptome.  
The blue circle represents data from Chambers et al. [99]; the green represents that of Rossi et al. [94], while the red represent 
data from this study. Analysis was performed by identifying genes that were represented in common to the studies compared. 
Results  Chapter 5 
 
125 
 
0 2 4 6 8
cell adhesion
cellular process
immune system process
cell-cell adhesion
cell communication
Up with Chambers 
-Log(p-value)
0 2 4 6 8 10
cellular process
developmental process
cell communication
cell adhesion
ectoderm development
Up with Rossi 
-Log(p-value)
0 1 2 3 4 5
cell adhesion
cell-cell adhesion
immune system process
cellular process
blood coagulation
Comparison Analysis 
-Log(p-value)
0 2 4 6
system development
mesoderm…
immune system process
primary metabolic…
developmental process
Chambers up with 
Rossi 
-Log(p-value)
From the comparison analysis, I identified 100 age-upregulated genes that were shared 
between this study and that of Chambers et al., as well as 81 that were upregulated in 
common between the current study and Rossi et al. Of these, 34 genes were common to all 
three studies and I identified the top age upregulated biological processes by performing 
gene ontology (PANTHER) analysis of these genes (‗Comparison Analysis‘). I also 
investigated the biological processes common to this study and 1) Chambers et al. (‗up with 
Chambers‘) and 2) Rossi et al. (‗up with Rossi‘). Finally, I determined the process common 
to the Chambers and Rossi studies (‗Chambers up with Rossi‘). The results of these 
analyses are displayed in Figure 5.6 and show that cell adhesion is the most significantly 
upregulated process that is common to all three data sets (Fig. 5.6, ‗Comparison analysis‘). 
However this was not true for the Chambers and Rossi comparison. 
 
Genes that were identified as significantly upregulated in common, during HSC ageing between the specified studies, were 
analysed for enriched biological processes, using the PANTHER program. Top 5 enriched processes are shown. 
Figure 5-6: Biological processes that are common between multiple studies of HSC ageing. 
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5.6  Conclusion 
In this Chapter, I generated and analysed the transcriptomes of ageing LT-HSCs by RNA 
sequencing of cDNA obtained from LT-HSCs that were isolated from mice at three different 
age points. To my knowledge, these are the first RNA-seq data on ageing LT-HSCs. I 
observed a high correlation between all RNA-seq data sets, which represents a statistical 
indication of the high quality and reproducibility of the data generated in this study. Several 
age-differentially expressed genes were identified and I performed gene ontology analysis 
on these, revealing significant changes in key biological processes at specific stages during 
HSC ageing. This includes a downregulation of cell proliferation between young- and middle 
age as well as the upregulation of cell movement between middle- and old age. Overall i.e. 
up- and downregulated in Old compared to Young, I observed a highly significant change in 
the expression of several genes that are involved in cell movement. I also determined that 
the genes that were upregulated in common in this study and previous studies of HSC 
ageing are enriched in genes involved in cell adhesion. These findings indicate that several 
genes and key processes, involved in the interaction between HSCs and their bone marrow 
niche, are altered with age. 
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5.7 Discussion 
I have identified several novel changes and provided insights into the dynamics of gene 
expression during HSCs ageing. Adult HSCs are known to be quiescent, with more than 
90% of all HSCs in the bone marrow at the G0 stage of the cell cycle [41]. This is in stark 
contrast to FL haematopoiesis where HSCs are highly proliferative [29,41]. Although the 
above is a well-established fact in haematopoiesis, the exact stage and key regulators of the 
switch from foetal to adult haematopoiesis, is currently unclear. Previous studies have 
attempted to address this question by studying HSC cycling and have found that the switch 
from proliferative to quiescent HSCs does not occur until 3–4 weeks after birth [184]. 
However, I and others have found that several adult HSCs, of as old as 7 weeks, retain the 
FL HSC phenotype i.e. KLS CD34+ [12,18].  I also showed that a major change in gene 
expression from young to middle-age, involved the downregulation of genes that were 
associated with cell proliferation. This suggests that although HSCs from pre-pubescent 
young mice are thought to be quiescent, the switch from proliferation to quiescence in HSCs 
is not instantaneous but involves the progressive downregulation of several genes that 
promote the proliferative phenotype. The identification of such genes is an important 
improvement in the understanding of HSC regulation and the mechanisms involved in their 
switch from a foetal/proliferative phenotype, to quiescence. 
Another key difference between foetal and adult haematopoiesis is the niche in which HSCs 
reside, and adult haematopoiesis is preceded by the migration of HSCs from the foetal liver 
at approximately 15 days post-conception, to the spleen and finally  the bone marrow, where 
they remain throughout adult life [29]. This transition is orchestrated by several adhesion 
molecules including selectins, integrins and chemokines, stromal cell-derived factor-1 (Sdf-1, 
also known as Cxcl12), which have crucial roles in the homing of HSCs to the bone marrow 
and their retention or lodgement once there [39,191-193]. The bone marrow provides a 
regulatory micro-environment for adult HSCs and this interaction is necessary for HSC self-
renewal and quiescence [34]. It is therefore important that homeostatic conditions are 
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maintained within the bone marrow for normal haematopoiesis to occur. Cell movement and 
adhesion to specialized niches are clearly important processes in the regulation of HSCs 
during ontogeny; it was therefore interesting to find that these processes were significantly 
altered during ageing. It is tempting to explain these findings simply as another wave of HSC 
migration to a different niche i.e. away from an aged bone marrow; however, this is unlikely, 
as the bone marrow is the final known residence of adult HSCs [29], and although, 
extramedullary haematopoiesis is known to occur in adults, this is pathological [194]. 
Therefore, a more likely explanation could be the movement of HSC to a more supportive 
niche, within the bone marrow, during ageing. Indeed, It is thought that multiple niches exist 
within the bone marrow i.e. endosteal and vascular niche [14,33,182]. However, the exact 
nature of these niches and their exact physiological relationship with HSCs is highly debated 
[39]. Nevertheless, it is possible that intrinsic changes in aged HSCs cause them to move to 
a different niche within the bone marrow, which in turn alters their differentiation potential, 
resulting in increased quantity and myeloid bias, as seen in HSCs isolated from old mice. 
Interestingly, a study of haematopoietic stem and progenitor cell (HSPC) movement found 
that aged HSPCs showed increased motility and were found further away from the 
endosteum than their young counterparts [195]. These findings, and the change in the 
expression of cell movement and adhesion genes observed in this study, strongly suggest 
that altered cell movement is involved in HSC ageing. 
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Chapter 6 
Methylomic Analysis of Ageing LT-HSCs 
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6  
6.1 Introduction 
I showed in Chapter 4 that the DNAm profile of HSCs is altered with age. I identified a 5% 
reduction in global DNAm levels and found several genes to be differentially methylated with 
age. As discussed in Chapter 1, DNAm is involved in gene regulation, and changes in 
DNAm result in altered gene expression, and compromised cell fate [51]. In line with 
previous findings [88,90,151], age-related changes in the DNAm of HSCs were 
accompanied by significant changes in gene expression (Chapter 5). DNAm regulates gene 
expression by various mechanisms, several of which are only beginning to be uncovered. 
Some of these mechanisms, such as epigenetic modification of promoter regions, are well 
established and known to have a major impact on gene expression, while the role of DNAm 
at other non-canonical regulatory regions, for instance, splice sites, CGI shores and non-
coding intergenic regions, are just beginning to be elucidated [80,172,196]. The role of 
DNAm in gene regulation was highlighted in Chapter 1, and will not be discussed here; 
however, in order to understand the functional consequence of the changes in DNAm that 
were uncovered during HSC ageing, it was necessary to integrate the methylomes and 
transcriptomes of ageing HSCs. A key strength of this thesis is its study design; HSC DNAm 
and gene expression analysis were conducted on DNA and RNA from the same primary and 
functionally relevant cells. As a result, it was possible to assess the direct effects of aDMRs 
on gene expression. In this Chapter, I report the methylomics analysis of LT-HSC ageing, 
which was performed with the following aims;  
1. Identify the relationship between global DNAm and gene expression in HSCs  
2. Elucidate the dynamics of this relationship during ageing 
3. Assess the effects of aDMRs on differential expression. 
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6.2 Methylomic Analysis of Ageing LT-HSCs  
In order to understand the relationship between global DNAm and HSC gene expression, 
50,601 annotated Ensembl transcripts, that were covered by the RNA-seq of HSCs in 
Chapter 5, were grouped according to four expression levels (0-25, 25-50, 50-75 and 75-
100%). DNAm for these transcripts were then determined by the MEDIPS algorithm and 
aggregated over canonical gene features [197].  
The analysis was done in two parts. Firstly, DNAm at putative promoter regions (-5kb 
upstream, transcription start site (TSS) and 1st exon) was analysed and pooled for each of 
the four gene expression levels, revealing a significant (Kruskal-Wallis, p-value < 0.001), 
step-wise decrease in promoter methylation with increasing gene expression, across all 
three age groups (Fig. 6.1). This indicates a negative correlation between promoter 
methylation and gene expression in LT-HSCs, and shows that this relationship is not altered 
during ageing.  
 
Figure 6-1: The relationship between DNA methylation and gene expression. 
Box plot showing the negative correlation between DNAm and gene expression in HSCs, at different age points. MEDIPS score 
is proportional to DNAm levels. 
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As DNAm in non-promoter regions is also known to influence gene expression [60], it was 
important to assess the relationship between DNAm and global gene features, such as 3‘ 
and 5‘ UTRs, intragenic, intergenic, as well as introns and exons. To achieve this, HSC 
transcripts at two extreme mean expression levels (Low = 0-25% and High = 75-100%), 
were assessed for DNAm, over nine canonical gene features defined by Li et al [197]. 
Whereas, the negative correlation between promoter methylation and gene expression was 
maintained with age (Fig. 6.1), analysis of global gene features revealed significant (Kruskal-
Wallis, p-value < 0.001) age-related alterations in the relationship between DNAm and HSC 
transcripts (Fig. 6.2).  This analysis showed that while the DNAm profile of HSC transcripts 
were largely similar in Young and Mid HSCs; this profile was markedly altered in Old HSCs. 
The most prominent alteration shown in Figure 6.2 is the global decrease in DNAm that was 
identified in Chapter 4; however, closer examination of each gene features revealed a 
number of notable differences. For instance, the clear demarcation between the first exon, 
first intron and main exons, at positions 4–6 (arrowed), was lost in old HSCs. The flat-lining 
effect at these positions in Old samples is mostly attributable to loss of DNAm in the first 
intron (Fig. 6.2, position 5). Additionally, a loss in DNAm (∆DNAm) at the 5–10 kb 
downstream positions (3‘-untranslated region (UTR) can be observed. These findings show 
that loss of DNAm at gene bodies and intergenic regions occurs during HSC ageing and 
may be involved in this process. Likewise, the observation that DNAm at promoter regions 
was the only distinguishing feature between low and high expressed HSC genes, and the 
fact that this relationship is strictly maintained with age, confirms the importance of DNAm at 
this region and in HSC gene regulation. 
6.3 The Role of DNA methylation in Age Differential Gene Expression 
I examined the functional consequence of the aDMRs identified in Chapter 4, by 
investigating the correlation between age-dependant differential methylation and age-
dependent differential expression. 13.5% of age differentially methylated genes (aDMG) 
were also found to be differentially expressed (Table. 6.1, Table 6.2). Hypo-aDMRs were 
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Figure 6-2: Genome-wide DNA methylation profiles of high and low expressed genes.  
DNAm was aggregated and averaged for 9 canonical gene features for high (red line) and low (black line) expressed genes in Young, Mid and Old LT-HSCs. 3‘UTR (locations 8 and 9) shows the 
most prominent drop in DNA methylation with age (∆DNAm) while the negative correlation between DNAm levels and gene expression is maintained during ageing (green line). Loss of gene body 
methylation is indicated by single arrow heads. 
. 
Results Chapter 6 
 
134 
 
more significantly associated with altered gene expression (p-value < 0.0001) than hyper-
aDMRs (hyper-aDMR p-value = 0.04690). Additionally, 80% of differentially expressed 
aDMGs (DE-aDMGs) were upregulated, which is consistent with the global upregulation of 
genes identified in Chapter 5. These findings also suggest that loss of DNAm and increased 
gene expression are the predominant changes underlying ageing of HSCs. 
 
Table 6-1: Summary of Methylomic Analysis Data 
 
Analysis 
Total Increased 
with age 
Total Decreased 
with age 
Total Observed 
with age 
Age Differential Methylation  71 40 111 
Age Differential Expression 860 430 1290 
Age Differentially expressed aDMGs 
  
14 
 
Table shows a summary of the aDMR or age differentially expressed transcript counts from; methylation, gene expression and 
integrated (methylomics) analysis performed in this thesis. Change is from Young to Old. 
 
 
Table 6-2: Differentially expressed aDMGs 
 
 
 
 
 
 
 
 
 
 
 
 
Blue Shading represents Hypermethylation and Yellow, Hypomethylation. Decreasing colour intensity depicts increasing FDR. 
Log2 FC is Log2 fold change in gene expression. Change is from Young to Old 
aDMG Log2 FC 
Kiss1r 1.83 
Nav2 2.21 
Nav1 1.52 
Rusc2 1.88 
Hsf4 -5.55 
Amotl2 1.33 
Trim30a -4.71 
Mrc1 -2.46 
Pfkfb3 1.13 
Itgb3 2.33 
Wdfy1 2.38 
Nav2 2.21 
Slco2a1 1.56 
Sdpr 1.98 
Pde8a 0.98 
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6.4 Mechanisms of HSC ageing  
The DE-aDMGs that were identified and listed in Table 6.2, were too few for gene ontology 
analysis, however, bearing in mind that cell movement was the most significantly altered 
process during HSC ageing (Chapter 5), I assessed the frequency of DE-aDMGs that were 
involved in cell movement and found that at least 40% of these genes are involved in cellular 
migration, which is a cell movement process [162,166,198-201]. These include Itgb3, Nav1, 
Nav2, Amotl2, Kiss1r and Pde8a, and suggest that age-related changes in DNAm are 
involved in the dysregulation of HSC cell movement genes with age. 
6.4.1 SDPR and HSC ageing 
As well as the cell movement genes highlighted above, Sdpr is another gene that was found 
to be differentially expressed and methylated with age. Sdpr, which is also known as Cavin-
2, was originally identified as a gene whose expression was increased in serum-starved cells 
[167]; however, an independent role in caveolae formation and cell signalling has since 
emerged [168]. Caveolae are invaginated lipid rafts that provide a common platform for 
various signalling molecules, leading to enhanced cell signalling and potent signal 
transduction. Over-expression of Sdpr in cultured cells leads to caveolae elongation [168] 
and perhaps results in an increased surface area for interacting cell signalling molecules. 
Furthermore, previous studies of HSC ageing have identified a significant upregulation of 
Sdpr gene expression with age [94,99], suggesting that this gene is involved in HSC ageing.  
I identified a progressive loss of promoter DNAm in the Sdpr gene with age (Fig. 6.3), and in 
agreement with findings from the integrated methylome/transcriptome analysis, described in 
Section 6.2; this reduction in promoter methylation was accompanied by a significant (FDR < 
5E-09) age-dependent upregulation of the Sdpr gene. In addition, I found the Sdpr promoter 
aDMR to be conserved in several mammals and between other CAVIN family members (Fig. 
6.3). These suggest that this aDMR is important for SDPR‘s involvement in caveolae 
biogenesis and may be involved in HSC ageing. 
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Figure 6-3: UCSC genome browser screenshot of MeDIP-seq profile of the Sdpr gene in ageing HSCs.  
Tracks are colour-coded blue, orange and green for Young, Mid and Old samples, respectively. Three biological replicates, 
each consisting of pools of 5-30 mice, are shown for each age group. Peak height represents DNA methylation levels. The two 
aDMRs identified in the Sdpr gene are boxed in red and black. The red box depicts the aDMR that aligns with other members 
of the human CAVIN gene family and is highly conserved from human to fish (except dog) as indicated.  
 
6.5 Validating the Role of DNAm in Age-dependent Differential Expression of 
the Sdpr Gene 
I performed bisulfite pyro-sequencing of the Sdpr gene promoter aDMR (Fig. 6.3, red box), 
as a technical validation of MeDIP-seq, and to confirm the mechanism of age-dependent 
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upregulation of the Sdpr gene (upregulation of Sdpr was previously validated in Chapter 5, 
by qRT-PCR).  
6.5.1 Bisulfite Pyro-Sequencing of Low Amount of Cells 
Because of the harsh nature of the bisulfite conversion process, which causes DNA to 
degrade, large amounts of DNA are often required as input. This ensures that there is 
enough DNA left for PCR and pyro-sequencing reactions. The amount of LT-HSCs that were 
available for this thesis was limited; as a result, I used the Qiagen EpiTect Plus LyseAll 
Bisulfite Kit (EpiTect kit) for bisulfite conversion of DNA directly from cells. This helped to 
minimize DNA loss by eliminating the extra DNA extraction step. Additionally, the EpiTect kit 
is optimized to minimize degradation of DNA, during bisulfite conversion and thus allows the 
bisulfite conversion of low number of cells. As bisulfite conversion of DNA directly from cells 
was not a standardized or well established method, I validated its use by comparing its 
conversion efficiency with that of bisulfite conversion from equivalent amounts of DNA. To 
this end, I bisulfite converted 1x104 cells and 50 ng of DNA in separate reactions, using the 
EpiTect kit, and compared conversion efficiencies by qPCR (materials and methods). This 
was performed for three technical replicates. As shown in Figure 6.4, bisulfite conversion 
efficiencies were remarkably high and comparable for both cells and DNA, thus validating 
the method of direct bisulfite conversion of DNA from cell lysates.  
6.5.1.1 Bisulfite Pyro-sequencing Assay Validation 
Next, I designed (materials and methods) and validated the Sdpr promoter BS-Pyroseq 
assay. This involves the validation of BS-PCR primer sets (Table. A-1), to ensure that 
primers are able to amplify DNA of various methylation levels, with equal efficiency. There 
are multiple steps involved in this process. These include:  
1. Construction and validation of in vitro methylated DNA that will be used to test BS-
PCR primers. 
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Figure 6-4: Validation of bisulfite conversion of DNA directly from cells lysates.  
Plot shows that bisulfite conversion from cells (10k_cells_BS) is as efficient and reliable as from DNA (50ng_DNA_BS). Blue 
bars show the fraction of converted DNA over unconverted DNA (red bar). Genomic DNA that had not been treated with 
sodium bisulfite was used as control (Genomic DNA). Three replicates of 10000 cells and 50 ng DNA and one replicate of 
genomic DNA are shown. Error bars represent standard error of the mean. 
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2. PCR amplification of in vitro methylated DNA, over a range of methylation levels 
i.e.100%, 75%, 50%, 25% and 0%.  
3. Pyro-sequencing of amplified products to ascertain assay linearity. 
 
The Sdpr assay was tested by following the outlined steps. I in vitro methylated mouse 
genomic DNA as described in materials and methods, and verified that this was indeed 
methylated. Verification was achieved by digesting test DNA with methylation sensitive 
restriction enzymes (materials and methods). Figure 6.5 shows that the in vitro methylated 
DNA that was used to validate the Sdpr assay had been successfully methylated. This was 
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inferred from the presence of a single undigested DNA band for in vitro methylated DNA, 
compared to genomic DNA, which was digested and therefore appeared as a smear when 
electrophoresed.  
 
Figure 6-5: In vitro DNA methylation. 
The ‗SSS1‘ lane shows a single band of undigested high molecular weight DNA after treatment with methylation sensitive (MS) 
restriction enzymes. The ‗WGA‘ lane contains DNA that has been completely demethylated (by whole genome amplification) 
and has therefore been digested by MS-restriction enzymes (smear). Far left lane shows a 50 bp size ladder. 
 
 
Following validation of in vitro methylated DNA, I constructed 100%, 75%, 50%, 25% and 
0% methylated DNA, by diluting the in vitro methylated with an appropriate amount of whole 
genome amplified, unmethylated DNA. These were bisulfite converted and used to test the 
Sdpr BS-PCR primers. Figure 6.6 shows that this primer set was able to specifically (no 
primer dimers or unwanted products) and consistently amplify the Sdpr promoter aDMR, 
regardless of methylation level. 
 
50 bp 
200 bp 
500 bp 
1350 bp 
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Figure 6-6: Validation of the Sdpr BS-PCR primers. 
These primers show efficient amplification of DNA, irrespective of methylation status. Outer left lane shows the 50 bp ladder. 
The Sdpr amplicon is expected to be 118 bp and the bands seen in all sample wells, appear to be about this size. 
 
Finally, I pyro-sequenced the amplified BS-converted DNA in order to test the linearity of the 
Sdpr assay, over the aforementioned methylation range. Figure 6.7 shows that the Sdpr 
assay is sensitive enough to discern the different levels of DNAm, and can therefore be used 
to validate the age-dependent Sdpr promoter hypomethylation that was detected by MeDIP-
seq. 
50 bp 
200 bp 
500 bp 
1350 bp 
100 bp 
150 bp 
Results Chapter 6 
 
141 
 
 
Figure 6-7: Validation of the Sdpr BS-Pyroseq assay. 
Plot shows the range at which the Sdpr assay can detect DNAm levels. In vitro methylated and whole genome amplified (WGA) 
mouse DNA from WBM cells were used for this calibration. DNA of shown ‗actual methylation levels‘ were constructed by 
appropriate mixing of 100% (In vitro) methylated DNA with 100% unmethylated (WGA) DNA, or by using undiluted versions of 
either, where appropriate.  
 
 
6.5.2 Validation of the Sdpr Promoter aDMR 
Following the establishment of the BS-Pyroseq method for use on low amount of cells, I 
bisulfite converted and pyro-sequenced four biological replicates of Mid and Old HSCs, as 
well as three biological replicates of Young HSCs. I confirmed by qPCR that the conversion 
efficiency was at least 99% for all samples (Appendix-Figure 2). These samples were 
independent of those used in MeDIP-seq reactions and were pyro-sequenced using the Sdpr 
assay (Table. A-1) described in Section 6.5.1.1. 
Consistent with MeDIP-seq (Fig. 6.3), bisulfite pyro-sequencing of the Sdpr promoter 
revealed a progressive loss of DNAm at this region with age (Fig. 6.8). Because the Sdpr 
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assay was not 100% accurate in detecting absolute methylation values (Fig. 6.7), I 
normalised all measured values against the Sdpr calibration curve. This was necessary to 
correct for any measurement bias that may ensue. Nevertheless, similar trends of age-
dependent Sdpr hypomethylation were observed, regardless of whether the measured or 
adjusted DNAm values were used (Fig. 6.8). 
 
Figure 6-8: Validation of progressive Sdpr promoter hypomethylation with age, using BS-Pyro-seq.  
Measured values (blue) and values normalized to the Sdpr calibration curve (red) are shown.  Error bars represent standard 
error of the mean. 3 biological replicates of Young and 4 biological replicates of Mid and Old are shown. 
 
6.5.3  Validating the Link between DNAm and Gene Expression 
DNAm is known to regulate gene expression (Section 1.7.2), and I showed in Section 6.2 
that promoter DNAm was negatively correlated with the gene expression of HSCs, 
irrespective of biological age. In this section, I sought to validate the link between promoter 
methylation and altered gene expression. As a result, I ex vivo cultured FACS purified LSPs, 
and treated them with 5-Aza‘dC, to induce global demethylation. 5-Aza‘dC is a methylation 
resistant analogue of cytosine, which can be incorporated into DNA to induce passive 
demethylation, following multiple rounds of cell division [202] (Fig. 6.9). To ensure that 
cultured LSPs divided sufficient times to allow 5-Aza‘dC incorporation and demethylation, I 
sought to optimize the ex vivo expansion assay, to allow maximum self-renewal, without 
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inducing differentiation. I cultured LSPs ex vivo for five days and visually assessed cell 
growth, by culture well coverage, and primitiveness, by cell surface marker phenotyping, at 
days three and five. Three day ex vivo culture of LSPs resulted in insufficient amount of cells 
(Fig. 6.10a, left), while five day culture resulted in adequate expansion (Fig. 6.10a, right) but 
yielded less phenotypically defined HSCs. 
 
 
Figure 6-9: Ex vivo DNA demethylation by 5-Aza’dC treatment. 
5-Aza‘dC is incorporated during cell division and DNA replication. DNMT1 binds irreversibly to 5-Aza‘dC and limits its 
availability for the maintenance of DNAm at hemi-methylated sites, leading to passive DNAm.  
 
(Fig. 6.10b). Primitiveness was measured by the phenotyping of HSC cell surface antigens 
using fluorescent antibodies and flow cytometry. KLS antibodies were used to assess the 
presence of HSPCs, while this in combination with Slam markers (CD48 and CD150) were 
used to measure primitive HSCs i.e. LT-HSCs. Based on these criteria, I observed more 
primitive HSCs at day three, regardless of the marker combinations that were assessed. 
Additionally Old HSCs appeared to maintain their LT-HSC phenotype better than Young 
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HSCs, during ex vivo culture (Fig. 6.10b). Flow cytometry plots for the data displayed in 
Figure 6.10b are shown in Appendix-Figure 3. 
 
 
 
   
 
 
These results indicated that intermediate culture duration between three and five days was 
required for optimal phenotypically defined LT-HSCs expansion, I therefore ex vivo cultured 
FACS purified LSP cells for a maximum of four days. Subsequently, I treated LT-HSCs with 
a range of 5-Aza‘dC concentrations and found that 1–2 µM was the optimum dose range 
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Figure 6-10: Ex vivo culture of HSCs. 
A) Appearance of LSP cells after three or five days ex vivo culture. More cells can be seen in the culture well at day 5. B) 
Phenotype of ex vivo cultured Young (E_Y) and Old (E_O) LSP cells. KLS antibodies are as previously described and 
measures HSPCs, KLS_Slam shows the frequency of KLS cells that are CD48- and CD150+, Slam measures these CD 
markers without KLS, while KLS_Slam shows the overall frequency of cells that are KLS, CD48
-
 and CD150
+
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that was required to induce demethylation with minimal cytotoxicity in these cells. 
Morphological examination and antibody phenotying of treated cells showed that LT-HSC 
integrity had not been markedly compromised by the treatment (Appendix-Figure 4).       
6.5.3.1 Sdpr Gene Regulation 
I assessed the expression of Sdpr in 5-Aza‘dC treated LT-HSCs and observed a dose-
dependent up-regulation of its gene expression (Fig. 6.11a, p-value = 0.028 for 2 µM 
treatment). Additionally, bisulfite pyro-sequencing of LT-HSCs revealed Sdpr promoter 
hypomethylation following 5-Aza‘dC treatment (Fig. 6.12b, p-value < 0.005). These findings 
are consistent with the age-dependent difference in Sdpr methylation and expression 
observed in Young and Old LT-HSCs and suggests that age-related up-regulation of Sdpr is 
due to DNA hypomethylation. 
Figure 6-11: Functional analysis of the Sdpr promoter aDMR. 
 
Analysis was by ex-vivo culture of LT-HSCs in the presence of 5-Aza‘dC (Aza) and (a) expression analysis using qRT-PCR. 
Data was obtained from independent experiments for a total of four biological replicates. Expression values shown are relative 
to ex vivo cultured, untreated control. (b) Validation of same Sdpr aDMR for promoter hypomethylation following ex-vivo 
culturing in the presence of 5-Aza‘dC (Aza). Data is shown for two biological replicates (red and blue bars). 2-3 middle-aged 
mice were pooled per replicate and average values for two treatment replicates are shown for each biological replicate. Sdpr 
DNAm level for freshly isolated (uncultured) LSP cells from Mid mice is shown in Fig. 6.8. A lower methylation level is expected 
in the cultured equivalents, as these cells have undergone more cell divisions, and are therefore of a higher replicative age. FC 
is fold change. Error bars depict standard error of the mean (S.E.M) in all cases (*P < 0.05; **P < 0.005; ***P < 0.0005). 
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6.6 Conclusion 
I performed the first known methylomics (integrated gene expression and DNAm) analysis of 
primary HSC ageing and began to investigate the regulation of gene expression by DNAm, 
during mammalian ageing. Consistent with several other studies [60,82,83], I found that 
DNAm, at gene promoters, is negatively correlated with gene expression in HSCs and 
showed that this relationship is stable with age. Age-related changes in DNAm at non-
canonical regulatory gene features were also observed. Integrated analysis of aDMGs and 
age differential expression identified several cell movement genes such as Itgb3 and Nav2, 
which appear to be age-differentially regulated by DNAm. Finally, I demonstrated a link 
between loss of promoter methylation and upregulation of Sdpr during HSC ageing. The 
findings in this thesis suggest that dynamic changes in DNA methylation constitute an 
epigenetic mechanism that possibly contributes to the decline of HSC functionality with age. 
6.7 Discussion 
Several studies have provided evidence for the intrinsic nature of HSC ageing, however, the 
mechanisms involved in these changes remained unclear. The integrated methylome and 
transcriptome analysis of purified HSCs that was described this thesis has provided novel 
insights into the underlying cause of HSC age-related dysregulation. A significant finding is 
that several genes involved in cell movement, migration and adhesion, are significantly 
altered in ageing LT-HSCs. Notable examples include up-regulated targets of the Aryl 
hydrocarbon receptor (AHR) ligand-dependent nuclear receptor (Table. A-5). Additionally, 
Integrin beta-3 (ITGB3), a key signalling and adhesion molecule, was upregulated by more 
than two fold in Old HSCs (Table. 6.2) and showed age-dependent hypomethylation  at 
approximately 500bp downstream from  at what appears to be a regulatory region (Fig. 
4.7D), with binding sites for several HSC transcription factors [203].  Sdpr was also found to 
be differentially regulated with age and I demonstrated that age-dependent up-regulation of 
this gene is correlated with progressive hypomethylation of the Sdpr promoter region. While 
Results Chapter 6 
 
147 
 
age-related upregulation of Sdpr in HSCs has previously been observed [94,99], I showed 
that it is linked to loss of promoter methylation, using an ex vivo DNMT-1 inhibition assay for 
FACS purified HSCs. Sdpr, which is also known as Cavin-2, is involved in caveolae 
formation and cell signalling [168]. Interestingly, two out of the top five upregulated gene 
networks in this study involved cell-to-cell signalling and interaction. It is possible that age-
dependent upregulation of Sdpr is involved in this signalling process. ITGB3 is a member of 
the integrin family and integrins are known to form supramolecular complexes, which direct 
potent signal transduction cascades and metalloproteinases-mediated cellular migration 
[180].  Lipid rafts, such as the caveolae, associate with supramolecular complexes and may 
regulate their formation. It is possible that the age-dependent upregulation of Sdpr has an 
effect on caveolae formation, which alters the dynamics of supramolecular complexes and 
their role in signal transduction and cell migration. As well as Itgb3, several members of the 
integrin family were also found to be significantly up-regulated during HSC ageing in this 
study. 
The DNAm and gene expression data from this study provides a probable explanation for 
the functional decline in HSCs that has been reported during ageing [94,144]. Aberrant up-
regulation of genes like Sdpr and Itgb3 and their subsequent role in abnormal cell signalling, 
migration and adhesion could disrupt the ability of HSCs to interact appropriately with and/or 
be regulated by the bone marrow micro-environment. The ability of HSCs to respond 
appropriately to niche-associated signalling is crucial for processes like homing, migration 
and lodgement. Aged HSCs show reduced ability to home to the bone marrow [7,96,97], 
which could be due to reduced ability to respond to regulatory cues within the micro-
environment. Additionally, in vivo imaging of mouse HSPCs revealed that aged HSPCs are 
found at distances further away from the endosteal niche, compared with younger HSPCs 
[195], suggesting a reduced affinity for that niche with age. Other age-related defects such 
as reduced lymphopoiesis and expansion of My-bi HSCs could be a result of sub-optimal 
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response to signals required for normal lymphopoiesis to occur. Indeed, Dnmt1 mutant 
HSCs show global DNA hypomethylation and are unable to sustain lymphopoiesis [88].  
Taken together, the data presented in this thesis support a model where a shift from 
homeostatic levels of DNAm in ageing LT-HSCs has a wide-spread effect on transcription. 
This could be a consequence of altered transcription factor binding to epigenetically modified 
target sites, culminating in abnormal interactions of HSCs with their niche, as a result of the 
dysregulation of key genes involved in HSC migration, homing, adhesion, and signalling. 
Although it is possible that other biological and epigenetic factors, such as telomere 
shortening, genetic mutations, histones- and RNA- modifications, are involved in HSC 
ageing, the observations in this study suggest that global and gene specific changes in 
DNAm, may contribute to the decline of HSC functionality with age. While it remains possible 
that the identified changes in DNAm are a consequence, rather that the cause of HSC 
ageing, and functional validation of these findings remains technically challenging, I was able 
to demonstrate proof of principle for the Sdpr-associated aDMR. Functional assays, i.e. gene 
knock-down assays, will be required to investigate the relevance of the genes implicated in 
this study, and to further improve our knowledge of the dynamics of HSC regulation during 
physiological ageing.  
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7  
7.1 General Discussion 
The aim of this thesis was to investigate the involvement of DNAm in HSC ageing. This was 
done by whole genome methylation analysis and transcriptome analysis of mouse primary 
LT-HSCs. This study was undertaken at a time when methylome and transcriptome analyses 
of minute samples were not well established. As a result, a significant aspect of this thesis 
was focused on the development of suitable techniques for the analysis of the rare cells 
determining HSC ageing. To this end, I developed a protocol for the generation of 
methylomes from low input DNA [133] and performed methylome and transcriptome analysis 
on materials obtained from the same cells.  The data generated in this study represents a 
valuable resource for the study of mammalian stem cell regulation and ageing. Additionally, I 
utilised and optimised various technically challenging assays to functionally validate the 
findings in this study. I anticipate that these assays will be useful to several other studies in 
related fields. 
The findings in this thesis implicate migration and adhesion genes in the ageing of HSCs. 
Additionally, changes in the methylation and expression of Sdpr, which encodes a caveolae 
lipid raft protein, was identified and validated. In this chapter, I bring together the key findings 
of this thesis and discuss their implication in HSC regulation and ageing. I also provide 
recommendations for future development based on the work presented here. 
7.2 Methylome Analysis  
Nano-MeDIP-seq was developed and used to analyse ageing LT-HSC methylomes in this 
study. Based on multiple metrics, the data generated is of remarkably high quality (Chapter 
3). However, Nano-MeDIP-seq was not compared directly to the original MeDIP method. It is 
therefore not currently possible to identify the drawbacks of performing MeDIP-seq with 
lower starting DNA concentrations. It is important that these limitations are known, in order to 
make informed decisions regarding suitable methylome analysis methods, when designing 
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future experiments. For example, the CpG enrichment scores observed in the data 
generated using Nano-MeDIP-seq appeared slightly lower, when compared to existing data 
from other studies within the ‗Medical Genomics‘ group. A lower CpG enrichment score 
could be due to various reasons such as: 1) lower global methylation in HSCs compared to 
these other samples, which are typically cancer cells or tissues; 2) lower global methylation 
in the C57BL/6 mice compared to human samples, which are typically studied within the 
Medical Genomics group; 3) artificially lower CpG enrichment in Nano-MeDIP-seq data 
compared with the original MeDIP-seq method. In order to rule out the third scenario, it will 
be necessary for future studies to perform MeDIP-seq experiments with both methods, using 
the same samples. This will allow the direct comparison of methylomes generated by these 
methods, to determine any significant differences that may exist between them. 
Nevertheless, CpG coverage for all Nano-MeDIP-seq samples was comparable to that of 
MeDIP-seq [133], suggesting that Nano-MeDIP-seq is as efficient in detecting DNAm as the 
original MeDIP-seq method. 
Third generation sequencing technologies such as those by Helicos Bioscience [204], 
Oxford Nanopore Technologies [205] and Pacific Bioscience [206], are capable of single 
molecule sequencing and are thought to be able to distinguish between cytosine and methyl-
cytosine [205,207]. The advantages of these technologies are immediately apparent. 
Theoretically, only single molecules are required to generate an entire methylome. This 
eliminates the need for PCR, and removes the amplification bias that comes with it. 
Additionally the low input requirement of single molecule sequencing technologies allows the 
study of rare samples, without further optimizations. Although the Nano-MeDIP-seq method 
developed in this thesis was a significant breakthrough for unbiased methylome analysis, 
and makes the MeDIP-seq method available to studies where samples of interest are 
limiting, it is expected that third generation sequencing techniques will replace cumbersome 
bisulfite and enrichment based methods.  
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7.3 MeDIP-seq Data Analysis 
The remarkable advancement in high throughput whole genome analysis technologies, 
which allow the generation of high resolution methylomes in a relatively short period of time, 
presents a significant challenge in terms of data analysis.  Significant bioinformatics and 
statistical effort is required to analyse and interpret the enormous data set that is typically 
generated for methylome or transcriptome studies. As multiple tools and algorithms are 
required for data processing steps such as sequence alignment, filtering of clonal reads, 
data normalisation, read counts and differential read counts, it is often necessary to 
streamline the data analysis processes into discreet computational pipelines. Unfortunately, 
these packages are typically modelled around studies of gross abnormalities. This means 
that thresholds are often set too high to detect subtle deviations from the norm, such as 
those observed during HSC ageing. The MeDUSA pipeline [134] was used to generate HSC 
methylomes and to determine aDMRs in this study. Initial analysis with this pipeline yielded 
no differentially methylated regions, despite several obvious differences in sequence read 
counts between ageing samples. As a result, the threshold for DMR calling was lowered and 
rules within the pipeline were modified to allow the detection of subtle but significant 
changes during HSC ageing. This optimization yielded more DMRs, but also increased the 
incidence of false positive results (visual confirmation on UCSC genome browser). 
Subsequently, a more conservative version of the DESeq Bioconductor package (v2.10.2) 
was released and utilised. This version provided the highest level of true DMRs and the 
lowest incidence of false positives, as determined by visual confirmation of aDMRs on the 
UCSC genome browser. Nonetheless, the amount of aDMRs that were detected in this 
thesis remained relatively few, compared to most methylome analysis studies and this low 
amount of aDMRs appears at odds with the obvious decrease in global DNAm that was 
observed in aged HSCs. While the former could be attributed to the fact that a homogenous 
population of FACS purified cells was studied in this thesis, it is possible that the 5% 
difference that was observed in global DNAm is too small to be detected in discreet regions, 
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and several true aDMRs were missed, as a result of the low sensitivity of the available 
analysis tools. The MeDUSA pipeline and other similar analysis tools are constantly being 
further developed; it will be interesting to investigate the effects of these improvements on 
the data generated in this thesis. 
The MeDIP-seq method can be used to detect other forms of DNAm, such as 5-
hydroxymethylcytosine (5-HmC), however, this requires the use of 5-HmC specific 
antibodies and thus must be assayed separately to 5mC MeDIP reactions. Due to limited 
time and resources, this mark was not studied here; however, 5-HmC is an important feature 
of mammalian embryonic [67,68] and somatic stem cells [66]. The role of 5HmC DNAm in 
HSCs is currently unclear; however Tet2, a member of the Tet protein family, which catalyse 
the conversion of 5mC to 5HmC in vivo, has been shown to be important for 
haematopoiesis. Tet2 is highly expressed in bone marrow haematopoietic cells [208] and 
mutations in this gene are associated with various myeloproliferative malignancies [208]. 
Furthermore, Tet2 expression was upregulated during all-trans retinoic acid-induced 
granulocytic differentiation of the promyelocytic cell line, NB4 [208], suggesting that Tet2 is 
important in myelopoiesis and could therefore be involved HSC regulation. Future studies 
should be performed to ascertain the occurrence and relevance of this mark in HSCs.  
Non-CG methylation is also thought to be an important feature of mammalian stem cells and 
the MeDIP-seq data generated in this thesis is able to detect these forms of 5mC. This data 
should be further analysed to determine the presence and involvement of non-CG 
methylated in HSC regulation and ageing. 
7.4 DMR Validation 
aDMRs were validated technically by BS-pyrosequencing and functionally by ex vivo HSC 
culture and 5-Aza‘dC  induced hypomethylation. These assays were very cumbersome and 
time consuming in terms of assay design and assay validation. BS-pyrosequencing in 
particular is technically challenging and is of very low throughput, as individual assays for a 
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maximum of 50 bp DMRs must be designed, and separate reactions are required for each 
assay. As a result, a significant amount of starting DNA concentration is required to validate 
multiple targets. Furthermore, regions refractory to PCR such as repeat and GC-rich regions 
are typically impossible to validate by this method. Consequently, it was only possible to 
validate a single aDMR (Sdpr) in this study.  
Ex vivo demethylation of HSCs was performed, in preference to in vivo 5-Aza‘dC treatments, 
in an effort to limit the confounding effects of 5-Aza‘dC on other cell types. By isolating and 
selectively demethylating HSCs, I could be certain that subsequent changes are intrinsic to 
these cells. This assay was sufficient to confirm the link between Sdpr promoter 
hypomethylation and increased gene expression; however, it was unable to elucidate the 
relevance of changes in DNAm in HSC regulation and ageing. A more suitable endpoint for 
this ex vivo assay is the transplantation of 5-Aza‘dC demethylated HSC (Aza-HSC). 
Transplantation of Aza-HSCs into myelo-ablated mice will provide insights into the effect of 
DNA hypomethylation on processes such as homing, migration and key stem cell functions 
such as self-renewal and differentiation.  It must be noted that such experiments will yield 
very little information pertaining the effects of changes to specific genes. This is because 5-
Aza‘dC induces global demethylation, and several loci are expected to be hypomethylated, 
making it difficult to pinpoint the exact cause of any novel phenotypes.  
The functional relevance of candidate genes such as Sdpr and Itgb3, in HSC regulation, is 
currently unknown. In vivo knock-down and overexpression assays that investigate the 
specific roles of the candidate aDMGs will further elucidate the mechanisms of HSC ageing. 
Likewise, novel technologies such as micro-droplet multiplexing PCR [209] and sequence-
specific genome editing nucleases e.g. Transcription Activator-Like Effector Nucleases 
(TALENs) [210], will greatly improve the feasibility of functionally validating multiple 
candidate genes in future studies. 
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7.5 Transcriptome analysis 
Transcriptome analysis by RNA-seq revealed several interesting changes in gene 
expression, during HSC ageing (Chapter 5). High quality data sets were generated from the 
RNA-seq analysis performed in this thesis and these data have the potential to be analysed 
for other changes in gene regulation, which may accompany HSC ageing. These changes 
include alternative splicing and variations in transcript isoforms at different age points. 
Although the gene expression data provided isoform specific expression for each age group, 
these were only used to determine differential gene expression, irrespective of the specific 
isoform. Detailed analyses that specifically identify changes in the representation of 
transcript isoforms, at specific age points, are required to identify isoform-specific regulation 
of HSC ageing. Likewise, due to time constrains, the possibility of alternative splicing during 
HSC ageing was not pursued.  It is possible that certain genes, whose overall expression 
appeared unaltered with age, do in fact express different isoforms of distinct functions, at 
different stages during HSC ageing. For instance, a manual scan of selected candidate 
genes revealed that multiple isoforms of Itgb3, Dnmt1 and Selp are differentially expressed 
at different age points. Some of these isoforms showed age dependent up or down 
regulation, while others showed age specific expression (Appendix-Figure 5). Methylome 
analysis of HSC ageing identified an overrepresentation of aDMRs at CTCF binding sites 
(Chapter 4). CTCF is a zinc-finger DNA binding transcription factor, which binds to target 
sites at alternatively spliced exons, to promote their inclusion during transcription [172]. 
Conversely, DNAm at these sites prevents CTCF binding, and allows exon exclusion [172]. 
The enrichment of aDMRs at CTCF binding sites in HSCs suggests that DNAm at these 
sites could result in differential splicing and isoform expression during ageing. Further 
analysis of the RNA-seq data should be performed to investigate these possibilities. 
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7.6 SDPR and Cell Movement in HSC Ageing 
I showed for the first time that cell movement is the main process that is altered during HSC 
ageing. This was inferred by the overrepresentation of differentially expressed cell 
movement genes in ageing HSCs. I also identified Sdpr as a differentially methylated and 
differentially expressed candidate gene that could be important in HSC regulation and 
ageing. Sdpr was selected based on the observations in this thesis, its known functions, and 
previous reports from independent studies [94,99], which also identified this gene as being 
differentially expressed in ageing HSCs. As detailed in Section 6.4.1, Sdpr is involved in 
caveolae biogenesis and its overexpression leads to caveolae elongation [168]. Caveolae 
are flask shaped lipid rafts and these cholesterol rich structures are thought to be essential 
for the establishment of cell polarity during migration [211]. Cell polarity is necessary for 
directional cellular migration and loss of caveolae scaffold protein, Caveolin-1, results in the 
loss of cell polarity and impaired cellular migration [212,213]. SDPR and Caveolin-1 are 
functionally inter-dependent [168]; It is possible that age dependent hypomethylation of the 
Sdpr promoter, and its subsequent overexpression, is involved in the dysregulation of cell 
movement genes during HSC ageing. In support of this, several genes coding for lipid raft-
associated cell movement molecules such as Integrins, G protein-coupled receptors, CD44 
and MPPs [214], were found to be differentially expressed in ageing HSCs. The findings in 
this thesis are indicative of a role for Sdpr in the regulation of HSC cell movement during 
ageing. This is perhaps achieved by an increased surface area for lipid raft associated 
proteins to interact and generate signalling cascades, which alter cell polarity and cellular 
migration. 
Increased activity of RhoGTPase Cdc42, which regulates cell polarity and cell-extracellular 
matrix adhesion, has recently been shown to result in HSC ageing and loss of polarity [104]. 
Additionally, loss of this gene leads to loss of HSC quiescence and altered HSC niche 
interactions [215]. This thesis implicates the involvement of several other cell movement 
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genes in HSC ageing. Future studies should investigate the link between Sdpr, Itgb3 and 
Cdc42 in HSC functionality with age. 
7.7 Epigenetic Regulation of HSCs  
This thesis focused on DNAm modifications during HSC ageing and identified several 
significant changes that accompanied HSC ageing. Although there was a modest overlap 
between aDMGs and differentially expressed genes, several changes in the ageing LT—
HSC transcriptome could not be directly explained by DNAm. Similarly, differential 
methylation in several genes did not appear to have an effect on gene expression. It is 
possible that subtle changes in the methylome, which were not significant enough to be 
detected as aDMRs, have an indirect and widespread effect on gene expression. This effect 
could result from alterations in HSC transcription factors binding to DNA, as a result of 
changes in DNAm. In support of this, haematopoietic transcription factors binding was found 
to be negatively correlated with DNAm in HSCs [216]. 
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Figure 7-1: Hypermethylation at the 3’ region of the Obscn gene in aged HSCs (red box).  
This aDMR overlaps a CTCF binding site and is flanked by binding sites (brown box) for several HSC transcription factors. 
 
It was surprising to note that highly significant aDMRs that were associated with certain 
genes had no effect on their gene expression. For example, one of the most significant 
aDMR (FDR < 0.01) was found at the 3‘ end of the Obscn gene (Chapter 4, Fig. 7.1). 
Antisense microRNA (miRNA) can cause gene repression by binding to the 3‘UTRs of 
mRNAs [217,218]. Age-dependent hypermethylation of the 3‘ end of the Obscn gene could 
interfere with the transcription of its 3‘UTR, and thus with miRNA binding. While Obscn was 
not identified as upregulated with age in this study, miRNA has been suggested to induce 
gene repression without a change in mRNA level [218]. It is possible that age-dependent 
hypermethylation of genes like Obscn do indeed prevent gene repression, but this effect is 
only reflected in their protein abundance. Although, translation-only repression is a rare 
event [218], future studies should investigate the proteome of ageing HSCs, in order to 
obtain a more complete picture of HSC gene regulation, during ageing. 
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A hypermethylation hotspot was observed on chromosome 5, which corresponds to the 
location of several members of the Speer gene family (Chapter 4). Most of the Speer genes 
that were differentially methylated in this region were known pseudogenes. Pseudogenes 
were recently reported to modulate the expression of corresponding coding genes by 
competing for miRNA binding [219]. However, while Speer genes where not identified as 
differentially expressed in this thesis, it is possible that the hypermethylation of Speer 
pseudogenes have an effect on the expression of other coding genes.  
The final example highlighted here is the age-related hypomethylation of Trim30a. This was 
the most significantly hypomethylated gene during HSC ageing and was also significantly 
down regulated with age (Table. 6.1, Fig. 7.2). This DNAm/gene expression correlation 
appears counter intuitive. However, the DMR overlaps a U6 non-coding small nuclear RNA 
(snRNA), and it is possible that the loss of DNAm in this region results in the activation of the 
snRNA, which perhaps causes the down regulation of Trim30a, through aberrant splicing. It 
will be interesting to investigate the effects of this snRNA on Trim30a regulation, and the 
impact this has on HSC functionality and ageing. Future studies could design synthetic forms 
of the ncRNA described here and transfect it into Young HSCs, in order to carry out this 
investigation.  
In aggregate, DNAm is on its own an important epigenetic modification that is involved in the 
regulation of gene expression; however, it may act in collaboration with other forms of 
epigenetic mechanisms to modify gene expression. It is therefore important that these 
mechanisms are taken into consideration when designing future experiments.    
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Figure 7-2: aDMR in the Trim30a gene 
 
This DMR overlaps a non-coding small nuclear RNA (arrowed) 
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7.8 Conclusion 
I have generated and analysed methylomes and transcriptomes of phenotypically defined 
LT-HSCs, at key stages during physiological ageing. This thesis was, at the time of 
submission (Jan 2013), the most comprehensive study of HSC ageing (with regards to 
integrated methylome and transcription analysis). However, a very similar study was 
subsequently published, which performed and compared DNAm and gene expression in 
HSCs from foetal, young and old mice [220]. This study reported DNA hypermethylation in 
HSCs during ageing, which appears to be in contrast with the findings of this thesis. RRBS 
was the method used to quantify DNAm in the aforementioned study, and this method has 
been shown to be biased towards CGIs and promoter regions [118,125,221]. Additionally, its 
theoretical genome coverage is ~10% [125], while MeDIP-seq is able to determine truly 
global DNAm (1theoretical genome coverage of 100% [118,125,221]). As a result, the age-
dependent hypermethylation that was reported in this newly published study, most likely 
reflects the fact that CG rich regions were compared during ageing. In support of this, I also 
observed an increase in DNAm at CGIs, during HSC ageing, while a significant loss (p < 
0.001, Kolmogorov-Smirnov test) of DNAm was observed globally.  
The methylomic analysis described in this thesis is particularly powerful, as DNA and RNA 
were concurrently isolated from the same functionally relevant cells. The findings in this 
thesis suggest that an epigenetic control of lipid raft associated proteins may be involved in 
the dysregulation of HSC cell movement during ageing. Further study of these lipid raft 
components is expected to improve our knowledge of the mechanisms directing HSC 
                                                                
 
 
1
Genome coverage is not to be confused with global CG (methylome) coverage, which will be less than 100% in 
MeDIP-seq. This is because approximately 60-80% of CpGs are thought to be methylated in mammals [222] and 
MeDIP enriches for methylated portions of the genome. The methylome coverage in this thesis was ~60%. 
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ageing. The work presented in this thesis should be extended to other cell types and 
mammalian models, in order to gain insight into any universal mechanisms that underlie 
stem cell ageing. 
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7.9 Outlook 
I found that locus specific alterations in the DNAm of aged HSCs potentially account for 1% 
of the gene expression changes that were observed in this thesis. While DNAm could also 
have an indirect effect on the gene expression of ageing HSCs (Section 7.5), it is likely that 
HSC ageing and age differential gene expression is multifactorial and regulated by several 
other mechanisms. As detailed in Chapter 1, the HSC niche is important in HSC regulation 
and interestingly, cell movement, which is a process that involves the dynamic interaction 
between HSC and their niche, was most significantly altered with age. It is therefore likely 
that age-related changes in the bone marrow will have a negative impact on the functionality 
of HSCs during ageing. Indeed fatty infiltration of the BM has been shown to occur during 
human ageing and BM fat and adipocyte contents are negatively correlated with HSC activity 
[223,224]. Increased cell movement in ageing HSCs could in part be a response to an 
altered BM, causing them to migrate to a more favourable niche. In support of this, active 
extramedullary haematopoiesis was observed in osteoblast deficient mice [225]. 
Furthermore, studies of muscle stem cells (satellite cells) suggest that circulating factors 
from young niches could rescue the functionality of aged stem cells [226]. However, 
transplantation of aged HSCs into a younger niche does not appear to rescue their 
functionality [94]. As a result, the role of the niche in regulating HSC ageing currently 
remains unclear. Nevertheless, it is possible that the process of transplantation somehow 
confounds these experiments; therefore, future studies should directly assess the effects of 
exposing aged HSCs to circulating factors from young mice. This could be achieved by 
heterochronic parabiotic pairing of young and old mice, where these pairs share the same 
circulation, or by ex vivo culture of aged HSCs on stroma that was derived from young mice. 
The former experiment was recently conducted with promising results [227], however, this 
article was subsequently retracted.     
Polycomb group (PcG) proteins are transcription repressors and are important regulators of 
stem cell fate and gene expression [228]. A study of aged blood cells found PcG proteins 
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target genes (PcGTs) to be hypermethylated with age [110]. PcG proteins form two main 
complexes in mammals, which include polycomb repressive complex 1 and 2 (PRC 1 and 
PRC 2) [228]. Either one of the histone methyltransferases Ezh1 or Ezh2 are required in  
PRC2 complexes [229]. These proteins are important for the establishment of the repressive 
H3K27me mark [230] and Ezh1, which was downregulated in aged HSCs in this thesis, has 
recently been shown to be essential for HSC maintenance and the prevention of senescence 
[231]. Furthermore, Runx1, Gata3, Myb, Cdc6 and Dntt, which were differentially expressed 
in aged HSCs in this thesis, were identified as Ezh1 targets [231]. Age related 
downregulation of Ezh1 could in part be involved in the dysregulation of HSCs during 
ageing. Future studies should perform chromatin immunoprecipitation of PcG proteins such 
as Ezh1, to investigate their role in HSC ageing. 
Young HSCs from short lived inbred strains such as the C3H/He, CBA/J and DBA/2 mice 
have a higher cycling activity than that of the longer lived C57BL/6 mice [232,233]. HSCs 
from these strains also show wide variations in cell frequency [234,235]. The genetic 
differences between these strains have been exploited by studies, which identified multiple 
quantitative trait loci (QTLs) and candidate genes that may underlie these differences 
[232,234,236,237]. This includes laxetin (Lxn), a gene whose expression is negatively 
correlated with the size of the HSC pool [237]. Acquisition of mutations in such genes could 
also influence the functionality of aged HSCs. Exome sequencing or resequencing of DNA 
from ageing HSCs could further elucidate the involvement of genetic factors in this process. 
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Table A-1: Oligonucleotide Sequences 
Sequence details of all oligonucleotides that were used in this thesis 
 
 
MM5_F 
Mouse MeDIP QC_qPCR 
CATGGCCCACAAAGTAATAAAA 
MM5_R AACGACTTACAACGAGCTCAAA 
MU1_F GGCTAGAACTGACCAGACAGAC 
MU1_R ATCTGTAGCCAATCCTAGAGCA 
   
15CpG_qPCR_F 
Lambda MeDIP (spike) 
QC_qPCR 
TATCACTGTTGATTCTCGC 
15CpG_qPCR_R GGTAAAGAGTTTGGATTAGG 
20CpG_L_qPCR_F GGTGAACTTCCGATAGTG 
20CpG_L_qPCR_R CAGTCATAGATGGTCGGT 
20CpG_S_qPCR_F GTTAGAGCCTGCATAACG 
20CpG_S_qPCR_R GAAAGAGCACTGGCTAAC 
   
N4bp3_F 
Mouse BS Conversion 
QC_qPCR 
TGGGGTTAGTTTTTATGGAGGATTT 
N4bp3_R ACCTCCAACTACAACTATTTATAACT 
Nasp_F GGCTAGAACTGACCAGACAGAC 
Nasp_R ATCTGTAGCCAATCCTAGAGCA 
   
Sdpr1_F 
Mouse Sdpr BS pyro-seq 
primers 
GGTTTTTATTAGTAATATAGTGAGTAAGTTG 
Sdpr1_R [Btn]CTCCAATCTCTTCACCTAAAC 
Sdpr1_S GTAAGTTGTTAGAGAAGTTT 
   
PE.Adapter.1.0 Custom Illumina NGS 
Adapters (Sigma) 
ACACTCTTTCCCTACACGACGCTCTTCCGATC*T 
PE.Adapter.2.0 [Phos]GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
PCR.primer.PE.1.0 Custom Illumina NGS PCR 
Primers (Sigma) 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T 
PCR.primer.PE.2.0 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC*T 
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Figure 1: Amplification efficiency of MeDIP QC2 primers as assessed by qPCR of serially diluted DNA 
 
Mouse methylated 5 (MM5) and Mouse unmethylated 1 (MU1) primers were used for MeDIP QC2. These primers show equal 
amplification efficiencies 
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Age Differentially Methylated Regions between Young and Old Samples 
Table A-2: Age Hypermethylated regions 
FDR scores of ≥20, ≥ 13, ≥ 10 and ≥ 7 equals FDR of ≤ 1%, ≤ 5%, ≤ 10% and ≤ 20% respectively 
DMR_
chr 
DMR_start DMR_stop Length CpG_
count 
CpG_density C_ 
count 
C_density FDR 
Score 
Near_gene_ID_up_100000
_down_50000 
Gene_coordinates Strand Associated Gene 
Name 
9 3017681 3018217 537 13 4.841713 117 21.78771 126.3403 ENSMUSG00000074563 chr9:3017408-3019022 + Gm10719 
5 15195610 15197136 1527 10 1.309758 288 18.86051 75.43196 ENSMUSG00000089871 chr5:15186528-15220414 + Speer7-ps1 
5 15052419 15054269 1851 14 1.512696 349 18.85467 54.64918 ENSMUSG00000091897 chr5:15028950-15032998 - Gm17019 
5 15186252 15187052 801 12 2.996255 145 18.10237 47.01436 ENSMUSG00000089871 chr5:15186528-15220414 + Speer7-ps1 
5 14944958 14945908 951 11 2.313354 261 27.44479 37.3376 ENSMUSG00000091255 chr5:14933221-14938429 - Speer4e 
11 58807486 58808395 910 44 9.67033 221 24.28571 36.7908 ENSMUSG00000061462 chr11:58807758-58949904 - Obscn 
1 1.36E+08 1.36E+08 821 11 2.679659 238 28.98904 32.89294 ENSMUSG00000026458 chr1:136193360-136229505 - Ppfia4 
5 15005308 15007171 1864 15 1.609442 353 18.93777 29.10988 ENSMUSG00000072188 chr5:14974113-14978935 - Gm10354 
10 79383519 79384680 1162 82 14.1136 378 32.53012 28.42895 ENSMUSG00000035773 chr10:79379716-79385018 + Kiss1r 
5 14931969 14932505 537 3 1.117318 123 22.90503 28.02147 ENSMUSG00000091255 chr5:14933221-14938429 - Speer4e 
3 1.02E+08 1.02E+08 714 9 2.521008 230 32.21289 27.34599 ENSMUSG00000048540 chr3:101814068-101819415 + Nhlh2 
9 69589616 69590327 712 13 3.651685 148 20.78652 26.24206 ENSMUSG00000087375 chr9:69606547-69678652 + B230323A14Rik 
1 1.22E+08 1.22E+08 562 5 1.779359 134 23.84342 25.86844 ENSMUSG00000026389 chr1:122087334-122169282 - Steap3 
5 64421726 64422178 453 6 2.649007 93 20.5298 24.43467 ENSMUSG00000077209 chr5:64393592-64393723 - SNORA17 
5 14955913 14956552 640 0 0 117 18.28125 21.5311 ENSMUSG00000091255 chr5:14933221-14938429 - Speer4e 
5 15030146 15030726 581 7 2.409639 155 26.67814 21.23281 ENSMUSG00000091897 chr5:15028950-15032998 - Gm17019 
5 1.14E+08 1.14E+08 715 16 4.475524 241 33.70629 21.05837 ENSMUSG00000025825 chr5:114222757-114228297 + Iscu 
8 12133307 12134332 1026 0 0 555 54.09357 20.91275         
1 1.36E+08 1.36E+08 512 5 1.953125 137 26.75781 20.48887 ENSMUSG00000041559 chr1:135933831-135944854 + Fmod 
5 15176301 15177135 835 38 9.101796 259 31.01796 19.31867 ENSMUSG00000089871 chr5:15186528-15220414 + Speer7-ps1 
9 3020610 3021111 502 10 3.984064 109 21.71315 19.11427 ENSMUSG00000079719 chr9:3020155-3021593 + Gm11167 
13 66244325 66245141 817 21 5.140759 116 14.19829 17.61613 ENSMUSG00000074838 chr13:66222141-66222842 + Gm16512 
1 1.32E+08 1.32E+08 835 4 0.958084 164 19.64072 17.55861 ENSMUSG00000042581 chr1:131169879-132115855 + Thsd7b 
5 15039850 15040291 442 6 2.714932 131 29.63801 17.23883 ENSMUSG00000091897 chr5:15028950-15032998 - Gm17019 
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19 5756493 5757280 788 44 11.16751 245 31.09137 16.27778 ENSMUSG00000024940 chr19:5740904-5758532 + Ltbp3 
1 1.37E+08 1.37E+08 501 6 2.39521 127 25.3493 15.67206 ENSMUSG00000066885 chr1:137007746-137008883 - Ptprv 
12 24781837 24782470 634 65 20.50473 225 35.48896 15.26373 ENSMUSG00000073158 chr12:24729566-24781833 - 9030624G23Rik 
5 15178759 15179583 825 6 1.454545 177 21.45455 14.92996 ENSMUSG00000089871 chr5:15186528-15220414 + Speer7-ps1 
1 1.31E+08 1.31E+08 535 5 1.869159 90 16.82243 14.49169 ENSMUSG00000091877 chr1:130667176-130670998 - Gm17699 
5 14928379 14928962 584 4 1.369863 76 13.0137 14.08238 ENSMUSG00000091255 chr5:14933221-14938429 - Speer4e 
11 1.02E+08 1.02E+08 1036 58 11.19691 314 30.30888 14.00703 ENSMUSG00000006575 chr11:102254717-
102263869 
+ Rundc3a 
4 1.52E+08 1.52E+08 781 5 1.28041 138 17.66965 13.79534 ENSMUSG00000028931 chr4:151764851-151851980 - Kcnab2 
11 51457270 51457950 681 28 8.223201 238 34.9486 12.1521 ENSMUSG00000001053 chr11:51456565-51464344 - N4bp3 
4 1.09E+08 1.09E+08 547 0 0 270 49.36015 12.13526 ENSMUSG00000086483 chr4:108615448-108644682 - 8030443G20Rik 
7 56777668 56778256 589 23 7.809847 150 25.46689 12.06944 ENSMUSG00000052512 chr7:56501559-56865457 + Nav2 
2 56961684 56962234 551 13 4.718693 142 25.77132 11.66154 ENSMUSG00000026826 chr2:56959241-56976414 - Nr4a2 
3 78822359 78822885 527 0 0 182 34.5351 11.66154 ENSMUSG00000077487 chr3:78783844-78783973 + SNORA17 
17 29779939 29780556 618 5 1.618123 152 24.59547 11.588 ENSMUSG00000090083 chr17:29751735-29840304 + Rnf8 
5 15159419 15159918 500 2 0.8 134 26.8 11.44099 ENSMUSG00000069720 chr5:15158104-15162877 - 4930572O03Rik 
5 1.48E+08 1.48E+08 818 12 2.933985 264 32.27384 11.38917 ENSMUSG00000053129 chr5:148000272-148002523 + Gsx1 
12 23094511 23094977 467 58 24.8394 168 35.9743 11.31543 ENSMUSG00000073164 chr12:22990656-23046943 + 2410018L13Rik 
12 56639267 56640004 738 3 0.813008 284 38.48238 11.2481 ENSMUSG00000063129 chr12:56666226-56667883 + Aldoart2 
5 16973699 16974252 554 6 2.166065 147 26.5343 10.6545 ENSMUSG00000058643 chr5:16981916-16986754 + Speer4f 
1 1.37E+08 1.37E+08 598 11 3.67893 129 21.57191 10.38529 ENSMUSG00000009418 chr1:137331157-137481932 - Nav1 
4 43438124 43438886 763 31 8.125819 212 27.78506 10.27773 ENSMUSG00000035969 chr4:43394851-43439960 + Rusc2 
5 14972978 14973486 509 3 1.178782 108 21.21807 10.09287 ENSMUSG00000072188 chr5:14974113-14978935 - Gm10354 
8 1.08E+08 1.08E+08 536 34 12.68657 144 26.86567 10.05293 ENSMUSG00000033249 chr8:107793729-107799745 + Hsf4 
9 1.03E+08 1.03E+08 349 6 3.438395 61 17.47851 9.945994 ENSMUSG00000032531 chr9:102619002-102635748 + Amotl2 
X 34655763 34656411 649 0 0 56 8.628659 9.862435 ENSMUSG00000036572 chrX:34631673-34650335 - Upf3b 
9 97319946 97320447 502 6 2.390438 188 37.4502 9.862435 ENSMUSG00000077208 chr9:97339920-97340046 - SNORA17 
X 1.38E+08 1.38E+08 724 3 0.828729 101 13.95028 9.858895 ENSMUSG00000079418 chrX:137491446-137598813 + Atg4a 
5 64429438 64429915 478 11 4.60251 116 24.26778 9.719966 ENSMUSG00000077209 chr5:64393592-64393723 - SNORA17 
18 47313657 47314225 569 25 8.787346 112 19.68366 9.587079 ENSMUSG00000042705 chr18:47118515-47393938 + Commd10 
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13 56143687 56144200 514 2 0.77821 62 12.06226 9.526354 ENSMUSG00000089379 chr13:56182824-56182883 + AC163338.1 
8 12131257 12131756 500 2 0.8 276 55.2 8.871338         
8 74213734 74214292 559 24 8.586762 161 28.80143 8.706437 ENSMUSG00000079019 chr8:74213113-74214474 + Insl3 
X 1.38E+08 1.38E+08 890 1 0.224719 125 14.04494 8.701147 ENSMUSG00000079418 chrX:137491446-137598813 + Atg4a 
1 1.32E+08 1.32E+08 536 4 1.492537 125 23.3209 8.449773 ENSMUSG00000042581 chr1:131169879-132115855 + Thsd7b 
4 1.4E+08 1.4E+08 512 2 0.78125 210 41.01563 7.95336 ENSMUSG00000086960 chr4:139947063-139952519 + Gm13017 
12 1.04E+08 1.04E+08 509 4 1.571709 207 40.66798 7.915029 ENSMUSG00000041669 chr12:104435118-
104480360 
- Prima1 
5 14905168 14905436 269 3 2.230483 24 8.921933 7.818868 ENSMUSG00000033219 chr5:14910122-14914899 - Gm9758 
11 82743854 82744714 861 127 29.50058 464 53.89082 7.818868 ENSMUSG00000086058 chr11:82738405-82746884 - Gm12575 
8 14534678 14535179 502 2 0.796813 175 34.86056 7.737277 ENSMUSG00000047495 chr8:14095865-14847684 + Dlgap2 
4 1.45E+08 1.45E+08 498 59 23.69478 189 37.95181 7.65151 ENSMUSG00000052912 chr4:145054107-145057323 + Smarca5-ps 
X 1.31E+08 1.31E+08 508 1 0.393701 32 6.299213 7.620456 ENSMUSG00000000223 chrX:130939090-130991112 + Drp2 
1 1.37E+08 1.37E+08 459 3 1.30719 120 26.14379 7.346188 ENSMUSG00000048096 chr1:137221384-137264642 + Lmod1 
5 1.13E+08 1.13E+08 502 6 2.390438 163 32.47012 7.215984 ENSMUSG00000058153 chr5:112848180-113006205 - Sez6l 
11 1.01E+08 1.01E+08 504 25 9.920635 153 30.35714 7.208128 ENSMUSG00000045007 chr11:101017221-
101023101 
+ Tubg2 
5 15169336 15169837 502 3 1.195219 152 30.27888 7.17555 ENSMUSG00000069720 chr5:15158104-15162877 - 4930572O03Rik 
5 14995989 14996496 508 0 0 128 25.19685 7.118167 ENSMUSG00000072188 chr5:14974113-14978935 - Gm10354 
1 1.31E+08 1.31E+08 497 3 1.207243 99 19.91952 7.022499 ENSMUSG00000091877 chr1:130667176-130670998 - Gm17699 
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Table A-3: Age Hypomethylated regions 
FDR scores of ≥20, ≥ 13, ≥ 10 and ≥ 7 equals FDR of ≤ 1%, ≤ 5%, ≤ 10% and ≤ 20% respectively 
DMR_ 
chr DMR_start DMR_stop Length 
CpG_ 
count CpG_density 
C_ 
count C_density FDR Score 
Near_gene_ID_up_100000 
_down_50000 Gene_coords Strand 
Associated Gene 
 Name 
7 1.12E+08 1.12E+08 218 9 8.256881 38 17.43119 158.8895 ENSMUSG00000064907 chr7:111571788-111571894 + U6 
6 18118918 18119201 284 9 6.338028 68 23.94366 40.91621 ENSMUSG00000041301 chr6:18120687-18272768 + Cftr 
6 62964837 62965100 264 7 5.30303 48 18.18182 35.64826         
4 1.24E+08 1.24E+08 849 15 3.533569 204 24.02827 35.59651 ENSMUSG00000028907 chr4:124355404-124370844 - Utp11l 
2 14263017 14263967 951 18 3.785489 237 24.92114 25.83163 ENSMUSG00000036949 chr2:14309943-14416602 + Slc39a12 
11 87029807 87030541 735 18 4.897959 182 24.7619 24.4732 ENSMUSG00000018548 chr11:86940579-87034185 + Trim37 
9 30122131 30122752 622 12 3.858521 176 28.29582 24.24417 ENSMUSG00000064713 chr9:30099453-30099559 - U6 
15 5190435 5191234 800 11 2.75 160 20 23.12683 ENSMUSG00000039942 chr15:5156661-5194187 - Ptger4 
17 34355295 34356229 935 18 3.850267 293 31.3369 20.46584 ENSMUSG00000081512 chr17:34348257-34351404 - Gm15821 
9 34968957 34969885 929 12 2.583423 185 19.91389 20.2128 ENSMUSG00000032040 chr9:34931993-34983646 - Dcps 
17 39983239 39984285 1047 85 16.23687 299 28.55778 19.11427 ENSMUSG00000088272 chr17:39984071-39984165 + mmu-mir-2133-2  
8 67597647 67598343 697 14 4.017217 146 20.94692 17.9525 ENSMUSG00000074302 chr8:67598932-67601379 + Gm10663 
13 95903505 95904385 881 10 2.270148 207 23.49603 15.94277 ENSMUSG00000021684 chr13:95794409-96020291 - Pde8b 
2 11278297 11278847 551 6 2.177858 136 24.6824 14.26289 ENSMUSG00000080905 chr2:11274141-11274396 + Gm13295 
2 11434396 11435180 785 12 3.057325 174 22.16561 13.86083 ENSMUSG00000026773 chr2:11393057-11423728 - Pfkfb3 
2 84651064 84651726 663 24 7.239819 167 25.18854 13.18236 ENSMUSG00000027077 chr2:84651333-84662809 - Smtnl1 
11 1.04E+08 1.04E+08 919 14 3.04679 237 25.7889 13.11545 ENSMUSG00000020689 chr11:104469370-104531790 + Itgb3 
6 65487659 65488061 403 6 2.977667 88 21.83623 11.79247 ENSMUSG00000044162 chr6:65540392-65584034 + Tnip3 
1 79719216 79719541 326 9 5.521472 56 17.17791 11.66154 ENSMUSG00000073643 chr1:79698837-79772718 - Wdfy1 
17 39980211 39981034 824 66 16.01942 254 30.82524 11.66154 ENSMUSG00000076004 chr17:39981081-39981190 + Mir715 
11 46122379 46122890 512 11 4.296875 148 28.90625 11.65005 ENSMUSG00000020340 chr11:46007357-46125852 - Cyfip2 
7 56652863 56653697 835 20 4.790419 221 26.46707 11.566 ENSMUSG00000052512 chr7:56501559-56865457 + Nav2 
7 87918952 87919462 511 12 4.696673 130 25.44031 10.98418 ENSMUSG00000030536 chr7:87856469-87948217 - Iqgap1 
8 97067698 97068372 675 14 4.148148 221 32.74074 10.82393 ENSMUSG00000034361 chr8:97056890-97094429 + Cpne2 
10 1.03E+08 1.03E+08 501 8 3.193613 81 16.16766 10.67865 ENSMUSG00000090638 chr10:102492113-102492978 - Gm17028 
3 53157405 53158119 715 10 2.797203 158 22.0979 10.26196 ENSMUSG00000085174 chr3:53256541-53261719 + Gm16206 
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8 8968710 8969450 741 23 6.207827 205 27.66532 10.21662         
9 1.03E+08 1.03E+08 502 5 1.992032 126 25.0996 10.14504 ENSMUSG00000032548 chr9:102910817-102990179 + Slco2a1 
5 1.39E+08 1.39E+08 500 5 2 137 27.4 9.859645 ENSMUSG00000090903 chr5:139461462-139461950 + Gm17247 
12 54823522 54824052 531 9 3.389831 112 21.09228 8.932791 ENSMUSG00000021010 chr12:54349664-55173162 + Npas3 
1 51348728 51349162 435 6 2.758621 80 18.3908 8.922945 ENSMUSG00000045954 chr1:51345970-51359803 + Sdpr 
4 88787486 88788071 586 13 4.43686 137 23.37884 8.591598 ENSMUSG00000062937 chr4:88783026-88826985 + Mtap 
7 38982135 38982636 502 3 1.195219 118 23.50598 8.585563 ENSMUSG00000054676 chr7:38968236-38982582 + 1600014C10Rik 
5 1.25E+08 1.25E+08 504 6 2.380952 116 23.01587 8.297465 ENSMUSG00000029401 chr5:124913274-124928375 - Rilpl2 
4 93852965 93853469 505 9 3.564356 93 18.41584 8.214479 ENSMUSG00000085931 chr4:93756267-94092279 - Gm12648 
6 6141710 6142250 541 8 2.957486 152 28.09612 7.907489 ENSMUSG00000015112 chr6:5991219-6167173 - Slc25a13 
6 1.35E+08 1.35E+08 348 10 5.747126 92 26.43678 7.90583 ENSMUSG00000042992 chr6:134589645-134661202 + Loh12cr1 
6 47335738 47336239 502 8 3.187251 122 24.30279 7.371706 ENSMUSG00000029686 chr6:47403397-47476138 + Cul1 
13 46031365 46031859 495 9 3.636364 101 20.40404 7.369538 ENSMUSG00000046876 chr13:45650262-46060345 - Atxn1 
7 88359509 88360005 497 11 4.426559 99 19.91952 7.230497 ENSMUSG00000025584 chr7:88358482-88479419 + Pde8a 
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Table A-4: Age differentially expressed cell movement genes. 
Process Upregulated Downregulated 
Cellular Movement AGTR1 ABR 
 ALCAM ADAM15 
 AMICA1 ANGPTL4 
 ANKRD28 ANXA2 
 APBB2 ARHGAP24 
 APOB CACNA1E 
 AR CAMK1D 
 ARFGEF1 CAPN1 
 ARID5B CAPN2 
 ARNT CAST 
 BCR CAT 
 BMP4 CCR7 
 BMPR1A CCR9 
 C4B (includes others) CD19 
 C5AR1 CD34 
 CD28 CD44 (includes EG:100330801) 
 CD38 CD86 
 CDCP1 CDH5 
 CDKN2C CDK1 
 CHRM3 CFH 
 CHRNA7 CTGF 
 CLASP2 E2F2 
 CLU EBF1 
 CMKLR1 EGFL7 
 COL18A1 EPB41L5 
 CXCR5 EPHB2 
 CYSLTR2 EPS8 
 DCBLD2 EVL 
 DCN FABP4 
 DDR1 FLT1 
 DNM2 FLT4 
 EFNA1 FOXO3 
 EPB41L5 FSCN1 
 F10 FUT7 
 FAP GFRA1 
 FBLIM1 IL15 (includes EG:16168) 
 FBLN5 IL15RA 
 FCER2 IL33 
 FGFR2 IL6R 
 FHL2 ITGA9 
 FOSL2 ITGAE 
 FOXC2 ITGB5 
 FYB LCK 
 GATA3 LEF1 
 GNAO1 LGALS1 
 GPR183 LSP1 (includes EG:16985) 
 GRB7 LTB 
 HNRNPA2B1 LY6D 
 HOXB9 MCF2 
 HRH1 MMP2 
 HRH2 MYB 
 HTATIP2 NES 
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 HTRA1 NOV 
 ID1 P2RY2 
 IL10 PBK 
 IL18BP PF4 
 IL33 PIP5K1A 
 ISL1 PLEC 
 ITGA3 POSTN 
 ITGA6 POU2AF1 
 ITGAE PPARG 
 ITGAV PPBP 
 ITGB3 PRKCB 
 JAG1 PTPRO 
 KANK1 RAPGEF2 
 KISS1R RELN 
 LAMA5 RGS4 
 LIF ROBO4 
 LMO7 RUNX2 
 LOX (includes EG:16948) S100A10 
 LRP6 SDC1 (includes EG:20969) 
 LSP1 (includes EG:16985) SELE (includes EG:20339) 
 LTBP2 SEMA3A 
 MAGI2 SLC9A3R2 
 MAP1B SPARC 
 MAPK8IP3 ST3GAL5 
 MCF2 ST6GAL1 
 MINK1 STAB1 
 MMP14 STAT1 
 MTA1 STMN1 
 MUC1 TLR9 
 NAV1 TUBB2B 
 NBL1 (includes EG:17965) VIM 
 NCK1 WNT11 
 NEO1 ZYX 
 NR1H4  
 NTN4  
 PARK2  
 PDCD1  
 PDE4D  
 PDGFD  
 PENK  
 PLAT  
 PLCL1  
 PLEC  
 PLXNB2  
 PMP22  
 PPAP2A  
 PRKCZ  
 PRNP  
 PTGS2  
 PTK2B (includes EG:19229) 
 PTP4A3  
 PTPRK  
 PTPRU  
 RAMP2  
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 RASSF5  
 ROBO3  
 ROR2  
 RORC  
 SELP  
 SEMA3E  
 SEMA6D  
 SERPING1  
 SFRP1  
 SKIL  
 SORBS3  
 SPP1 (includes EG:20750) 
 SPRY4  
 STAT3  
 SYNM  
 TAC1  
 TACR1  
 TGM2  
 THBD  
 THBS1  
 THRB  
 TNK2  
 TRPM4  
 VLDLR  
 VWF  
 WASF3  
 WWTR1  
 ZBTB16  
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Figure 2: Bisulfite conversion efficiency  
 
Plot of BS conversion efficiency in Old (O_1, 2, 3 and 4), Mid (M_1, 2, 3 and 4) and Young (Y_1, 3 and 4) samples. Genomic 
DNA was also assessed as an untreated control. 
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Figure 3: Antibody phenotype of ex vivo cultured LT-HSCs 
LT-HSC shown are from (a) Young mice after three (top plot) and five (bottom plot) days in culture; (b) Old mice after three (top plot) and five (bottom plot) days in culture. 
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Figure 4: Assessment of 5-Aza’dC (Aza) treated ex vivo cultured LT-HSCs.  
a) Aza treated cells were growth retarded, however their morphology appeared consistent with untreated cells and b) the phenotype of treated cells (1 µM) appeared consistent with primitive LT-
HSCs. Cells shown in c-Kit, Sca-1, CD48 and CD150 plots were gated side scatter (R1) and the murine CD45.2 marker (R20) 
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Table A-5: AHR target genes that were age differentially expressed 
Ensembl ID Genes  
ENSMUST00000039559 THBS1 
ENSMUST00000025875 SLC1A1 
ENSMUST00000140739 SLC16A5 
ENSMUST00000031594 SDSL 
ENSMUST00000035065 PTGS2 
ENSMUST00000033941 PLAT 
ENSMUST00000164721 NRG4 
ENSMUST00000034214 MT2A 
ENSMUST00000034215 MT1E 
ENSMUST00000002073 LTBP2 
ENSMUST00000028735 JAG1 
ENSMUST00000155249 ITGA6 
ENSMUST00000003818 INSIG2 
ENSMUST00000016673 IL10 
ENSMUST00000169036 HECTD2 
ENSMUST00000117872 FGFR2 
ENSMUST00000021603 FBLN5 
ENSMUST00000027632 EPB41L5 
ENSMUST00000105287 DCN 
ENSMUST00000031668 COL1A2 
ENSMUST00000044565 COL16A1 
ENSMUST00000039267 CHD7 
ENSMUST00000063531 CDKN2C 
ENSMUST00000097981 CDKN2B 
ENSMUST00000050918 CAMK2N1 
ENSMUST00000149051 ARNT 
ENSMUST00000130229 ACOX1 
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Figure 5: Multiple transcript isoforms appear to be differentially regulated with age.  
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Figure 6: Heatmap of all 111 age differentially methylated regions.  
Blue represents regions that are hypermethylated in Old age, while Yellow represents those that are hypomethylated. 
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Table A-6: Pearson correlation of MeDIP-seq samples.  
Values are from 0 to 1, with 1 being the highest. 
 
 
 
 
 
 
 
 
 
 
 
 
MeDIP-seq 
         
Samples Y1 Y2 Y3 M1 M2 M3 O1 O2 O3 
Y1   0.81 0.83 0.83 0.84 0.82 0.91 0.74 0.82 
Y2 0.81   0.94 0.92 0.93 0.92 0.83 0.66 0.92 
Y3 0.83 0.94   0.93 0.94 0.93 0.85 0.66 0.92 
M1 0.83 0.92 0.93   0.93 0.92 0.85 0.67 0.92 
M2 0.84 0.93 0.94 0.93   0.93 0.86 0.66 0.93 
M3 0.82 0.92 0.93 0.92 0.93   0.84 0.68 0.92 
O1 0.91 0.83 0.85 0.85 0.86 0.84   0.73 0.84 
O2 0.74 0.66 0.66 0.67 0.66 0.68 0.73   0.68 
O3 0.82 0.92 0.92 0.92 0.93 0.92 0.84 0.68   
MeDIP_seq Samples Platform 
Y1, O1, O2 GAIIx 
Others Hi-seq 
Correlation codes_MeDIP-
seq 
Comparison Platform 
Black GAIIx 
Red Hi-seq 
Green Cross Platforms 
Blue fill Self-correlation 
Table Key 
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